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 | ANTIGEN PRESENTATION FOR CD8 T-CELL IMMUNITY 
CD8+ T-cells
The immune system plays a crucial role in the surveillance of the host, detecting and 
eradicating threats such as bacterial and viral infections, as well as transformed tumor 
cells. The triggering of this effective defense mechanism starts with the activation of 
antigen presenting cells (APC), such as dendritic cells (DCs), that are able to detect the 
presence of pathogens in the body, for instance via surface innate receptors called “Toll-
like receptors” (TLR). Through other types of receptors they can detect dying cells, for 
instance derived from a cancer.  To initiate a pathogen-specific immune response, the DCs 
ingest the extracellular pathogens, infected cells or transformed cells and process them 
into single antigens (normally peptides). Then, they present these disease-related antigens 
to other cells of the immune system. This process enables the priming and activation of 
T-cells, such as the CD8+ T-cells, that are critical effector cells in the adaptive immune 
response. Activation of CD8+ T-cells occurs when their T-cell receptor (TCR) binds 
specifically to Major Histocompatibility Complex class I (MHC-I) molecules and small 
peptides displayed into these MHC-I molecules at the surface of APCs. Once activated, 
the CD8+ T-cells are potent effector cells that release effector molecules like interferon-γ 
(IFNγ), perforin and granzyme B to induce apoptosis (cell death) in their targets. CD8+ 
T-cells are well known for their function to kill their target cells via the release of effector 
molecules and because of this they are often called as Cytotoxic T-lymphocytes (CTL).
CD8+ T-cells develop in the thymus from precursors called thymocytes. During their 
development thymocytes are subjected to two subsequent processes called positive and 
negative selection. According to the affinity model of thymocyte selection, the affinity 
of the TCR-peptide-MHC interaction is the key determinant of T-cell selection1. 
During positive selection, thymocytes with intermediate affinity for self-peptide-MHC 
complexes receive a survival signal and commit to the CD4 or CD8 T-cell lineage. T cells 
that express MHC class II-restricted receptors are positively selected to the CD4 lineage, 
while T cells expressing MHC class I-restricted TCRs are selected to the CD8 lineage2. 
High-affinity binding of the TCR to self-peptide-MHC complexes induces cell death by 
apoptosis, a process that is known as negative selection (or clonal deletion). Negative 
selection is necessary for the maintenance of self-tolerance as it induces the deletion or 
inactivation of potentially autoreactive thymocytes. In the thymic medulla, the medullary 
thymic epithelial cells (mTECs) have a key function in this process as they express a large 
number of tissue-specific self-antigens that are presented to developing T cells1, 3. After 
positive and negative selection, thymocytes migrate out of the thymus and become part 
of the peripheral T cell pool.
MHC-I processing and presentation pathway
MHC-I molecules are present on the surface of virtually all cells of the body where they 
present peptides to ensure that rogue cells can be recognized by CTL. These peptides 




Potentially, a multitude of proteolytic systems may generate antigenic peptides, but the 
proteasome is responsible for the liberation of the majority. Other endo- and exoproteases 
complement proteasome activity by further degrading proteasomal products or, sometimes, 
by directly generating the defined peptide sequences that fit into MHC-I molecules. For 
instance, tripeptidyl peptidase II (TPPII), thimet oligopeptidase (TOP) and nardilysin 
have been implicated in the generation of some CTL epitopes4. Peptides generated in the 
cytosol need to be translocated into the ER by the TAP peptide transporters, to have access 
to the peptide loading complex (PLC) which is located in the ER. Once in contact with 
the PLC, the suitable peptides for binding are associated with the different nascent MHC-I 
heavy chains and β2-microglobulin (β2m) with help from chaperones such as calreticulin, 
tapasin and ERp57of the PLC5-7. Figure 1 summarizes the MHC-I presentation pathway.
Figure 1. MHC-I antigen presentation: the basics. Small peptide sequences derived from proteolysis 
in the proteasome are generated in the cytosol and loaded into the ER by TAP. These peptides bind to 
MHC class I molecules which are routed to the cell surface. Adapted from: Yewdell J.W. et al, Making 
sense of mass destruction 2003, Nature Reviews Immunology, 3(12):952-61.
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 | CD8+ T-CELL IMMUNITY AGAINST TAP-DEFICIENT CELLS
Importance of TAP-independent processing pathways 
The proteasome-TAP pathway is considered as the conventional processing route8-10. 
However, cells are equipped with alternative routes leading to liberation and loading 
of peptides into MHC-I molecules. These routes are independent of the molecules 
proteasome, tapasin or TAP from the conventional pathway. This has become apparent 
from studies on cells with deficiencies in the conventional processing pathway. The levels 
of surface MHC-I display are much decreased at the surface of cells from TAP-deficient 
mice11-13. However, the generation of TAP-independent peptides enables the residual 
expression of surface class I molecules. In human beings, TAP-deficiency syndrome is 
rare but can be observed in independent families and results from mutations in both 
subunits of the peptide transporter, TAP1 and TAP214. These patients suffer from chronic 
necrotising lesions in the lungs and skin associated with recurrent bacterial infections. 
Surprisingly, they are not unusually susceptible to infections by viruses despite the fact 
that the conventional MHC-I antigen processing pathway is considered very important 
for the presentation of viral peptides in infected cells. Peripheral TCRαβCD8+ T cells 
were present in TAP-deficient patients and their TCR repertoire is polyclonal. It was 
possible to isolate CTL recognizing a peptide from the EBV protein LMP2 presented 
by a HLA-B allele on TAP-deficient cells15. These observations argue that the TAP-
independent processing pathway sufficiently compensate for the loss of the conventional 
pathway in order to select a functional CD8+ T-cell repertoire and, moreover, to control 
virus infections14.  In fact, the phenotype of families with genetic TAP-defects resembles 
that of TAP-knockout mice, with lower surface expression levels of MHC-I but a 
remaining broad polyclonal repertoire of CD8+ T-cells11-13. In an attempt to identify the 
nature of TAP-independent peptides, pioneering studies by Peter Cresswell and Victor 
Engelhard in 1992 revealed that TAP-deficient T2 cells predominantly present peptides 
derived from signal sequences16, 17. Some of these peptides were also observed within 
HLA-A2 of normal, TAP-proficient cells, indicating that in normal cells alternative 
processing pathways operates side-by-side with the conventional route. 
TAP-independent processing routes: targeting to the ER
The best characterized alternative, TAP-independent processing pathway comprises 
peptides generated in the secretory compartments. Initial studies with TAP-deficient 
T2 cells showed that signal sequences can efficiently function as TAP-independent 
class I binding peptides. Signal sequences are typically composed of three domains: a 
hydrophobic core (h region) of 6-15 amino-acids, a polar C-terminal end (c region) 
with small uncharged amino acids and a polar N-terminal region (n region) with a 
positive net charge18. Signal sequences are targeted to the ER membrane and cleaved 
at their carboxyterminus by signal peptidase (SP). The remaining transmembrane 
trunks are then further processed by membrane-associated signal peptide peptidase 




fragments16, 19, 20. Peptide fragments in the vicinity of the ER lumen can serve as TAP-
independent class I ligands. The other fragments get access to the cytosol again and are 
further processed. The precise loading mechanism of TAP-independent signal peptides 
into MHC-I molecules is not known, since processing by SP and SPP is thought to take 
place outside of the PLC. Thus the question arises how TAP-independent signal peptides 
find their way to peptide-receptive MHC-I molecules in the ER. Normally, the transport 
by TAP, trimming by ERAAP and loading into MHC all occurs in the PLCs, which are 
specialized multi-unit machines. The PLC greatly facilitates peptide loading by physical 
bridging transporters to chaperones for loading and also ‘edits’ the repertoire of bound 
peptides to maximize their affinity5. In the absence of TAP however, the PLC misses one 
of its important components and thereby detaches the peptide influx from the loading 
machinery. Therefore loading of TAP-independent peptides, such as signal peptides, 
might take place outside of the PLC. The hydrophobicity of signal peptides might enable 
them to quickly associate with nearby proteins of the PLC, however, signal peptides are 
efficiently loaded in the ER, suggesting a strong degree of regulation and organization. 
These considerations prompt us to speculate the existence of specialized chaperones or 
loading complexes for TAP-independent peptides.
Snyder et. al. (1997) showed that peptides located at the C-terminus of ER-targeted 
proteins can be generated and presented very efficiently. In this case the very end of the 
C-terminus of the protein should represent the epitope, not requiring C-terminal trimming, 
in line with the fact that there is poor carboxypeptidase activity in the ER21. They described 
the presentation of TAP-independent peptides from one ER-resident protein, Jaw1, and 
proteins in the secretory pathway, like ovalbumin and CD2322-25. In each case the peptides 
were efficiently liberated from the very C-terminus by the activity of yet unidentified endo-
proteases to be generated as class I ligands. Based on this “pathway” of peptide liberation, 
the authors gave the term “C-end rule” to highlight the capacity of ER-resident proteases to 
liberate class I ligands from the C-terminal ends of ER-targeted proteins.
TAP-independent processing routes: the secretory route
A second characterized processing pathway that bypasses TAP is active in the secretory 
route. The work of Margarita del Val demonstrated that presentation of TAP-independent 
peptides can also start in the trans-Golgi network26, 27. This pathway was studied with the 
use of a model peptide at the C-terminus of the secreted Hepatitis HBe protein. The 
responsible proteolytic enzyme was shown to be furin, a known protease of the trans-
Golgi network normally required for the maturation of secreted proteins (e.g. growth 
factors and neurotransmitters) by cleaving at precise stretches of three to four basic 
residues28. Furin processes a wide variety of precursor proteins after the C-terminal 
arginine residue in the preferred consensus motif -Arg-X-Arg/Lys-Arg↓-X- (X is any 
amino acid and “↓” indicates the cleavage position)29. Furin-processed peptide-epitopes 
have been described but the exact MHC-I loading compartments are still unknown. One 
theoretical option is that recirculating surface MHC-I molecules pick up these peptides 
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in endosomal vesicles. Some MHC-I molecules are actually observed in endolysosomal 
compartments and seem to be chaperoned by the invariant chain, which is known to 
guide MHC-II molecules to their loading vesicles. A recent paper confirmed this role for 
the invariant chain in cross-presentation of exogenous antigens for MHC-I, leaving the 
option that the MHC-I antigen presentation system is equipped with such a vesicular 
route, at least in dendritic cells 30. Strikingly, complexes of MHC-I and invariant chain 
seem more pronounced in cells with TAP deficiency, suggesting that the importance of 
alternative processing pathways increases in the absence of a functional conventional 
pathway 31, 32. The invariant chain-derived peptide CLIP was detected on HLA-I molecules 
at the surface of leukemic cells. Interestingly, one eluted CLIP peptide efficiently bound 
a wide variety of HLA-I molecules (-A2, -B7, -A3, -B40) suggesting that this reflects a 
general non-allele specific mechanism33.
Other alternative processing pathways have also been described but are poorly 
characterized. Viral peptides from the LMP2 protein of the Epstein-Barr virus (EBV) can 
be produced by a TAP-independent and proteasome-dependent pathway and presented 
by MHC-I34. The TAP-independent peptides were highly hydrophobic, so it was 
speculated that due to their highly hydrophobicity these cytosolically produced peptides 
traversed to the ER membrane to reach MHC-I loading compartments. Furthermore, 
a recent study by Tey et al. showed that the presentation of a peptide antigen from the 
human cytomegalovirus (HCMV) latency associated protein, pUL138, occurs via a 
TAP-independent and proteasome-independent mechanism35. Interestingly, the MHC-I 
presentation of this antigen occurred entirely in the vesicular pathway and was mediated 
by autophagy. The autophagy-mediated pathway generated the same epitope as that 
generated through the conventional pathway and the MHC-I loading of the peptides 
occurred within the autophagolysosomal compartment. This shows that the autophagy-
mediated pathway can contribute to circumvent viral immune evasion strategies that are 
common to target the MHC class I machinery, such as viral TAP-inhibiting molecules. 
 | THE CASE OF IMMUNE ESCAPE OF TUMORS
Tumors frequently display processing defects
One hallmark of tumors is their ability to evade immune recognition36. Among others, a 
common way to escape is through loss of antigen presentation by MHC-I molecules37-41. 
Defects in the intracellular processing pathway are often the underlying mechanism of the 
MHC-I downregulation. For instance, TAP impairment is observed from 10% to 74%, 
varying with tumor types39-42. Interestingly, MHC-I downregulation has been associated 
with progressive disease and is very frequent in metastases of cervical carcinoma, breast 
cancer, melanoma and Ewing sarcoma39, 43, 44. Moreover, several studies found a clinical 
correlation between MHC-I expression and enhanced survival in different malignancies 
as cervical cancer and head and neck squamous cell carcinoma (HNSCC)41, 45-47. Two 




melanoma lesions and progression of these individual lesions during immunotherapy 
with IFN-α48, 49. All regressing lesions maintained MHC-I surface expression, whereas 
progressing metastases were characterized by low levels of MHC-I. The underlying 
mechanisms of MHC-I downregulation include loss of genes encoding MHC class I 
heavy chain and β2m as in loss-of-heterozygosity (LOH), decreased transcription of 
MHC-I locus products and defects in components of the antigen-processing machinery 
(APM) comprising peptide transporter TAP, tapasin and proteasome subunits37. 
Conventional anti-tumor CTL recognize tumor-specific (TSA) or tumor-associated 
antigens (TAA) presented by MHC-I molecules on the surface of tumor cells. Upon loss 
of antigen presentation, tumor cells become invisible for recognition by these CTL and 
therefore turn resistant to CTL-mediated killing50. Since impairment of TAP leads to 
a limited availability of all peptide precursors in the ER, this dysfunction impacts on 
the total MHC-I surface levels and may lead to general impairment of recognition and 
elimination of tumor cells by tumor-reactive CTL51.
Discovery of a novel CTL specificity combating immune escaped tumors 
During the search for approaches to counteract immune escape via this route, the group 
of Dr. Klas Kärre originally discovered a CD8+ T-cell subset that selectively recognizes 
TAP-deficient cells52. This T-cell population was raised in mice after immunization with 
B7.1-expressing TAP-deficient RMA-S lymphoma cells. We performed an in-depth 
investigation of this phenomenon and characterized a unique category of CTL that 
exclusively recognizes tumor cells with defects in their APM, but not cells with proficient 
APM (Figure 2)52-60. Recognition depended on the β2m light chain and residual MHC-I 
molecules on the tumor cells60. Restoration of TAP function by gene transfer of TAP 
subunits or by IFN-γ treatment significantly decreased recognition of target cells 
by these CTL. Conversely, inhibition of TAP in dendritic cells by the varicella virus-
encoded evasion protein UL49.5, which mediates degradation of mouse and human TAP 
proteins61, induced recognition of these cells by the novel CTL category53, 56. Furthermore, 
reactivity of these CTL was clearly T-cell receptor dependent and their phenotype was 
indistinguishable from that of conventional CD8+ CTL60. These findings implied that the 
specificity of the novel CTL category is based on MHC-I/peptide complexes which are 
exclusively presented by processing deficient cells. This alternative peptide repertoire 
emerges due to their APM defects and therefore we named the target structures “T cell 
epitopes associated with impaired peptide processing” (TEIPP)60. 
Characterization of TEIPP antigens
TEIPP-specific CTL do not recognize processing proficient cells, which makes possible 
that these alternative peptides are immunogenic. Peptide elution studies combined with 
mass spectrometry and synthetic peptide libraries enabled the molecular identification 
of the first mouse TEIPP60. The peptide recognized by this first CTL clone was not 
derived from a tumor antigen as such, but from the housekeeping protein TRAM-
protein homolog 4 (Trh4 or CerS5)60. The epitope was located at the very C-terminus 
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of Trh4, which is an ER membrane spanning fatty acid regulator62. Since this protein is 
ubiquitously expressed, it is logical that every tumor type harboring an APM defect was 
recognized by this CTL60. This implies that TEIPP antigens constitute a novel category 
of CTL epitopes presented by a broad range of tumors with APM defects. Furthermore, 
these studies showed that the identified TEIPP-specific CTL clones had distinct MHC 
restriction patterns including not only the classical MHC-I molecules Kb and Db, but also 
the non-classical MHC-I molecule Qa-1b 57, 60.
TEIPP antigens in the human population
Alternative peptide repertoires presented by TAP-deficient human cells have been 
described and provided first indications for the presence of TEIPP candidates17, 63, 64. Further 
evidence of human TEIPPs was provided by experiments with TAP inhibitors derived 
from herpes viruses. Many viruses, in particular of the herpes family, deploy mechanisms to 
target APM components in order to circumvent immunosurveillance by CTL65. Examples 
of viral proteins targeting TAP are ICP47 (HSV), US6 (HCMV), BNLF2a (EBV), and 
Figure 2. Schematic diagram of TEIPP-specific CTL. Tumor cells with defects in the antigen 
processing machinery are recognized by TEIPP-specific CTL, but not tumors with intact processing. 
TEIPP antigens in mouse models are presented by classical MHC-I (upper part) as well as the non-
classical MHC-I Qa-1 molecule (lower part). Qa-1-restricted TEIPP CTL recognize TEIPP peptides 




UL49.5 (varicella viruses). By introducing UL49.5 via gene transfer in human DCs, 
TAP activity was successfully inhibited55. These human TAP-impaired DCs were used as 
stimulators for autologous T-cell cultures and the resulting CTL displayed selective killing 
of TAP-impaired target cells. These findings formally demonstrate the existence of TEIPP-
specific CTL which are likely to come with a relative high frequency among the precursor 
population in the human CD8+ T-cell pool as they are readily detectable at the bulk T-cell 
culture level55. Furthermore, in silico predictions for immunogenic TAP-independent 
classical HLA-I-binding peptides and HLA-E peptide elution studies with TAP-deficient 
cells provided a great variety of potential TEIPP candidates. The most immunogenic 
peptides among them will be defined in current investigations.
Interestingly, a CTL epitope derived from the precursor signal peptide of 
preprocalcitonin (ppCT) was recently shown to be processed in a TAP-independent 
manner66. The described HLA-A2 restricted CTL clone was isolated from a lung cancer 
patient and recognizes autologous lung carcinoma cells in which overexpression of 
ppCT transcripts was detected. Recent data of the group of Dr. Mami-Chouaib show 
that downregulation of TAP is required to allow presentation of this ppCT peptide67. 
Therefore, we consider this CTL epitope, derived from a primary human tumor, as the 
first molecular defined human TEIPP.
 | SCOPE OF THIS THESIS 
The studies of TEIPP antigens thus far have revealed that these antigens are promising 
candidates for the combat of immune escaped tumors. However, several aspects about 
TEIPPs are poorly understood: what are the processing pathways that lead to generation 
and presentation of TEIPP antigens; what is the mechanism behind the immunogenicity 
of TEIPP; what are characteristics of TEIPP peptides presented by non-classical MHC-I. 
The studies presented in this thesis are focused on these topics. In chapter 2 the mechanism 
underlying the immunogenicity of TEIPP antigens was explored. The mouse TEIPP 
antigen from the Trh4 protein was used as a model. We induced the overexpression of the 
Trh4 protein and MHC-I heavy chains in TAP-intact cells, to identify the limiting step of 
Trh4 presentation. The increased expression of Trh4 was the only mechanism that achieved 
Trh4-peptide presentation in these TAP+ cells.  On the other hand, decreased TAP-activity 
gradually induced the presentation of Trh4-peptide and inhibited the presentation of 
the TAP-dependent repertoire. Therefore, we proposed a model of competing peptide 
pools that are governed by TAP-activity, which can be seen as a control lever in shifting 
the presented peptide repertoire gradually towards TAP-independent or TAP-dependent 
peptides. In chapter 3 we studied the processing pathway that lead to the liberation of the 
Trh4-derived peptide. To identify the involved proteolytic enzymes, a panel of chemical 
protease inhibitors was used in cellular assays and the re-appearance of the MHC-I/Trh4 
complexes in the presence of the inhibitors was measured. These experiments revealed 
that the SPP enzyme, which belongs to the family of intramembrane cleaving aspartyl 
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proteases (I-CLiPs), liberated the 9-mer Trh4-antigen in the ER. The participation of SPP 
in this process was independent from its known role in the release of leader peptides in the 
ER membrane and therefore revealed a new role for SPP in the liberation of immunogenic 
C-terminal peptides. In chapter 4 additional processing pathways participating in the 
liberation of TEIPP antigens were studied. Here, we studied a TEIPP antigen presented by 
the classical MHC-I molecule Kb to CTL. Protease inhibitor experiments were performed 
to identify the proteolytic enzymes responsible for the liberation of this antigen, similarly 
to what was done in the study of the Trh4 peptide. Surprisingly, we found that the 
presentation of this antigen was strictly dependent on proteasome function. Furthermore, 
our data suggested a role of autophagy in the presentation of this TAP-independent and 
proteasome-dependent antigen. 
In chapter 5, the topic of TEIPP-specific T-cells restricted by conserved non-classical 
MHC-I molecules was studied. The non-classical MHC molecule Qa-1 normally presents 
monomorphic leader-derived peptides and binds CD94/NKG2 receptors on natural killer 
(NK) cells and CD8+ T-cells. The presentation of these Qa-1 determinant modifier (Qdm) 
peptides is strictly dependent on TAP activity. However, primary studies on TEIPP-specific 
CTL revealed that Qa-1 molecules activated the Qa-1-restricted TEIPP-CTL in a TCR-
dependent manner under conditions of TAP-deficiency but not TAP-proficiency. This 
prompted us to analyze the repertoire of ligands presented by Qa-1 in TAP-deficient cells. 
We set out to determine this via biochemical purification and tandem mass spectrometry 
(MS). A list with more than 80 sequences was elaborated. Several of these peptides were 
highly immunogenic in vivo in mice, showing that they are promising targets in the combat 
of TAP-deficient cells, such as tumor cells. These data revealed a new role for Qa-1 in 
adaptive immunity by displacing the monomorphic leader peptides and by presenting a 
novel repertoire of immunogenic peptides to CD8+ T-cells in processing-deficient cells. 
In chapter 6 we reviewed the known roles of Qa-1 and the human variant, HLA-E, in 
immunity in the context of the new findings concerning Qa-1 as described in chapter 5. In 
Chapter 7, an overview of the findings presented in this thesis is discussed.
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 | PEPTIDE TRANSPORTER TAP PREVENTS PRESENTATION OF 
ALTERNATIVE PEPTIDES
The peptide transporter TAP mediates the entry of peptide precursors from the cytosol 
into the ER where they are loaded into MHC-I molecules. Part of the MHC-I presented 
peptides do not require the action of TAP or the proteasome and derive from alternative 
processing pathways. Interestingly, some of these alternative peptides are only presented 
when there are impairments in the classical processing pathway and do not reach the 
cell surface in normal cells. In this issue, Oliveira et al now describe that the peptide 
transporter TAP actually prevents the presentation of this alternative repertoire due to 
the overwhelming influx of competitor peptides in the ER. Strong over-expression of 
the antigen-encoding gene was needed to push the alternative peptide towards MHC-I 
surface display. Thus, TAP behaves like a lever of control to shift the presented peptide 
repertoire gradually towards TAP-independent or TAP-dependent peptides.
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 | ABSTRACT
We recently described a category of TAP-independent peptide-epitopes that are selectively 
presented by cells with processing defects in the classical MHC class I (MHC-I) pathway. 
Here, we studied the ER-resident ceramide synthase Trh4 as a prototypic example of these 
neo-antigens and found that moderate inhibition of TAP permits cell surface presentation 
of the Trh4 peptide. The absence of this peptide from WT cells was not related to the 
binding or stability of the Trh4/Db complexes, or to the availability of MHC-I heavy 
chains, but rather to the limited expression of the antigen. Strongly elevated antigen levels 
were needed to reach comparable peptide display on WT as on TAP-deficient cells. Our 
data suggest that the normal influx of TAP-transported peptides in the ER during routine 
processing creates an efficient barrier for peptides from alternative processing routes. 
Impairment of TAP function, as commonly found in cancers and virus-infected cells, 
lowers this resistance allowing for MHC-I presentation of other peptide sources.
 | INTRODUCTION
Cytotoxic T lymphocytes (CTLs) are key effector cells of the adaptive immune system 
and circulate throughout the body in search for their cognate peptides that are presented 
by MHC class I (MHC-I) molecules. T-cell receptors determine the antigen specificity 
of CTLs and engagement with peptide/MHC-I complexes leads to their activation 
and elimination of target cells. Therefore, the process of MHC-I antigen processing 
and presentation, which operates in all nucleated cells of our body, is crucial for CTL 
immune surveillance1-3.  The highly complex repertoire of MHC-I presented peptides 
reflects the total proteome of cells and derives from physiological turnover of proteins, 
a process that is largely operated by the multicatalytic enzyme proteasome4, 5. In addition 
to the proteasome, other proteolytic enzymes in the cytosol have been implicated in the 
liberation of peptides for MHC-I presentation, some of which can compensate for the lack 
of proteasome activity1, 6, 7. For instance, tripeptidyl peptidase II (TPPII), insulin-degrading 
enzyme (IDE), thimet oligopeptidase (TOP) and nardilysin have been implicated in the 
generation of some CTL epitopes8-10. However, the relative contributions of these novel 
peptidases and their cooperation with the proteasome have not been fully characterized. 
The intermediate peptide products are rescued from total breakdown by these 
cytosolic proteases through translocation into the ER. Subsequently, peptides are 
trimmed and loaded into the grooves of MHC-I molecules, a dynamic process that is 
mediated by the peptide loading complex (PLC) consisting of MHC-I, β2m, ERp57, TAP, 
tapasin and chaperones11-13. The TAP peptide transport is operated by the heterodimer 
pump TAP1/TAP2, members of the ABC transporter family. The importance of the TAP 
transporter is highlighted by the strong decrease in cell surface MHC-I molecules in 
the absence of TAP14. Furthermore, this bottleneck of the antigen processing pathway 
is frequently targeted by viruses, especially from the herpes group, which successfully 
evade complete eradication by CTL immunity15, 16. Moreover, loss of TAP expression 
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is often found in cancers and results in resistance to CTL attack17-19. All these findings 
together convincingly demonstrate that the conventional proteasome-TAP pathway plays 
a dominant role in the surface display of peptide/MHC-I. 
In addition to the conventional MHC-I processing pathway described above, cells 
are equipped with alternative routes that lead to the liberation and loading of peptides 
in MHC-I molecules. The exact contribution of these alternative routes to the overall 
peptide repertoire is difficult to assess, but it is intriguing that TAP-knockout mice 
still harbor a rather diverse CD8+ T-cell repertoire that can functionally respond to 
viral antigens14, 20. Moreover, TAP-deficient patients seem to cope quite well with viral 
infections, in contrast to infections with Gram-negative bacteria21-24. Apparently, TAP-
independent processing pathways can partly compensate for the loading of peptides in 
MHC-I molecules. Biochemical analysis of the peptide repertoire of TAP-deficient T2 
cells revealed abundant presentation of signal sequence derived peptides25-27. Indeed, 
signal sequences are liberated by the combined action of signal peptidase (SP) and signal 
peptide peptidase (SPP) and are directly available for loading into MHC-I28, 29. A second 
characterized processing pathway that bypasses TAP is active in the secretory route and 
is mediated by members of the proprotein convertase (PC) family, like furin30-32. This 
enzyme is located in the trans-Golgi network and mediates the proteolytic maturarion of 
many proproteins, e.g. growth factors and matrix metalloproteinases33. Peptides located 
at the C-terminus of secreted proteins can be liberated by furin and subsequently gain 
access to MHC-I in a TAP-independent way30, 32. 
Previously we reported the TAP-independent presentation of a C-terminal peptide 
from the ceramide synthase Trh4, which is a multiple membrane-spanning protein in the 
ER 34-36. This peptide was the first natural example of a C-terminal processing pathway of 
ER resident proteins, while previous studies suggested the existence of this route37-39. The 
Trh4 protein has a housekeeping function and is ubiquitously expressed. Intriguingly, 
the C-terminal peptide-epitope was not presented by processing-intact cells, but only 
emerged in MHC-I of cells with processing defects, like proteasome, tapasin or TAP36. 
In our current study, we show that peptide repertoires from the conventional processing 
route and the TAP-independent route are shifting arrays controlled by TAP function. The 
TAP-mediated peptide influx in the ER seems to constitute a resistance barrier for the 
presentation of peptides from alternative processing routes. 
 | RESULTS
Selective presentation of self-peptide Trh4 by processing-deficient cells
The surface presentation of the Trh4 peptide was determined for two panels of tumor 
cells using previously established CTL clones. RMA-S lymphoma cells are TAP-deficient 
due to an incomplete TAP2 chain and the Trh4 peptide, but not a proteasome- and TAP-
dependent control peptide, was detected at the surface of these cells (Fig 1A). Vice versa, 
TAP-intact RMA cells efficiently presented the control epitope, but the Trh4 peptide 
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was not detected by the CTL clone (Fig 1A). In the fibrosarcoma tumor model MCA, a 
chemically induced tumor isolated from a TAP1-knockout mouse, we observed the same 
dichotomy in presented peptide repertoires between TAP-deficient and TAP-proficient 
cells (Fig 1B). MCA cells only presented the Trh4 peptide, but not the TAP-dependent 
control. Importantly, restoration of the mouse TAP1 gene in this tumor resulted in 
decreased stimulation of the Trh4-specific CTLs and simultaneously in an increased 
stimulation of the control CTLs (Fig 1B). This indicated that MCA.TAP1 cells display a 
mixed peptide repertoire in their MHC-I molecules comprised of both TAP-dependent 
and -independent peptides. The introduction of the TAP1 subunit did not fully restore 
TAP function in these cells but showed an inhibitory effect of TAP on Trh4 presentation. 
This effect was potentiated by IFN-γ treatment of MCA.TAP1 cells, a strong inducer of 
the conventional antigen processing and presentation machinery. IFN-γ-treated MCA.
TAP1 cells displayed the other extreme of the peptide profile, in that the Trh4 peptide 
was virtually absent from the cell surface (Fig 1B). IFN-γ treatment of parental TAP-
knockout MCA cells did not abrogate Trh4 presentation, suggesting that deficiency of 
TAP is sufficient for the surface display of Trh4/MHC-I complexes. 
Next, we studied the presentation of the Trh4 peptide by dendritic cells, which are 
highly efficient antigen presenting cells (APCs). Introduction of the viral evasion protein 
UL49.5 that targets TAP function40 resulted in modest inhibition of peptide transport 
and MHC-I presentation of these cells as we previously showed41. Control CTLs specific 
for a TAP-dependent epitope were still capable of recognizing these UL49.5-expressing 
dendritic cells, albeit to lower extent, attesting to the partial inhibition of TAP (Fig 1C). 
Nevertheless, this partial TAP impediment led to the emergence of the Trh4 peptide on 
these dendritic cells (Fig 1C). 
These data corroborated our previous work and showed that the endogenous Trh4 
protein is ubiquitously present in cells, but its C-terminal epitope is only presented 
by MHC-I on cells harboring a partially impaired TAP function. Furthermore, these 
results demonstrated that the peptide repertoire from the conventional proteasome-TAP 
pathway can co-exist with that of alternative routes and that TAP function mediates the 
shift between these repertoires. 
Trh4 peptide presentation by primary tissue cells 
Trh4 presentation was thus far studied with in vitro cultured cell lines. To obtain a 
broader profile of Trh4 peptide presentation by primary tissues we examined a panel 
of ex vivo isolated tissue cells from organs of wild type mice and TAP1-knockout mice. 
Parenchymal cell populations were purified by mechanical and enzymatic disruption 
of organs that were perfused with heparin. Ex vivo depletion of CD45+ hematopoietic 
cells, including antigen presenting immune cells resulted in purified epithelial with 
stromal cell populations. Tissue cells from TAP1-knockout mice were recognized by the 
Trh4-specific CTLs, except from spleen and liver (Fig 2A). Interestingly, the degree of 
recognition varied between the organs and was particularly high for bone marrow, lymph 
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Figure 1. The Trh4 peptide is only presented on cells with impaired TAP function. Peptide 
presentation was evaluated by incubating CTLs (Trh4-specific or controls) with target cells and 
measuring IFN-γ levels in the supernatant by ELISA after culture for 18 hours. The Trh4-specific CTL 
clone recognizes the MCLRMTAVM peptide from the Trh4 protein; the control T cells recognize the 
TAP- and proteasome-dependent peptides (A) CCLCLTVFL, an MuLV-derived peptide, and (B, C) 
the H-2Db-leader derived peptide AMAPRTLLL.  The target cells are (A) RMA, a TAP-proficient 
lymphoma cell line; RMA-S, a TAP2-mutant variant of RMA; and C4.4-25, a β2m-deficient lymphoma 
cell line; (B) MCA fibrosarcoma cells derived from TAP1-/- mice either untreated or reconstituted 
with the TAP1 gene (MCA.TAP1) and, where indicated, pre-treated with IFN-γ to boost the antigen 
processing and presentation machinery before culture with the CTLs; (C) D1 dendritic cells transduced 
with the viral TAP-inhibitor UL49.5 (D1.UL49.5) or an empty vector (D1.vector). Means and standard 
deviations of triplicates are shown from one out of three independent experiments.
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nodes and thymus, suggesting that the epithelial and connective tissue cells of these 
organs efficiently support MHC-I antigen presentation. Parenchymal cell populations 
of liver and spleen appeared to lack Trh4/MHC-I complexes and we speculate that 
these organs do not express the processing enzymes for Trh4 peptide liberation. 
None of the tissue populations of wild type mice was recognized by the Trh4-specific 
CTLs (Fig 2A). Analysis of Trh4 gene expression by the tissues revealed no difference 
between wild type and TAP1-knockout cell populations, indicating that the Trh4 gene 
was expressed by all tissue cells of the wild type mouse as well (Fig 2B). To determine 
Trh4 gene expression in thymus in more detail, we performed expression analysis 
on separated thymus subpopulations that are known to mediate negative selection42. 
Trh4 transcripts were detected in medullary thymic epithelial cells (mTEC), dendritic 
cells and macrophages (Fig 2C). In addition, Trh4 was also expressed by thymocytes. 
Notably, thymus stromal cells from wild type mice did not present the Trh4 epitope in 
contrast to their TAP1-knockout counterparts, suggesting that negative selection of this 
CTL specificity in wild type mice is negligible.
These results implied that Trh4 is ubiquitously expressed in situ in the body, including 
thymic cells that mediate negative selection, but that the conventional TAP-facilitated 
peptide repertoire prevents its MHC-I presentation. As a consequence, T cell receptors 
with Trh4/H-2Db specificity will not be deleted from the CTL repertoire in normal mice.
Trh4 is a stable and high affinity peptide for binding to H-2Db
In order to study the underlying mechanisms leading to the absence of the Trh4 peptide 
on cells with normal antigen processing functions we assessed the capacity of the Trh4 
peptide to compete for MHC-I loading as weak interactions with the presenting molecule 
H-2Db might explain its failure to stimulate T cells. It is known that the ER-resident 
peptide loading complex actively selects high quality peptides for MHC-I binding11, 43 
and, potentially, weak binding affinity might thus preclude Trh4 loading. We determined 
the binding affinity of Trh4 to H-2Db as well as the dissociation rate of these complexes 
and compared these values with those for a viral CTL epitope and five other tumor-
associated CTL epitopes (Fig 3). The measured peptide binding affinities showed that 
Trh4 was positioned in the group of high affinity binders, comparable to the viral gp33 
epitope from LCMV (Fig 3A). Trh4 was clearly distinguishable from low affinity peptides 
like the MDM2- and gp100-derived epitopes. Moreover, the stability of Trh4/H-2Db 
complexes, a parameter that strongly associates with immunogenicity44, was superior to 
all the other tested peptides (Fig 3B). After 6 hours, virtually all Trh4/H-2Db complexes 
were still detected, whereas the tumor-associated peptides showed a fast decay. 
Considering these results, we concluded that the Trh4 peptide binds to its presenting 
MHC-I molecule with high affinity and stability. These features would rather facilitate 
than avoid its presentation by normal cells. 
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Figure 2. Trh4 is widely expressed and presented on TAP-deficient primary tissue cells. (A) The 
indicated organs/tissues were collected from C57BL/6 and TAP1-/- mice and processed in vitro by 
mechanical and enzymatic disruption. CD45+ cells were depleted from the isolated tissue cells by use of 
magnetic CD45 MicroBeads and the remaining cells were incubated with the Trh4-specific CD8+ T-cell 
clone and IFN-γ production determined. (B-C) Total RNA was extracted from the isolated primary cells 
derived from (B) the indicated tissues/organs of C57BL/6 and TAP1-/- mice or (C) the specific thymic sub-
populations of C57BL/6 mice. cDNA was synthesized from the RNA samples and Trh4 mRNA expression 
determined by quantitative PCR with normalization to the (B) GAPDH or (C) β-actin housekeeping 
genes and expressed relative to (B) thymus TAP1-/- and (C) mTEC CD80high Trh4 mRNA levels. Means 
and standard deviations of triplicates are shown from one out of three independent experiments.
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MHC availability is not the limiting step for Trh4 loading and 
presentation
Next, we tested whether the availability of MHC-I molecules was limiting for the 
presentation of Trh4. Higher expression levels for the heavy chain might enable the Trh4 
peptide to be loaded into H-2Db molecules even in the presence of the peptide repertoire of 
the conventional processing pathway. A retroviral expression vector containing the H-2Db 
gene was introduced into TAP-positive RMA cells and MHC-I protein levels were analysed 
by flow cytometry. The surface display of H-2Db molecules increased nearly two-fold, 
indicating that extra availability of heavy chain proteins indeed enhances peptide loading 
and surface presentation of peptide/MHC-I complexes (Fig 4A). Nevertheless, analysis 
of Trh4 presentation showed that additional heavy chains did not bring this peptide to 
the cell surface (Fig 4B). These data suggested that the supplementary MHC-I molecules 
predominantly accommodated peptides from the classical repertoire. Furthermore, a three-
fold increase of H-2Db molecules at cell surface of TAP-deficient RMA-S cells neither 
enhanced the surface display of Trh4 peptides (Fig 4A and 4B). This result suggested that 
TAP deficiency, which blocks the presentation of the classical peptide repertoire, creates 
the opportunity for all available Trh4 peptides to be loaded, irrespective of MHC-I levels. 
Together, these results showed that the availability of MHC-I molecules is not the rate-
limiting step for the restricted presentation of Trh4 by processing-deficient cells.  




















































Figure 3. Binding and stability of Trh4 peptide/H-2Db complexes. (A) The binding affinity of the 
Trh4 peptide to H-2Db was evaluated. RMA-S cells were incubated with varying concentrations of the 
indicated H-2Db binding peptides and H-2Db cell-surface levels after 4h incubation were determined by 
flow cytometry. The binding index of peptides to MHC was calculated as the ratio of the mean fluorescence 
intensity (MFI) between loaded and unloaded cells. The index of a control H-2Kb binding peptide was 
one in all concentrations (not depicted). (B) The decay of the Trh4/H-2Db complexes was tested by 
incubation of RMA-S cells with the indicated peptides and evaluation of surface H-2Db levels by flow 
cytometry over time. The data are the percentages of remaining peptide/H-2Db complexes on the cell 
surface as compared to initial levels. Results shown are representative of three independent experiments.
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Higher antigen levels in TAP-intact cells allow Trh4 presentation 
Then we assessed whether the restricted presentation of our Trh4 peptide was based on 
quantity limitations. Processing-intact cells encounter large influxes of peptides into the 
ER via the TAP transporter. This peptide pool from the conventional proteasome-TAP 
processing pathway might easily overwhelm the peptides arriving in the ER via alternative 
routes and compete with the Trh4 peptides for MHC-I binding. We over-expressed Trh4 
by gene transfer using vectors with a strong heterologous promoter. RMA and RMA-S 
cells were stably transfected with cDNA encoding the long transcript variant of Trh4, 
which contains the CTL epitope at the very C-terminus. The short Trh4 transcript lacks 
one exon and does not encode for the epitope due to a reading frame shift 36. Analysis of 
processing-proficient RMA cells with higher Trh4 gene expression revealed that the Trh4 
peptide was efficiently presented by these cells to an extent that was comparable with 
RMA-S cells (Fig 5A). On the other hand, over-expression of Trh4 in the TAP-negative 
RMA-S hardly enhanced the Trh4 presentation. This suggested that rate limiting steps 
other than peptide quantity might be in place, for example related to processing enzymes. 
These results indicated that the processing pathway for the generation of Trh4 is active in 
normal TAP-positive cells and, moreover, that physiological quantities of the Trh4 peptide 
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Figure 4. Over-expression of MHC-I does not facilitate presentation of the Trh4 peptide. (A) H-2Db 
was over-expressed in RMA and RMA-S cells (RMA.Db and RMA-S.Db) by retroviral transduction and 
cell surface expression of H-2Db was determined in transduced and control (RMA and RMA-S) cells. 
The filled grey line represents the background staining with the secondary antibody alone. The results 
are representative of three independent experiments. (B) H-2Db over-expressing RMA and RMA-S target 
cells (RMA.Db and RMA-S.Db), non-transduced RMA and RMA-S cells or medium alone were incubated 
with Trh4-specific CTLs and IFN-γ production determined. The black bar represents culture with 20,000 
target cells and the grey bars represent culture with five fold serial dilutions of the target cells. Means and 
standard deviations of triplicates are shown from one out of three independent experiments.
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of the antigen, a successful competition with the peptide repertoire of the conventional 
pathway was achieved. To assess the expression level of Trh4, quantitative PCR analysis 
was performed, since antibodies against the protein were not available. The Trh4 gene in 
our RMA.Trh4 cells was expressed 120 times higher than the endogenous levels in RMA 
cells (Fig S1). The expression of the short Trh4 transcript did not vary between the cell 
lines, because this cDNA was not involved in gene transfer (Fig S1). We anticipated that 
over-expressed Trh4 protein was still ER localized like the endogenous protein, since 
a previous study confirmed this using HA-tagged Trh435. Moreover, the over-expressed 
Trh4 is not shuttled to the cytosol for proteasome-mediated degradation, because 
epoxomicin did not inhibit the presentation of the Trh4 peptide by these RMA.Trh4 
cells (Fig S2). Interestingly, the proteasome inhibitor rather increased the presentation 
of the TAP-independent epitope, again confirming that the classical processing route of 
proteasome-TAP hampers the presentation of peptides from alternative pathways. 
We then examined the quantity range that was needed for the presentation of Trh4 on 
TAP-positive cells. RMA.Trh4 cells were sorted in three populations on basis of fluorescent 
GFP proteins levels, which corresponded to Trh4 levels due to a coupled translation 
initiation by an internal ribosome entry site in our gene construct. Gene expression analysis 
showed that the three RMA.Trh4 populations harbored approximately 800, 400 and 20 
times the amount of endogenous Trh4, respectively (Fig 5B). Again, over-expression of 
the long Trh4 transcript did not influence the expression of the shorter isoform. RMA.
Trh4 cells with 20 times over-expression were recognized by the CTL clone, but just 
above the quantity threshold (Fig. 5C). RMA.Trh4 cells with 400 times over-expression 
presented the epitope to convincing levels. However, this high expression level was still 
not saturating, as RMA.Trh4 cells with 800 times over-expression were clearly better 
recognized by the Trh4-specific CTL clone (Fig 5C). The fact that these extreme levels of 
Trh4 expression were needed to reach optimal peptide presentation in TAP-positive cells 
implied that the conventional peptide repertoire entering the ER via TAP mediates strong 
resistance to the presentation of the alternatively processed Trh4 peptide. Importantly, 
vigorous over-expression of this one transcript did not alter or inhibit the presentation 
of the TAP-mediated control peptide (Fig 5C). We wondered if the over-expressed Trh4 
gene in RMA.Trh4 cells would reach transcript levels comparable to those of classical 
antigens. The endogenously expressed retroviral gag gene encodes the immunodominant 
H-2Db-presented epitope CCLCLTVFL, which is TAP- and proteasome-dependent45. 
Whereas endogenous Trh4 expression in the tumor cells was very low, the over-expressed 
gene approached levels comparable to the gag gene (Fig. S3). This indicated that the Trh4 
epitope is not presented by TAP-positive cells because its expression level is too low.
Increased Trh4 expression in professional antigen-presenting cells (dendritic D1 cells) 
also induced recognition by Trh4-CTLs (Fig S4). Stimulation of the conventional 
processing route through LPS-mediated maturation of these cells decreased Trh4 peptide 
presentation, supporting our notion on competing peptide repertoires (Fig. S4). 
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Figure 5. Trh4 peptide is presented on TAP-proficient cells upon over-expression of Trh4. (A) 
Reactivity of Trh4-specific T-cell clone against TAP-proficient RMA cells and TAP2-deficient RMA-S 
cells transduced or not with the Trh4 gene (RMA.Trh4, RMA-S.Trh4) or an empty vector (RMA.
LZRS) as determined by IFN-γ production. Four fold serial dilutions of targets were performed starting 
at 20,000 target cells as indicated by the grey scale bars. (B) mRNA expression, in the indicated cells, 
of Trh4 and a natural Trh4 splice variant as determined by quantitative PCR using specific primers to 
distinguish both transcripts. The splice variant, used as a control, is a shorter transcript that does not 
contain the sequence of the Trh4 peptide MCLRMTAVM. Trh4 expression levels were normalized with 
the β2m housekeeping gene and expressed relative to the RMA sample. (C) RMA cells over-expressing 
Trh4 protein (RMA.Trh4) either weakly or at medium or high levels (low, interm. or high respectively) 
were incubated with Trh4-specific or MuLV control T cell clones and IFN-γ production measured. Two 
fold (control CTLs) or four fold (Trh4-CTLs) serial dilutions of targets were performed starting at 
20,000 target cells and are indicated by the grey scale bars. Means and standard deviations of triplicates 
are shown from one out of three independent experiments.
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We concluded that the TAP-independent peptide repertoire needs to compete with 
the conventional repertoire for loading and presentation by MHC-I. This resistance to 
the alternative repertoire is swiftly alleviated by decreasing levels of the TAP transporter. 
The newly emerging peptides on TAP-impaired cells therefore represent immunogenic 
neo-antigens and constitute unique CTL targets for TAP-deficient tumors and cells 
infected with immune evading herpes viruses. 
 | DISCUSSION
MHC-I presented peptides constitute protein breakdown intermediates that are rescued 
from complete destruction in the catabolic milieu of the cytosol. The total pool of cytosolic 
peptides formed by proteolysis is very diverse and estimated to be composed by millions of 
peptides2, 3, 46-48. From this pool only a small repertoire is selected for presentation by MHC-I 
molecules at the surface of cells. In our current study we demonstrate that this repertoire 
selection is largely governed by the peptide transporter TAP, which pumps peptides from 
the cytosol into the ER. The TAP complex behaved like a lever of control to shift the 
presented repertoire gradually towards TAP-independent or TAP-dependent peptides. 
Cells with normal antigen processing function did not present the TAP-independent 
Trh4-derived peptide at the cell surface, despite the fact that this peptide is generated in 
TAP-positive cells and is capable of forming stable complexes with H-2Db (Fig 3). Modest 
inhibition of TAP function, however, resulted in surface display of this Trh4/Db complex. 
In addition, partial deficiencies still allowed the presentation of TAP-dependent peptide 
species, yielding a mixed peptide repertoire of both pools. The highest presentation of Trh4 
peptide occurred when TAP function was completely blocked. These data revealed that TAP 
supports a highly competitive environment for class I loading in the ER most likely due to 
the overwhelming flow of peptide species that it pumps from the cytosol. Partial inhibition of 
TAP function alleviates this competition and induces the presentation of novel peptides and 
gradually inhibits the presentation of the classical TAP-dependent pool. This hypothesis is 
corroborated by the finding that over-expression of the Trh4 protein results in higher amount 
of peptide epitopes that are able to successfully compete for presentation in processing-intact 
cells (Fig 5). Alternatively, the selective Trh4 presentation could be explained by difference 
in organization of the peptide-loading complexes in the absence of TAP. A change in 
stoichiometry of the peptide-loading complex might favor an alternative peptide repertoire. 
This alternative hypothesis is, however, less likely because over-expression of the Trh4 protein 
is not expected to change the loading complex, while it still leads to surface presentation 
of the CTL epitope by H-2Db. This forced presentation of a TAP-independent peptide was 
operable in leukemia cells as well as in primary dendritic cells (Fig 5 and Fig S4), illustrating 
the general character of this mechanism. We therefore conclude that TAP activity normally 
contributes to the retention of this TAP-independent peptide inside the cell. Apparently, not 
all peptides that can be presented on basis of accessibility to the ER and of binding affinity 
are actually presented. A consequence of this reasoning is that peptide availability is not the 
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rate limiting step in antigen presentation. The fact that MHC-I surface expression can be 
enhanced by gene transfer of heavy chains, further supports this notion (Fig. 4). 
The studied Trh4 peptide represents a much broader repertoire of TAP-independent 
peptides, as we have shown that TAP-deficient cells are recognized by a diverse pool of 
CTL clones with distinct MHC restriction patterns36, 41. Interestingly, the non-classical 
MHC molecule Qa-1b seems to play a dominant role in the presentation of these TAP-
independent antigens49-51. Recently, we showed the existence of the human equivalent 
of this novel CTL category52, 53. These peptide sequences, called TEIPP (T-cell epitopes 
associated with impaired peptide processing) are not presented by normal cells and we 
can speculate, based on the results of the present study, that one mechanism governing the 
absence from normal cells is related to the low expression level of the cognate proteins. In a 
parallel study, a proteasome- and TAP-independent tumor antigen from the signal sequence 
of the preprocalcitonin protein (ppCT16-25) was found to represent a human TEIPP, in 
that this HLA-A2 presented peptide was selectively presented by tumor cells with TAP-
deficiency54. This peptide is liberated in the ER lumen by sequential cleavage with SP and 
SPP56 and is a clear example of the alternative TAP-independent peptide repertoire. 
We like to emphasize that not all TAP-independent peptides fail to be presented 
by processing intact cells. Mass-spectrometry analyses have revealed that part of this 
repertoire can be detected on the surface of TAP-proficient cells25-27. We anticipate that 
the expression levels of these proteins or the rate of peptide formation is higher than that 
of TEIPPs. Consequently, the immunogenicity of these peptides is expected to be much 
lower, due to central and peripheral T cell tolerance, as these peptides are derived from 
ubiquitously expressed housekeeping proteins. 
The emerging picture of MHC-I antigen processing incorporates novel proteolytic 
enzymes next to the multicatalytic proteasome complex as the central player6-9. Most of 
these novel breakdown systems liberate peptides in the cytosol and produce substrates 
that still need TAP transport for MHC-I loading. However, processing by yet other 
proteolytic systems deliver peptides that are presented in a TAP-independent way. The 
above mentioned SP and SPP proteases produce such TAP-independent peptides within 
the ER and proprotein convertases like PC7 and furin have been shown to facilitate 
TAP-independent presentation in the secretory route29-32. Interestingly, our preliminary 
data show that presentation of the Trh4 peptide is independent of these known enzyme 
systems, indicating that yet other pathways exist. 
In this study we show that TAP influences the balance of peptide repertoires and that 
potential MHC-I ligands compete for loading and surface display. TAP down-modulation 
facilitates the presentation of the suppressed repertoire. Importantly, inhibition of this 
processing bottleneck is a common feature in cancer55, 57 and TAP is also a frequently 
targeted molecule by most viruses that cause lifelong infections15. The direct consequences 
are a generalized decrease in MHC-I presentation and the emergence of alternative 
peptide repertoire. These TAP-independent peptides might constitute an important line 
of host defense that might be exploited in therapeutic intervention strategies.
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 | MATERIAL AND METHODS
Cell lines and mice
The tumor cell lines RMA, RMA-S (TAP2 deficient), C4.4-25 (β2m deficient), MCA 
(TAP1 deficient) and the D1 dendritic cell line have been described previously36, 41, 49. 
Cell variants overexpressing H-2Db or Trh4 (accession number UniProtKB/Swiss-Prot 
Q9D6K9 LASS5_MOUSE) were generated by retroviral gene transfer using the LZRS 
vector containing GFP behind an internal ribosome entry site50. RMA.Trh4 cells were 
differentially sorted according to GFP levels to generate variants with low, intermediate 
and high expression of Trh4. MCA.TAP1 is a variant of MCA fibrosarcoma where the 
mouse TAP1 gene was introduced. UL49.5 is a gene from the Bovine Herpes Virus-1 and 
blocks mouse TAP activity40, 50. Generation and culture of T cell clones was described 
previously36, 45, 50. CD8+ T cell clones used in this study: Qa-1-resticted CTL B12i is specific 
for the TAP-dependent peptide Qdm (AMAPTRLLL); H-2Db-restricted CTL clone 1 is 
specific for the TAP-dependent MuLV gag-leader peptide (CCLCLTVFL); H-2Db-restricted 
CTL clone B5 is specific for the TAP-independent Trh4 peptide (MCLRMTAVM). All 
cells were cultured in complete IMDM medium (Invitrogen, Carlsbad, CA) containing 8% 
heat-inactivated FCS, 100 U/mL penicillin, 100 μg/mL streptomycin (Life Technologies, 
Rockville, MD), 2mM L-glutamine (Invitrogen) and 30 μmol/L of 2-mercaptoethanol 
(Merck, NJ, USA) at 37°C in humidified air with 5% CO2. 
C57BL/6 mice were purchased from Charles River Laboratories (France and 
Germany) or were bred at the German Cancer Research Center (DKFZ) and housed in 
the animal facility of the Leiden University Medical Center and DKFZ under specified 
pathogen-free conditions. Mice were used between 8 and 12 weeks of age. TAP1-
knockout mice were purchased from Jackson laboratories. Experiments were performed 
in accordance with national legislations and institutional guidelines and were approved 
by the local ethical committees.
T-cell activation assays and flow cytometry
T cell activity was measured by IFN-γ secretion. Supernatants were harvested after 
overnight incubation of T cells with target cells and concentrations of IFN-γ were 
measured by ELISA as previously described58. Surface expression of H-2Db molecules 
was determined using purified mouse anti-H-2Db mAb (clone 28.14.8S; BD Biosciences, 
NJ, USA) followed by allophycocyanin labeled goat anti-mouse Ig (Southern Biotech, 
Birminghan, USA). Cells were analyzed using a FACS Calibur with Cellquest software 
(BD Biosciences) or Flowjo software (Tree Star, Ashland, OR).
Quantitative PCR analysis
Total RNA isolation and cDNA preparation was performed using RNeasy Mini Kit 
(Qiagen, Maryland, USA). 500 ng of purified total RNA was used to synthesize cDNA 
using High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, USA). 
Quantitative PCR on short and long transcripts of Trh4 was done as described before36. 
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SensiMix™ SYBR No-ROX kit from GC Biotech Bioline (Alphen aan den Rijn, NL) 
was used in a C1000™ Thermal Cycler (Bio-Rad, Hercules, CA, USA) and results were 
analysed using Bio-Rad CFX manager software.
Quantitative PCR on thymic stromal cells purified by cell sorting was performed as 
published59. Long Trh4 transcripts were amplified with Power SYBR Green Master Mix 
(Applied Biosystems) on a GeneAmp 7300 System (Applied Biosystems).
Peptide binding and stability assays
Peptides for which MHC-I binding and stability were analyzed were Trh4379-387 (MCLRMTAVM), 
LCMV gp3333-42 (KAVYNFATC), CEA571-579 (CGIQNSVSA), MDM441-449 (GRPKNGCIV), 
WT1126-134 (RMFPNAPYL), cyc20-28 (TNLLNDRVL), gp10025-33 (EGSRNQDWL). RMA-S 
cells were cultured for 2 days at 26°C to accumulate peptide receptive MHC-I molecules on the 
cell surface60. Cells were washed in serum free medium and incubated at 2x105 cells/well with 
varying concentrations of peptides for 4h at 37°C. Cells were washed and stained for H-2Db 
as described above. For peptide/MHC-I stability determination, the RMA-S cells were plated 
(3x106 cells/mL) with peptides (10 or 100 μg/mL) and 10 μg/mL Brefeldin A for 1h at 26°C. 
After incubation, cells were washed 3 times, plated at 3x105 cells/well with Brefeldin A and 
incubated at 37°C for 1h, 2h, 4h and 6h to study the decay of peptide/MHC complexes. Cells 
were washed, fixed with 1% paraformaldehyde and stained for H-2Db.
Proteasome inhibition assay
RMA.Trh4 cells were incubated at 2x106 cells/mL with 2 uM epoxomicin (Sigma) 
before (1h) and after (6h) peptide-stripping with acetic acid as previously described45. 
Control cells were treated with peptide-stripping, but not with epoxomicin. Target cells 
were then incubated with CTLs in a 2:1 ratio with Brefeldin A to retain produced IFN-γ 
intracellular. Incubation was performed overnight at 37°C and percentage of cytokine-
producing CTLs was analysed by flow cytometry as described60. 
Isolation of primary cells from mice
Anaesthetized mice were perfused with heparin solution to remove blood cells from 
the tissues. To obtain single cell suspensions, spleens were mechanically disrupted 
with cell strainer and bone marrow cells were obtained from femurs by flushing with 
RPMI medium. Other tissues were mechanically disrupted or sliced in small pieces and 
incubated with enzyme mixes. Thymuses were incubated with 0.5 mL of collagenase IV 
solution (0.5 mg/mL, Sigma-Aldrich, MO, USA) per thymus at 30 °C and slowly agitated 
for 15 minutes. Two incubations were performed. The remaining fragments were digested 
with a mixture of collagenase and dispase I (0.1 mg/mL, Sigma-Aldrich) during three 
incubations of 30 minutes at 37 °C (0.5 mL of enzyme mix per thymus). Enzyme mix 
was replaced and fractions were collected and “pooled” at the end. Lymph nodes were 
incubated with 0.2 mg/mL collagenase IV, 0.1 mg/mL DNase I (Sigma-Aldrich) and 
0.8 mg/mL dispase I at 37 °C under agitation. After 15 minutes the enzyme mix was 
replaced and the fragments were incubated again. This procedure was repeated 5 times61. 
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Lung tissue fragments were collected to gentleMACS C tubes (Miltenyi Biotec, Bergisch 
Gladbach, Germany) and mixed with 0.05mg/mL DNase I and 250 U/mL collagenase 
IV diluted in serum-free medium (5 mL enzyme mix/2 lungs). Tubes were transferred 
to gentleMACS Dissociator (Miltenyi Biotec) and the protocol was run according to 
manufacturer’s recommendations. Cell suspension was passed through a cell strainer 
to remove cell clumps. Livers were collected to gentleMACS C tubes and mixed with 
0.05 mg/mL DNase I and 500 U/mL collagenase IV diluted in serum-free medium (5 mL 
enzyme mix/2 livers). The fragments were incubated at 37 °C for 30 minutes under slow 
mixing. After incubation, tubes were transferred to gentleMACS Dissociator and the 
protocol was run according to the manufacturer’s recommendations. Cell clumps were 
removed with a cell strainer.
Blood-derived CD45+ cells were depleted from the tissue cell suspensions by 
negative selection with magnetic CD45 MicroBeads (Miltenyi Biotec) according to 
manufacturer’s protocol. Contamination with CD45 cells was estimated by staining with 
antibodies against the epithelial cell marker CD326 (Ep-CAM) and CD45.
For the isolation of thymic subpopulations, thymic lobes were cleaned of fat and 
connective tissue, cut in little pieces and stirred for 10 min in 15mL RPMI medium at 
room temperature to release thymocytes. Tissue fragments were then resuspended in 
1 mL medium per thymus containing 0.2 mg/mL Collagenase IV (Worthington), 10mM 
HEPES and 2% FCS. The mixture was slowly stirred for 15 min at 30°C, released cells 
removed and fresh enzyme mixture added for a total of 3 incubations. The remaining 
fragments were digested with a mixture of Collagenase IV and Neutral Protease 
(0.2 mg/mL each; Worthington), 25 mg/mL DNaseI (Roche), 10 mM HEPES and 2% 
FCS in RPMI1640. Five incubations for 25 min at 37°C were performed. For DC and 
macrophage isolation all cells from the collagenase incubations and the first round of 
collagenase/neutral protease digestion were pooled, washed and rosettes dissociated by 
5 min incubation at 37°C in PBS containing 25mM EDTA. Cells were stained with anti-
CD11c microbeads (Miltenyi Biotec), run on an AutoMACS (Miltenyi Biotec) using 
the “Possel_S” program, blocked with anti-FcR mAb 2.4G2 supernatant including 5 % 
rat serum and stained with anti-CD11c-PE (clone HL3; BD), anti-F4/80-FITC (clone 
CI:A3-1; Serotec) and PI. Thymic epithelial cells were enriched by pooling cells from 
collagenase/neutral protease digestion rounds two to five, followed by staining with 
anti-CD45 microbeads (Miltenyi Biotec), run on an AutoMACS using the “Deplete” 
program, blocked with anti-FcR mAb 2.4G2 supernatant and stained with anti-Ly51-
FITC (clone 6C3; BD), anti-CD80-PE (clone 16-10A1; BD), anti-EpCAM-Alexa 647 
(clone G8.8; BD), anti-CD45-PECy5 (clone 30-F11; BD) and PI. Dendritic cells were 
identified as CD11c+F4/80- and macrophages as CD11c-/lo and F4/80+. mTECs were 
identified as CD45-Ly5.1-EpCAM+ and sorted according to their CD80 expression, as 
CD80hi or CD80lo, representing the top and bottom 30% of the population. Cell sorting 
was performed with a FACSAriaI cell sorter (Becton Dickinson).
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Figure S1. Expression levels of Trh4 on RMA and RMA-S cell targets. RMA and RMA-S targets 
were transduced with Trh4 (RMA.Trh4, RMA-S.Trh4) or an empty vector (RMA.LZRS, RMA-S.
LZRS) to over-express the Trh4 protein. Trh4 expression levels were determined by quantitative PCR 
with specific primers. The expression of a natural splice variant which does not encode the C-terminal 
peptide MCLRMTAVM was included as control. Trh4 expression levels were normalized with β2m 
housekeeping gene and expressed relative to RMA sample. Means and standard deviations of triplicates 
are shown from one out of three independent experiments.
Figure S2. The presentation of Trh4 peptide in cells over-expressing the Trh4 protein is 
independent of proteasome activity. RMA.Trh4 cells were submitted to mild acid treatment to strip 
surface MHC-I molecules and then recovered in the presence of the proteasome-specific inhibitor 
epoxomicin. Target cells were tested for CTL recognition overnight and percentage CTL producing 
IFNγ was determined by flow cytometry. Control CTL (right panel) recognize the gag leader peptide 
CCLCLTVFL, which is TAP- and proteasome-dependent45. Means and standard deviations of triplicates 
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Figure S3. Relative mRNA expression of Trh4 and gag on TAP-positive and –negative cell targets. 
The expression levels of Trh4 and the MuLV-derived gag polyprotein were determined by quantitative 
PCR with specific primers. RMA and RMA-S are MuLV-induced T cell lymphomas. We compared the 
expression of gag, which produces a CTL epitope, with the expression of Trh4 on these targets and on 
an RMA-derived cell line that overexpressed Trh4. Trh4 and gag expression levels were normalized with 
GAPDH housekeeping gene and expressed relative to Trh4 splice variant for each sample. Means and 
standard deviations of triplicates are shown from one out of two independent experiments.
Figure S4. Trh4 peptide is presented on dendritic cells with increased Trh4 expression. D1 dendritic 
cells were transduced with a retroviral construct containing Trh4 long transcript (D1.Trh4) or an empty 
vector (D1). Immature dentritic cells or matured with LPS for 24 hours were incubated with Trh4-specific T 
cell clone. Activation of T cells was measured by IFNγ production on supernatants after overnight incubation 
with targets. Two fold serial dilutions of targets were performed starting at 5,000 and represented by grey scale 
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 | ABSTRACT
The signal peptide peptidase (SPP) is an intra-membrane cleaving aspartyl protease 
involved in release of leader peptide remnants from the ER membrane, hence its name. 
We now found a new activity of SPP that mediates liberation of C-terminal peptides. In 
our search for novel proteolytic enzymes involved in major histocompatibility complex 
class I (MHC-I) presentation, we found that SPP generates the C-terminal peptide-
epitope of a ceramide synthase. The display of this immunogenic peptide/MHC-I 
complex at the cell surface was independent of conventional processing components like 
proteasome and peptide transporter TAP. Absence of TAP activity even increased the 
MHC-I presentation of this antigen. Mutagenesis studies revealed the crucial role of the 
C-terminal location of the epitope and ‘helix-breaking’ residues in the transmembrane 
region just upstream of the peptide, indicating that SPP directly liberated the minimal 
9-mer peptide. Moreover, silencing of SPP and its family member SPPL2a led to a general 
reduction of surface peptide/MHC-I complexes, underlining the involvement of these 
enzymes in antigen processing and presentation. 
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 | INTRODUCTION
All nucleated cells of our body display a representative selection of the cellular proteome 
in Major Histocompatibility class I (MHC-I) molecules at their surfaces. This wide 
array of peptides serves as ligands for CD8+ T-cells for cellular immunity. The process 
of peptide presentation starts with the proteolysis of aged or misfolded proteins, a 
process mainly executed by the multi-catalytic action of proteasomes. The generated 
peptide sequences are translocated from the cytosol into the ER by the TAP peptide 
transporters, where they are assembled with different MHC-I molecules with help from 
members of the peptide loading complex, including calreticulin, tapasin and ERp57. 
Stable peptide/MHC-I complexes are routed to the cell surface. This proteasome-TAP 
pathway is considered as the conventional processing route, used to generate and shuttle 
the majority of peptides1-3. Additional players, like tripeptidyl peptidase II (TPPII) and 
nardilysin are responsible to further shorten proteasomal intermediates or, sometimes, to 
directly generate minimal peptide sequences that fit in MHC-I molecules4, 5.
Although these central elements of the conventional antigen processing pathway 
are important for the mainstream of peptides, substantial MHC-I antigen presentation 
is still detectable on cells in which the function of key components is compromised. 
For example, deficiency in the peptide transporter TAP, which can be regarded as a 
bottleneck in the pathway, results in a decreased surface MHC-I, but the residual peptide 
repertoire is sufficient to generate a diverse CD8+ T cell subset in mice6-8 and man9, 10. 
Importantly, this T cell repertoire is capable to control common viral infections and from 
some TAP-deficient patients TCRαβ+ CD8+ T-cell clones were isolated that recognized 
TAP-independent viral antigens11, 12. Therefore, TAP-independent processing pathways 
may sufficiently compensate for the loss of the conventional route in order to select a 
functional CD8+ T-cell repertoire in these patients. 
This reasoning is in line with our recent findings on a novel category of T cell epitopes 
presented by cancer cells with TAP-defects. We showed that deficiency in the expression 
of the peptide transporter TAP, a feature frequently found in human cancers, leads to the 
presentation of a broad repertoire of immunogenic peptides by MHC-I13-17. Biochemical 
characterization of peptide repertoires from TAP-deficient cells and their direct proficient 
counterparts indeed revealed unique complementing pools of peptides14, 18, 19.
Two pathways for TAP-independent peptide loading are described thus far20. One 
of these is active in the secretory route of the Golgi and is mediated by the protein 
convertase furin21-23. The other concerns N-terminal leader sequences, which are 
liberated after arrival in the ER by the signal peptidase (SP). Cleavage by SP leaves small 
transmembrane leader peptide remnants in the ER membrane, which are removed by the 
intramembrane-cleaving signal peptide peptidase (SPP). The ER-directing parts of these 
peptides end up in the lumen of the ER and can be loaded unto MHC-I molecules24, 25. An 
immunogenic human tumor antigen from the leader sequence of calcitonin is released by 
this means and TAP is dispensable for its presentation on cancer cell lines26, 27. 
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In the current study we reveal the processing pathway of a C-terminal peptide from  the 
ceramide synthase Trh4 (also known as CerS5). This protein resides in ER membranes and 
docks its C-terminal epitope-containing tail into the bilayer. Intramembrane proteolysis 
by SPP just in front of the epitope resulted in liberation and TAP-independent loading on 
Db molecules. This represents a novel role for SPP, acting independently from the signal 
peptidase (SP). Our data indicate that SPP is able to directly liberate minimal peptide-
epitopes from the C-terminus of proteins by intramembrane proteolysis and underlines 
the involvement of this enzyme in antigen processing.
 | RESULTS
The TAP-independent processing pathway of the Trh4-derived peptide 
is common and conserved
The Trh4-derived peptide MCLRMTAVM is presented by the MHC class I molecule 
H-2Db on TAP-deficient tumor cells17. We were interested in the nature of its TAP-
independent processing pathway that leads to the generation and surface presentation of 
the Trh4 peptide in Db, and therefore, analyzed the generality of this antigen processing 
pathway in different mouse and human tumor cell lines (Fig 1). Four mouse tumor cell 
lines of different origin and containing a TAP defect (a lymphoma, a fibrosarcoma, a colon 
carcinoma and a melanoma) were analyzed for recognition by a previously established 
MCLRMTAVM-specific CD8+ T-cell clone. These T cells efficiently recognized all TAP-
deficient tumors, irrespective of their tissue origin (Fig 1A). Importantly, the different 
mechanisms underlying the TAP impediment in these tumors, being TAP2 mutation (in 
RMA-S), TAP1 gene loss (in MCA), expression of a small viral inhibitor (in MC38) or 
TAP2 gene loss (in B78H1), all led to efficient presentation of the Trh4-derived peptide, 
indicating that presentation of the Trh4 peptide is related to TAP-deficiency as such and 
not to a specific molecular mechanism. The fact that TAP-positive counterpart tumors 
presented much lower Trh4 peptide at their cell surface was not surprising, since we 
previously showed that restoration of TAP function decreases Trh4/Db complexes at the 
cell surface, most likely due to competition28. Therefore, the Trh4 peptide presentation is 
TAP-independent and operates in different tumor types. 
The degree of CTL recognition of the tumor cell lines varied and we wondered if these 
differences could be explained by Trh4 expression levels. Trh4 transcripts were quantified 
by qPCR and indeed revealed higher expression in the lymphoma RMA-S compared to 
the solid tumors (Fig 1B). Expression of a splice variant of Trh4, which does not contain 
the Db-binding peptide, showed less variety in the tumor panel. We concluded that surface 
display of Trh4/Db complexes is determined by TAP function, Trh4 protein levels and 
possibly other factors like the protease responsible for peptide liberation.
We also wanted to know if human cells were equipped with the TAP-independent 
processing pathway. The mouse Trh4 gene was introduced into the human cell lines 






















































































































Trh4 Trh4 splice variant
Figure 1. The Trh4 processing pathway is conserved and broadly active. (A) Presentation of 
Trh4-derived peptide by MHC-I was evaluated on lymphoma (RMA), fibrosarcoma (MCA), colon 
carcinoma (MC38) and melanoma cells (B78H1.Db). Activation of Trh4-specific T cells is enhanced by 
the absence on peptide transporter TAP. (B) mRNA expression of Trh4 and a natural Trh4 splice variant 
was determined by quantitative PCR. The splice variant does not encode the Th4 peptide sequence due 
to a frame-shift. One out of three comparable experiments is shown. (C) Human 293T and HeLa cells 
were transfected with mouse Trh4 and H-2Db genes and used as targets. Mean and standard deviation of 
triplicates are shown from one out of three experiments.
this peptide. The Trh4-derived peptide was efficiently presented at the cell surface of 
both human lines, indicating that the involved processing pathway was indeed also active 
in human cells (Fig 1C). Although these human cells have intact TAP function and 
thereby impede Trh4 peptide presentation, the high expression levels of Trh4 protein, 
from strong heterologous promoters overcomes the competition of peptides from the 
proteasome-TAP pathway, as illustrated by efficient CTL recognition of TAP-positive 
RMA lymphoma cells in which Trh4 is expressed eight hundred times higher than the 
endogenous level28. Together, these data show that the TAP-independent processing 
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pathway that generates the Trh4 peptide is a common and conserved mechanism 
operational in mouse and human tumor cell lines of different histological origins.
The Trh4 protein is localized in the membrane of the endoplasmic reticulum
To unravel the processing pathway of the Trh4-derived peptide, we next determined the 
cellular localization the Trh4 protein. The Trh4 protein (also known as CerS5) belongs to 
a family of ceramide synthases (CerS1 to CerS6) and exists in two isoforms as a result of 
alternative splicing of the transcript17. The shorter protein variant (UniProt Q9D6K9-2) 
contains the Db-presented peptide MCLRMTAVM at the complete end of its C-terminus. 
The longer protein (UniProt Q9D6K9-1) lacks this peptide sequence due to a frame shift 
at the last intron-exon boundary17. Although the longer isoform was described to be a 
multi-transmembrane spanning protein in the endoplasmic reticulum32, no data were 
available concerning the Trh4 variant comprising the peptide-epitope. Algorithm programs 
predicting topology of transmembrane proteins anticipated that the short Trh4 protein 
would transgress membranes seven times with the C-terminal amino acids 373-384 located 
within the lipid bilayer, directed towards the lumen (Fig 2A). The V5 antibody epitope was 
introduced at two distinct sites of Trh4 gene constructs (C-terminal after the epitope and 
N-terminal at amino acid 32) and subcellular localization studies were performed using 
confocal microscopy. We observed a strong and clear co-localization with ER markers, but 
not with the Golgi with both constructs (Fig 2B for N-terminal tag and Suppl Fig 1A for 
C-terminal tag). ER co-localization was also observed in TAP-negative cells (Suppl Fig 1B). 
An intermediate degree of co-localization with mitochondria was found (Fig. 2B). It is 
known that the CerS1, CerS2 and CerS6 ceramide synthases can indeed be detected in 
mitochondria33, but, alternatively, this mitochondria co-localization might merely reflect 
ER membranes that are in close proximity of mitochondria. These data indicate that 
Trh4 is a multimembrane spanning protein in ER membranes and that its C-terminal tail, 
comprising the epitope, docks into this membrane directing towards the ER lumen.
Inhibitors of intramembranous aspartyl proteases prevent peptide liberation
Next, we investigated which family of proteases was responsible for the proteolytic 
cleavage of Trh4 resulting in liberation of the C-terminal peptide. An array of inhibitors 
blocking hydrolysis by different classes of proteases were applied in a recovery assay 
in which TAP-deficient RMA-S cells were briefly acid stripped to remove cell surface 
MHC-I and allow for re-emergence of Trh4/Db peptide complexes. Complete recovery 
of Trh4/Db was reached within six hours, as determined with a peptide-specific T cell 
clone (Fig 3A). This highlighted a continuous and efficient supply of Trh4 peptide from 
this alternative processing pathway. Two enzymes were likely candidates, since they were 
described to result in TAP-independent peptide loading: signal peptidase and furin20, 21. 
However, the specific inhibitors DCI and Dec-RVKR-CMK, respectively, failed to impair 
the generation of Trh4/Db complexes (Fig 3B), indicating that Trh4 processing is mediated 
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Figure 3. The Db-presentation of the Trh4-derived peptide is generated by intramembrane-cleaving 
aspartyl proteases. (A) Recovery kinetics of Trh4/Db complexes on TAP-deficient RMA-S cells after 
brief stripping with mild acid buffer. Cells were tested with Trh4-specific T cell clone in intracellular 
IFN-γ staining. (B) Recovery efficiency of Trh4/Db complexes was tested in the presence of an array of 
protease inhibitors. Inhibitors of proteasome and enzymes known to be involved in TAP-independent 
processing pathways, (C) inhibitors of calpain family, (D) all other tested inhibitors. (E) TAP-deficient 
fibrosarcoma MCA cells were tested with inhibitors for aspartyl proteases. (F) Concentration range of 
the functional inhibitor (z-LL)2-ketone and (G) DAPT on RMA-S cells. Trh4-specific T cells (filled 
bars) were used and control T cells (open bars) that recognize an independent Kb-presented peptide 
on RMA-S. All panels show compiled means and standard deviations from at least three independent 
experiments, setting the recovered cells at 100%.
increased Trh4/Db complexes (Fig 3B), suggesting that the proteasome somehow acts as 
a competitor for the novel processing mechanism28. 
Next, we observed that the common calpain inhibitor calpeptin partly decreased Trh4 
presentation at relatively high concentrations (> 20 uM) (Fig 3C and Suppl Fig 2A). The 
main targets for calpeptin are calpain 1 and calpain 2. We determined the expression of 
these two calpain members in RMA-S cells and observed that calpain 2 was expressed 
but calpain 1 was not detectable (Suppl Fig 2B). Therefore, we silenced the expression of 
calpain 2, but this did not lead to reduced Trh4/Db peptide complexes at the cell surface 
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(Suppl Fig 2C-D). Furthermore, more selective inhibitors for the calpain family did not 
affect the CTL response, collectively suggesting that the marginal blocking effect by 
calpeptin was based on cross-reactivity to other proteases (Fig 3C). 
We then continued the screen with several other classes of chemical inhibitors targeting 
serine-, cysteine-, aspartyl- and metallo-proteases, and aminopeptidases (Fig 3D). The 
results revealed two inhibitors for aspartyl proteases, (z-LL)2-ketone and DAPT, that 
strongly decreased presentation of the Trh4-derived peptide. Importantly, none of the other 
eight protease inhibitors influenced the Trh4/Db presentation, suggesting that the involved 
aspartyl protease was necessary and sufficient. The inhibitory effect was also observed when 
we tested fibrosarcoma cells, indicating that the inhibition was not cell-type restricted (Fig 
3E). Titration of the two active compounds demonstrated a 50% decrease at concentrations 
in the lower range in this cellular assay, 300 nM for (z-LL)2-ketone and 5 uM for DAPT (Fig 
3F and G). These concentrations were clearly not toxic for the target cells and, moreover, 
recognition of treated RMA-S cells by control T cell clones specific for another peptide 
epitope was unaltered, excluding a general defect in the MHC class-I presentation capacity 
by (z-LL)2-ketone and DAPT (Fig 3F and G). These two compounds were known to target 
aspartic acid proteases that are located within membranes, particularly members of the 
signal peptide peptidase (SPP) family34, 35. Interestingly, calpain inhibitors were shown to 
block the action of SPP at higher concentrations, corroborating our findings in the screen 
with calpeptin (Fig 3C)36. Together, these results let us conclude that the liberation of the 
C-terminal Trh4 peptide within the ER membrane is part of a novel processing pathway for 
TAP-independent peptides and is distinct from the previously described routes.
Signal Peptide Peptidase is responsible for the processing of  
the C-terminal peptide
The SPP family is also known as intramembrane-cleaving proteases (I-CLiPs) of the 
aspartyl type and this family is involved in many biological processes, including cell 
proliferation, differentiation and immunity34, 37, 38. SPP and SPPL3 were reported to 
be localized in ER membranes, forming catalytic cavities in which hydrolysis can take 
place within membranes39. We first analyzed the expression of the family members at 
mRNA level in the tumor cell lines active in Trh4 peptide processing (Fig 4A). All family 
members were expressed to varying degree in this cell panel, except SPPL2c, which was 
hardly detectable. High levels of SPP were measured in all cells. Differences in expression 
levels in the tumor cell panel prompted us to profile transcripts of these genes in normal 
mouse tissues, especially since this information is lacking in the current literature (Suppl 
Fig 2E). RNA extracts from whole mouse organs were analyzed for these intramembrane 
aspartic peptidases and a general low expression for SPPL2b and SPPL2c was found. 
Similar expression profiles were seen for SPP, SPPL2a and SPPL3 in that thymus and 
brain contained low transcript numbers and lung was high (Suppl Fig 2E). 
Next, we wanted to determine which family member was responsible for the liberation 
of the C-terminal Trh4 peptide in tumor cells and silenced each gene individually using 
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short hairpin RNA constructs. SPPL2c was not included in this analysis, since it was not 
expressed in the tumor cells (Fig 4A). Efficiency of gene silencing was approximately 
50-60% for all genes and, importantly, the shRNA constructs were specific in that the 
other members were not targeted (Fig 4B). We then used this cell panel to determined 
effects on recognition by Trh4-specific CTL. Downregulation of SPP clearly decreased 
the recognition by these CTL (Fig 4C). Similar decrease of Trh4 peptide presentation 
was observed in TAP-negative MCA fibrosarcoma cells (Suppl Fig 2F-G). Silencing 
of the other SPP family members resulted in a marginal variation of CTL recognition 
(Fig 4C). The presentation of the Trh4 peptide was not completely blocked by SPP 
silencing, most likely due to a substantial residual expression of the protease. The residual 
CTL recognition could furthermore be blocked by (z-LL)2-ketone, supporting this 
notion. Importantly, an independent other peptide-epitope presented by RMA-S was 
not affected by SPP silencing (Fig 4D). These data and the fact that SPP is expressed 
in all mouse cells that naturally display Trh4/Db complexes and the ER localization of 
Trh4 substantiate the conclusion that the SPP enzyme is crucial for the processing of the 
C-terminal peptide-epitope of Trh4 in a TAP-independent way. 
The transmembrane region directly upstream of the Trh4 peptide is 
crucial for Trh4 processing
To study the underlying mechanism of Trh4 peptide processing in detail and to determine 
critical regions for the proteolytic process, extensive mutagenesis analysis of Trh4 was 
performed. First, some larger segments at the N- and C-terminus of the protein were 
deleted. Removal of the first 32 aa did not diminish the processing efficiency of the peptide-
epitope (Fig 5A), whereas we hypothesized that this region functioned as a leader sequence 
routing the protein to the ER, as indeed was predicted by the online SignalP 4.1 Server 
(www.cbs.dtu.dk). Confocal microscopy analysis however confirmed that this construct 
was still localized in ER (Suppl Fig 1C). We then removed segments located near the 
C-terminus, starting with the sequence corresponding to amino-acids 340-374, which is a 
cytosolic loop located between the two last transmembrane domains (see Fig 2A). We did a 
progressive deletion in this construct comprising the upstream amino-acids 315-330, which 
includes most of the second last transmembrane domain. However, none of these large 
deletions decreased Trh4 peptide processing (Fig 5A). In order to exclude the possibility 
that these altered constructs delivered defective and thus proteasome-targeted proteins, 
we confirmed that the Trh4 peptide presentation from these mutant constructs was still 
(z-LL)2-ketone and DAPT dependent (Fig 5B). Then, nine amino-acids just upstream of 
the C-terminal peptide were removed. This resulted in a more than 60% impairment of 
CTL recognition (Fig 5A), indicating that this intramembrane stretch, just upstream of the 
peptide-epitope was critical for SPP cleavage. Furthermore, the C-terminus was extended 
by cloning small V5-containing tags of 14 and 47 amino-acids. Although these proteins 
were properly expressed, as tested by western blot (Suppl Fig 3A), and were localized in the 
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Figure 4. The intramembrane-cleaving signal peptide peptidase is involved in Trh4 processing. 
(A) mRNA expression of SPP, SPPL2a, SPPL2b, SPPL2c and SPPL3 genes was determined by qPCR 
in tumor cell panel. (B) Silencing of SPP family members in RMA-S cells was reached by lentiviral 
transfer of shRNA constructs. Empty shRNA vector served as control. Efficiency and specificity of 
downregulated levels is shown as measured by qPCR. (C-D) Cell panel with silenced single SPP family 
members was tested for recognition by Trh4-specific T cells (C) or control T cells (D) reactive to the 
independent Kb-presented peptide mi3 by RMA-S. Mean and standard deviation from one out of three 
experiments is shown. Difference between SPP and control vector is statistically significant (p<0.001, 
two way Anova test). Similar data were obtained in the fibrosarcoma cell line (Suppl Fig 2F-G).
57
3

































# 1 aa375 106...WWQLDSIILCMCLRMTAVM
# 6 aa377 82...WWQLDSSIACMCLRMTAVM
# 3 aa378 62...WWQLDSSILGMCLRMTAVM
# 5 aa374/375/378 109...WWQLDIIILGMCLRMTAVM
# 2 aa374-375 99...WWQLDIIILCMCLRMTAVM
# 7 aa376-377 38...WWQLDSSAACMCLRMTAVM
# 8 aa376-378 27...WWQLDSSAAGMCLRMTAVM
# 9 aa375-378 18...WWQLDSIAAGMCLRMTAVM
# 10 aa374-378 14...WWQLDIIAAGMCLRMTAVM


































































































































that the C-terminal location of the peptide in the Trh4 protein is crucial for its liberation. 
Failure to process the Trh4 peptide when it was not at the complete C-terminus might be 
related to the absence of carboxyl-peptidases in the ER and suggests that the SPP cleavage 
products do not travel through the cytosol. Furthermore, we also tested if the C-terminal 
region would function as a leader sequence for the Trh4 protein, but removal of the last 20 
amino-acids (aa368-387) did not change its subcellular localization (Supp Fig 1D). We 
therefore concluded that Trh4 peptide is directly liberated by SPP from the mature protein 
after which the peptide is available in ER for loading into MHC-I molecules.
Figure 5. The intramembrane region directly upstream of the Trh4 peptide is crucial for processing. 
(A-B) Trh4 constructs with deletions or extensions were tested for liberation and MHC-I presentation of 
the C-terminal peptide-epitope (aa379-387). (A) DNA plasmid constructs were transiently transfected 
into HeLa cells together with the mouse Db gene. Extend of IFN-γ release by T cells was quantified 
and scored as “+++” (wild-type construct, 100%), “++” (50-90%), “+” (10-50%) and “-“ (<10%). (B) 
Processing from mutant constructs was still sensitive for the protease inhibitors (z-LL)2-ketone and 
DAPT. All constructs were tested at least four times. (C-D) Site-directed mutagenesis directly upstream 
of the C-terminal peptide-epitope of the Trh4 gene. (C) The amino-acid substitutions and the position 
of the amino-acids in the protein are indicated. Degree of T cell recognition was quantified based on 
‘area under the curve’ values of line graphs as shown in (D). Compiled means and standard deviations 
of at least three independent experiments is shown in Suppl Fig 3B.
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The importance of the direct upstream amino-acids of the Trh4 peptide suggested that 
the SPP cleavage site was located within this last membrane region (aa374-387). Single 
amino acid substitutions were introduced using site-directed mutagenesis to determine 
the precise requirements for cleavage by SPP. Several publications demonstrated the strong 
preference of SPP for substrates with helix-destabilizing residues in their transmembrane 
domain40-42. Amino-acids like asparagine, serine and cysteine disturb a perfect alpha-
helical conformation of the transmembrane domain and are therefore referred to as 
‘helix-bending’ or ‘helix-breaking’ residues. Three of such amino-acids are present in the 
Trh4 membrane region: two serines (aa374 and 375) and one cysteine (aa378) (Fig 5C). 
First, the two serines were replaced by isoleucines, which strongly contribute to a perfect 
alpha-helical structure. In contrast to our expectations, these mutations did not affect Trh4 
presentation at all (Fig 5C and D; SDM #2). Second, the cysteine residue (aa378) in front 
of the epitope was substituted for a glycine (SDM #3), which still has some helix-breaking 
capacity, or an isoleucine (SDM #4), which removes the helix-breaking nature. These 
alterations had a very strong impact on peptide liberation and the C378I construct nearly 
completely failed to produce the Trh4 peptide. Third, we combined the cysteine mutation 
C378G with the serine mutations and surprisingly found that introduction of two 
isoleucines improved the Trh4 processing (Fig 5C and D; SDM #5), indicating that the 
more upstream serine residues were actually counterproductive for optimal SPP cleavage 
and support the importance of the cysteine residue directly upstream of the epitope. 
Fourth, we progressively substituted the complete stretch of amino-acids in this region also 
using alanines which are considered to promote helix-destabilization43. Collectively, these 
constructs displayed a clear gradual decrease in peptide presentation (Fig 5C and Suppl 
Fig 3B). Together, these data point to the importance of the cysteine directly upfront of the 
epitope, most likely marking the actual SPP cleavage site and suggest that nearby flanking 
residues indirectly influence this process via conformational change in the intramembrane 
alpha-helix. In line with this hypothesis is the finding that presentation of the Trh4 peptide 
does not depend on the N-terminal trimming peptidase ERAAP (Fig 3D), suggesting that 
the minimal 9-mer epitope is directly generated by SPP cleavage without further need 
for C-terminal nor N-terminal trimming. The C-terminal liberation of this CTL peptide-
epitope by the aspartyl protease SPP within the ER membrane exemplifies a novel way by 
which TAP-deficient cells are still able to present a diverse antigen repertoire.
Contribution of SPP protease family to MHC-I peptide repertoire of TAP-
negative cells
We further examined the contribution of the SPP family of proteases to the overall 
MHC-I presentation of TAP-deficient cells. We analyzed the surface display of the 
two alleles of this mouse strain, Db and Kb, on RMA-S cells in which individual SPP 
members were silenced by shRNAs. SPP and SPPL2a silencing resulted in reduction of 
Kb molecules to 77% and 65% of control, respectively (Fig 6). The presentation of Db 
molecules on these cells and MHC-I surface display on RMA-S cells in which SPPL2b 
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Figure 6. Silencing of SPP and SPPL2a leads to decrease in surface MHC-I. MHC-I surface display 
of RMA-S cells expressing shRNA constructs for SPP, SPPL2a, SPPL2b and SPPL3 was measured by 
flow cytometry (Kb and Db molecules separately). Percentages in the upper right corners reflect the 
residual MHC-I expression compared to control cells (‘vector’), based on mean fluorescence intensity. 
Data are representative for three independent experiments.
and SPPL3 were silenced, was not affected (Fig 6). These data underline the involvement 
of intra-membrane cleaving proteases in antigen processing, although precise underlying 
mechanisms remain to be elucidated. 
 | DISCUSSION
Studies with TAP-deficient cells showed that peptides can still gain access to MHC-I 
molecules, although with much lower efficiency. This peptide repertoire is different from 
that of processing-intact cells, indicating that alternative processing pathways partly 
compensate for a defective conventional route based on proteasome and TAP14, 18, 19. 
The processing mechanisms that lead to presentation of TAP-independent peptides are 
poorly characterized. Here we describe a new mechanism that leads to liberation of a 
C-terminal peptide-epitope from the ER membrane-spanning Trh4 protein. We found 
that the intramembrane-cleaving enzyme SPP was responsible for the cleavage event at 
the direct upstream region of the T cell epitope within the lipid bilayer. We speculate 
that SPP activity in the ER membrane is sufficient to liberate the minimal 9-mer peptide 
and release of this peptide into the ER lumen. Additional N-terminal trimming of the 
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cleavage product is unlikely, since inhibitors of amino-peptidases did not prevent Trh4 
peptide presentation and the cysteine just upfront of the 9-mer epitope appeared to be 
critical in the SPP cleavage process (see Fig 3 and 5C). Moreover, direct release of the 
liberated peptide into the ER lumen is very likely, due to the type II transmembrane 
orientation of the Trh4 protein tail (see Fig 2A) and the fact that the epitope is located 
at the very C-terminal end of the protein. The incompetence of C-terminally extended 
versions of Trh4 to present the peptide (see Fig 5A) corroborate the idea that the peptide 
is directly released in the ER lumen where it needs a free C-terminus for loading into 
MHC-I molecules. The exact peptide loading mechanism of the Trh4 membrane peptide 
however remains to be determined.
The involvement of SPP in the C-terminal processing of a transmembrane protein 
initially surprised us. The activity of SPP was thus far largely related to the removal of small 
trunks of signal-sequence-derived transmembrane peptides from the ER membrane34, 37, 42. 
The processing of leaders from nascent proteins requires a first cut by signal peptidase 
(SP), after which the remaining transmembrane stretch is cut in two parts by SPP. 
However, the liberation of the Trh4 peptide did not require SP activity, since its inhibitor 
DCI did not prevent the presentation of the epitope. Furthermore, the Trh4-peptide is 
not part of a signal sequence and removal of the N- or C-terminal domain did not route 
the Trh4 protein to a different subcellular localization (see Suppl Fig 1C-D). Nevertheless, 
the involvement of SPP with Trh4 cleavage fits with the strong preference for type II 
membrane segments and with the ‘helix-breaking’ residues that are often found in SPP 
target proteins25, 41, 42. Therefore it seems that the role of SPP is more extended than the 
release of transmembrane leader-sequences form the ER membrane. Interestingly, it has 
been suggested that SPP is physically associated with misfolded membrane proteins44, 45 
and as such might function as a chaperone to dispose membrane aggregates. 
The Trh4-derived peptide is an example of TAP-independently processed peptides. 
This particular SPP-mediated processing pathway is operational in TAP-negative as well 
as TAP-positive cells (see Fig 1) and also in tumor as well as healthy cells28. Therefore, 
the TAP-independent pathway described here seems to be part of the “normal activity” 
of cells and does not represent a disease-related feature. Over the years, some other TAP-
independent pathways have been characterized. They comprise peptides generated in the 
secretory and vesicular compartments by the protein convertase furin22, 23. Second, leader 
sequence derived peptides are frequently TAP-independently processed24. Peptides 
that arrive in the ER via this way overcome the need of TAP transport. Interestingly, 
TAP-independent processing was observed earlier using several C-terminally tagged 
constructs of ER-targeted proteins, feeding the speculation on a common ‘C-terminal’ 
processing rule46, 47. We hypothesize that SPP might be a central player for this category 
of TAP-independent antigen processing.
The family of intramembrane-cleaving aspartyl proteases (SPP family and presenilins) 
have important biological roles in signal transduction, cell differentiation and immunity25, 48. 
For instance, SPPL2a and SPPL2b were shown to be responsible for the release of the 
61
3
New role for signal peptide peptidase
TNF-α intracellular domain, leading to expression of the pro-inflammatory cytokine IL-12 
in dendritic cells38 and also for the release of the intracellular domain of fasL in T cells49. 
These proteases are mainly located in the vesicular pathway and at the cell surface. Recently, 
SPPL2a was reported to be involved in the proteolysis of the invariant chain (CD74) and 
thereby critical for the development and survival of B-cells and DCs50-52, maybe explaining 
the effect we found on MHC class I expression (Fig 6). We now extend on the involvement 
of SPP family members in immunity by showing their role in alternative pathways of 
MHC-I antigen processing, thereby enabling T cell immune responses.
 | MATERIAL AND METHODS
Cell lines
The mouse tumor cell lines RMA, RMA-S (TAP2-deficient), MCA (TAP1-deficient), MC38, 
B78H1 (TAP2-deficient) and human HeLa and 293T have been described previously14, 17, 28. 
Where indicated, cell lines were transfected with H-2Db or Trh4 genes (accession numbers: 
gene BC043059 (www.ncbi.nlm.nih.gov/nuccore), protein UniProtKB Q9D6K9-2 (www.
uniprot.org/uniprot) via retroviral transduction using the LZRS vector containing GFP 
behind an internal ribosome entry site16. The mouse TAP genes were introduced into MCA 
and B78H1 cells by gene transfer. MC38.UL49.5 cells contain the UL49.5 gene from the 
Bovine Herpes Virus-1 which blocks mouse TAP activity16, 29. 
Generation and culture of CD8+ T cell clones used in this study were previously 
described: Db-restricted CTL clone B5 specific for the TAP-independent Trh4 peptide 
(MCLRMTAVM); Kb-restricted CTL clone mi3 specific for a yet unknown TEIPP 
peptide and the Db-restricted CTL clone 1 specific for the TAP-dependent MuLV gag-
leader peptide (CCLCLTVFL)16, 17, 30.
All cells were cultured in complete IMDM medium (Invitrogen, Carlsbad, CA) 
containing 8% heat-inactivated FCS, 100 U/ml penicillin, 100 μg/ml streptomycin 
(Life Technologies, Rockville, MD), 2mM L-glutamine (Invitrogen) and 30 μmol/L of 
2-mercaptoethanol (Merck, NJ, USA) at 37°C in humidified air with 5% CO2. 
Protease inhibitor experiments
Cells were resuspended in X-vivo medium (Lonza) supplemented with 0,5% of BSA 
and incubated with protease inhibitors for 1h at 37°C, under continuous mixing. Cells 
were incubated for 2-4 min with mild acid citrate/phosphate buffer (pH 3.1) at room 
temperature to disrupt MHC class I/peptide complexes28. Cells were washed twice and 
incubated with protease inhibitors for additional 6h under the conditions mentioned 
above and then treated with brefeldin A. Inhibitor-treated cells were then incubated with 
the indicated T cell clones for 18h in the presence of brefeldin A and intracellular stained 
for IFNγ production28. Chemical inhibitors used in these assays are: epoxomicin (1µM, 
Sigma-aldrich), 3,4-Dichloroisocoumarin (5µM, Sigma-aldrich), Decanoyl-RVKR-CMK 
(10µM, Merck), calpeptin (30µM, Merck), calpain inhibitor IV (13µM, Merck), calpastatin 
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Table I. Primer sequences for quantitative PCR for the mouse SPP family.
Name Gene ID Forward primer (5’->3’) Reverse primer (5’->3’) Size (bp)
SPP 14950 CAGGATCTGCTGGAGAAG GAAGTAGGTGTGCGTGTT 138
SPPL2a 66552 CTGATGGCATAAGGAACAAG GAGGAAGGAATTAGGACACT 133
SPPL2b 73218 CATTGCCTTCTGCCTGTA GATGCTGTTGCCACTCTT 142
SPPL2c 237958 TGCATTGCCTCTGCTGTGGGC TGTGGCCCTCTGGACTCGTGG 181
SPPL3 74585 TCGCTATGACAACTACAAGA GCAGTGGAAGTAGGAGAC 93
peptide (10µM, Merck), PD151746 (50µM, Santa Cruz Biothecnology), PD150606 
(50µM, Santa Cruz Biothecnology), butabindide oxalate (400µM, TOCRIS Bioscience), 
captopril (100µM, Sigma-aldrich), leupeptin (100µM, Merck), (z-LL)2-ketone (5µM, 
Merck), 1,10-Phenanthroline monohydrate (400µM, Sigma-aldrich), aprotinin (10µM, 
Merck), DAPT (10µM, Sigma-aldrich), Bestatin hydrochloride (100µM, Sigma-aldrich), 
z-vad-fmk (10µM, Merck), L-leucinethiol (60µM, Sigma-aldrich) and DL-Dithiothreitol 
(5mM, Sigma-aldrich). None of the inhibitors was toxic at the applied concentrations, as 
determined by trypan-blue counting and annexin-V staining. 
T-cell activation assays and flow cytometry
Intracellular cytokine staining of IFN-γ in T cell clones was performed for the protease 
inhibitor screen and expressed as percentage positive cells31. IFN-γ secretion by T-cell 
clones was measured by ELISA as previously published28. Data shown represent mean 
values obtained from triplicate test wells and error bars represent standard deviation of 
these values. Flow cytometry analysis of surface expression of Db and Kb molecules was 
performed using directly labeled anti-Db mAb (clone 28.14.8S; BioLegend, California, 
USA) and anti-Kb mAb (clone AF6-88.5, BioLegend). Cells were measured using a FACS 
Calibur and analysed with Flowjo software (Tree Star, Ashland, OR).
Quantitative PCR analysis
Total RNA isolation was performed using RNeasy Mini Kit (Qiagen, Maryland, USA). 
500 ng of purified total RNA was used to synthesize cDNA using High Capacity RNA-to-
cDNA Kit (Applied Biosystems, Foster City, USA). Quantitative PCR on two different 
transcripts of Trh4 was done using unique forward primers. Forward primer for the 
Trh4-epitope containing transcript 5’-GCAGACCCCTTACTGGAAGCTGC-3’ and for 
the short transcript 5’-TACATCACTGCGGTCATC-3’. Common reverse primer was 
5’-CTGCGGTCATCCTTAGACACCTTTCC-3’. The primers used to detect the expression of 
mouse transcripts from SPP, SPPLs and calpains were designed by us using the Beacon designer 
software and are listed in Supplementary Table 1 (calpain family) and Table 1 (SPP family). All 
primer sets were validated to be specific for the cognate genes by sequencing of the amplified 
PCR products. For the PCR reaction SensiMix™ SYBR No-ROX kit from GC Biotech Bioline 
(Alphen aan den Rijn, Netherlands) was used in a C1000™ Thermal Cycler (Bio-Rad, Hercules, 
CA, USA) and results were analysed using Bio-Rad CFX manager software.
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Confocal microscopy
Human HeLa cells or mouse MCA cells were plated in 12-wells plates on glass coverslips 
and transfected the next day with the indicated Trh4 gene constructs using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s protocol. After one day cells were 
stained with monoclonal antibodies: cells were fixed with methanol for 30 minutes at 
4˚C, washed with TBSB (TBS with blocking reagent from Boehringer Mannheim) and 
incubated for 1.5 hours at room temperature with the first antibody diluted in 500 μl 
TBSB. The antibodies used were anti-V5 (Invitrogen, R960-25), anti-Giantin (Abcam, 
ab24586) and anti-BIP (Abcam, ab21685). Cells were then washed again with TBSB 
and incubated with second antibodies; anti-rabbit-Alexa488 (Invitrogen, a11008) and 
anti-mouse-Alexa594 (Invitrogen, a11005) for 1.5 hours at room temperature. Finally, 
cells were washed with TBSB and the coverslips were put on microscope glass slides with 
5μl of ProLong Gold antifade reagent (Invitrogen) containing Hoechst (Enzo, Hoechst 
33342). The stained cells were imaged with a TCS SP5 fluorescent confocal microscope 
(Leica, Germany) using LAS AF software. Stained samples were observed at room 
temperature. All images were acquired with a 63X glycerol immersion objective lens NA 
1.4 (Leica). Analysis of colocalization was performed with LAS AF software (Leica).
shRNA treatment
MISSION® shRNA constructs specific for mouse SPP, SPPL2a, SPPL2b, SPPL3 and calpain 
2 were obtained from Sigma-Aldrich and lentiviral encapsulation was reached in HEK.293T 
cells via transfections with calcium phosphate (Promega) of pCMV-VSVG, pMDLg-pRRE, 
pRSV-REV and pLKO plasmid with puromycin resistance gene and a shRNA sequence or 
empty vector. RMA-S cells were incubated with lentivirus particles encoding shRNA and 
particles encoding GFP in a 10:1 ratio for 20h at 37°C. Then the cells were washed and 
resuspended in complete medium supplemented with 1µg/ml of puromycin and cultured 
for 4 days. GFP expressing cells were sorted and used in experiments.
Trh4 gene constructs
Length variants of Trh4 (deletions and extensions) were performed on the cloned cDNA 
(accession number BC043059) in pcDNA3.1 plasmid. C-terminal extensions were created 
by removing the stop codon of Trh4 in the pcDNA3.1/V5-His vector (Invitrogen, Life 
Technologies), resulting in the in frame encoding V5 antibody epitope. The deletion variants 
were based on an N-terminally tagged V5 construct in which the antibody site was introduced 
after nucleotide nr 96, which was supposed to be the leader sequence. We introduced a 
NOT-I restriction site at this place by creating two complementary PCR products, resulting 
in two altered amino acids at position 32-33 (from DL to AA). Then the 14 aa long V5 
sequence was introduced at this NOT-I site using long synthetic oligonucleotides including 
NOT-I overhangs. Orientation and sequence of this insert was validated by sequencing. This 
‘N-terminal’ tagged Trh4 construct was then used to create several deletion variants using 
PCR primer sets. All PCR amplifications were performed with Accuprime kit (Invitrogen). 
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Western blot
Cells were lysed in 1% Nonidet P-40 lysis buffer (50 mM Tris-HCl, 150 mM NaCl 
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Supplementary Figure 1. Trh4 localizes in the ER of TAP-proficient and TAP-deficient cells. 
Confocal microscopy images were taken from transfected cells with V5-tagged Trh4 constructs. Cells 
were co-stained with antibodies against BIP (ER), giantin (golgi) and mitofilin (mitochondria). 
Computer-assisted analysis was performed using LAS AF software to calculate colocalization. At 
least ten images were included of two independent experiments. (A) HeLa cells transfected with 
the C-terminally tagged Trh4 construct. (B) TAP-deficient MCA cells with the N-terminally tagged 
Trh4 construct. (C) HeLa cells expressing the Trh4 construct lacking the first 32 amino acids (Del #1 
construct from Fig 5A), which was predicted to constitute the leader sequence by the SignalP 4.1 Server 
(www.cbs.dtu.dk). V5 antibody tag was located at the C-terminus of this construct. (D) HeLa cells with 
a Trh4 construct in which the C-terminal amino acids 368-387, including the peptide-epitope, were 
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Supplementary Figure 2. Presentation of Trh4-derived peptide is not affected by calpain 2 
silencing, but is SPP-dependent. (A) RMA-S cells were incubated with the protease inhibitor calpeptin 
at the indicated concentrations for 1h. Cells were washed and incubated with a mild acid solution to 
disrupt MHC-I/peptide complexes from the cell surface. After washing, cells were incubated again with 
calpeptin for additional 6h to allow recovery of MHC-I/peptide complexes and then incubated overnight 
with Trh4-specific CTL in the presence of Brefelding A, to prevent release of IFN-γ. Intracellular cytokine 
staining was performed and percentage of activated CTL was determined by flow cytometry. Control 
CTL recognized the MuLV gag-leader peptide (CCLCLTVFL) on RMA cells. At the given calpeptin 
concentrations no toxicity on target cells was detected. (B) Expression of the calpain family member genes 
was analysed in RMA-S cells with qPCR. Expression levels were normalized to GAPDH housekeeping 
gene and expressed relative to the calpain 1 gene. Primer sequences are given in Suppl Table I. (C) 
RMA-S cells were transduced with lentiviruses encoding shRNA sequences that target calpain 2 or an 




































































































































































































































































empty vector, leading to decreased mRNA levels of this gene. (D) CTL recognition of RMA-S cells with 
downregulated expression of calpain 2 was comparable to control RMA-S targets. Data are representative 
of three independent experiments. (E) Expression levels of SPP family members in mouse organs. RNA 
from complete mouse organs of wild type C57BL/6 mice  was extracted and expression of SPP family 
members was determined by qPCR. Expression levels were normalized to GAPDH housekeeping gene 
and expressed relative to the SPPL2c sample in liver. (F) Silencing of SPP in TAP-deficient MCA cells 
was reached by lentivirus-mediated expression of shRNA constructs. Empty shRNA vector served as 
control. Efficiency of downregulated levels of transcripts was measured by qPCR. (G) Cells with silenced 
SPP were tested for recognition by Trh4-specific CTL or control CTL reactive to an independent Kb-

































































Supplementary Figure 3. Detection of V5-tagged Trh4 constructs by western blot and CTL 
recognition efficiency of all side-directed mutagenesis constructs. (A) HeLa cells were transiently 
transfected with V5-tagged Trh4 constructs. The tag was introduced at the N-terminus of the protein 
(at aa position 33; ‘Del #1’ and ‘wt Trh4’) or as an extension at the C-terminus (‘Ext #2’), see Fig 5A. 
Two days later the cells were lysed and proteins were separated on SDS-page gel. Western blot analysis 
was performed with anti-V5 antibodies to confirm expression of these constructs after transfection. 
Data are representative of three independent experiments. Open triangle indicates full length Trh4 
protein, closed triangle represents Trh4 without the first 32aa, predicted to be a leader sequence and 
* indicates a non-specific band present in all HeLa lysates, serving as loading control. (B) The Trh4 
gene was mutated at single positions using site-directed mutagenesis. The construct numbers refer to 
the constructs mentioned in Figure 5C. These Trh4 constructs were transiently transfected into HeLa 
cells together with the mouse MHC-I molecule Db. Two days later HeLa cells were collected and 
incubated at different target concentrations with Trh4-specific CTL. CTL recognition was determined 
by IFN-γ release in the supernatants and quantified by ELISA and the efficiency of CTL recognition was 
calculated as a percentage compared to the wild type construct using ‘area under the curve’ results of 
original line graphs (see Figure 5D). Depicted data are compiled from three independent experiments 
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Tumors frequently display defects in the antigen processing pathway affecting molecules 
such as the peptide transporter TAP. TAP-deficiency results in decreased peptide/
MHC-I complexes at the cell surface, but they still have residual presentation of those 
complexes. Part of this collection is surprisingly not presented by normal cells and we 
called these TEIPP (T-cell epitopes associated with impaired peptide processing), 
since they constitute immunogenic neo-antigens for CD8+ T-cells. Thus far, only a few 
enzymes have been identified that liberate peptide ligands for this alternative repertoire: 
signal peptidase (SP) and signal peptide peptidase (SPP) in the ER and furin in the trans-
Golgi. Here we studied the presentation of a novel TEIPP peptide epitope presented by 
TAP-deficient lymphoma cells. We showed that the thus far known enzyme systems were 
not involved, but that the proteasome was required for the processing and presentation 
of this TAP-independent peptide. Interestingly, the proteasome was revealed as the 
major contributor to the alternative peptide repertoire, overruling the effect of SP, 
SPP and furin. The loading of the studied TEIPP peptide-epitope most likely occurred 
in the endocytic vesicular compartment. We conclude that TAP-deficient cells have a 
multitude of alternative pathways to generate and present their MHC-I ligands and that 
the proteasome has a surprisingly dominant role to shape this peptide repertoire. 
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 | INTRODUCTION
The Major Histocompatibility complex class I (MHC-I) processing pathway is a 
mechanism by which cells can sample the pool of peptides produced by cellular catabolism 
and display them on the cell surface for scrutiny by CD8+ T cells. In the conventional 
MHC-I processing pathway, a substantial fraction of the peptides presented by MHC-I 
molecules results from proteolysis in the cytosol, mainly via the action of the proteasome. 
These peptides are transported into the endoplasmic reticulum (ER) by TAP transporters, 
where they meet nascent MHC class I molecules. However, cells can perform the task of 
antigen presentation even in cases of malfunctioning of some molecules of the conventional 
MHC-I processing pathway, such as the proteasome and TAP1-8. Studies with TAP-
deficient cells and animals have shown that MHC-I ligands are formed in the secretory and 
vesicular compartments. Initial peptides identified in cells lacking the TAP transporters 
were derived from leader sequences9, 10. Leader sequences target fresh translational 
products to the ER and are cleaved by signal peptidases (SPase) in close proximity of the 
ER membrane and then by Signal Peptide Peptidase (SPP) in the intramembrane region, 
and thereby releasing these leader remnants from the ER membrane. After cleavage by SPP, 
partial domains of the signal peptides end up in the ER lumen and after further trimming, 
can be loaded into MHC-I molecules9-11. In addition to this TAP-independent peptide 
loading pathway, two proprotein convertases have been shown to generate MHC-I ligands 
in TAP-deficient cells: furin, located in the trans-Golgi network and PC7, located in the 
trans-Golgi network and endocytic vesicles12-15. Furin cleaves at polybasic sites on protein 
substrates in the process of protein maturation. The action of furin frequently liberates long 
peptides and thus strongly depends on trimming peptidases working progressively from 
either end of the oligopeptides to form the most suitable MHC-I ligands. 
We have recently shown a novel processing route for TAP-independent peptides by 
examining the liberation of a C-terminal peptide-epitope derived from the ceramide 
synthase Trh4 protein. The Trh4-epitope was liberated from the ER-membrane via the 
intramembrane-cleavage activity of SPP, independent from proteasome, SPase or furin 
activity (Oliveira et al., “Signal peptide peptidase liberates immunogenic C-terminal 
peptides for MHC class-I presentation” in press). We speculate on the existence of 
yet other processing pathways active in cells to load MHC-I peptides, since tumors 
with processing defects still present a broad repertoire of peptide antigens7, 16, 17. The 
characterization of these peptides, which we called TEIPP – “T-cell epitopes associated 
with impaired peptide processing”, showed that they derive from housekeeping proteins, 
are diverse in length and amino-acid composition, and are not presented on normal cells 
which makes them neo-antigens for CD8+ T-cells. 
In this report we studied the processing pathway of a new TEIPP epitope recognized 
by a specific CD8+ T-cell clone capable of killing TAP-deficient tumor cells17. Surprisingly, 
the proteasome was involved in the generation of this epitope, although TAP-positive 
cells do not present this peptide by Kb at their cell surface. Furthermore, we found that 
the proteasome strongly contributed to the general surface display of peptide/MHC-I 
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in TAP-deficient cells. This multicatalytic protease is even the dominant provider of this 
alternative peptide repertoire. Our results suggest that MHC-I loading of the TEIPP epitope 
occurred in the vesicular compartments associated with the cellular process of autophagy. 
We speculate that the majority of TAP-independent peptides are proteasome-mediated 
peptides that might gain access to MHC-I loading compartments in the vesicular pathway. 
 | RESULTS
TAP-independent presentation of a novel T cell peptide-epitope 
We wanted to unravel the intracellular presentation pathway of a peptide-epitope that we 
previously discovered in a mouse tumor model17. The peptide is presented by the classical 
MHC class I molecule Kb on several TAP-deficient tumor cells, including lymphoma, 
fibrosarcoma and melanoma, and is targeted by a CTL clone (mi3-CTL). Here, we 
studied the presentation of this mi3 peptide by non-transformed cells isolated from TAP1-
knockout and wild-type mice. LPS-stimulated B-cell blasts and fresh B-cells from the spleen 
were prepared and incubated with mi3-CTL to test for recognition. The mi3 antigen was 
presented by these TAP-deficient targets, and the level of presentation by the activated blasts 
was comparable to that of TAP2-deficient lymphoma line RMA-S (Fig. 1). The TAP-positive 
targets from the wild-type mice, did not present the mi3 antigen. These results showed that 
the mi3 antigen is presented in tumor as well as freshly isolated non-transformed cells as 
long as these cells display deficiency in TAP function. We speculate that normal cells did not 







































Figure 1. The TEIPP peptide mi3 antigen is presented by TAP-deficient targets. Presentation of the 
T-cell-epitope mi3 was evaluated by mi3-specific CTL. Activation of CTL was measured by IFN-γ release 
upon incubation with targets at different concentrations. Targets were composed by TAP2-deficient RMA-S 
tumor cells, freshly isolated B-cells and LPS-induced B-cell blasts from TAP1-deficient and wild-type mice as 
control. Mean and standard deviation of triplicates are shown from one out of two experiments.
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repertoire, as previously reported for another TAP-independent peptide18. These data show 
that the mi3 antigen represents the category of TEIPP antigens in that it originates from a 
‘self ’ protein and is selectively presented by cells with processing defects.
mi3 antigen is a H-2Kb-bound peptide
Next, we aimed to identify the molecular nature of the mi3 antigen. Therefore, MHC-
peptide complexes of mi3-positive RMA-S cells were purified by affinity chromatography 
using anti-Kb antibodies bound to sepharose beads. The peptide species were purified 
from heavy chains through 10kDa filters and eluted peptides were separated in fractions 
by SCX cation exchange reversed phase high-performance liquid chromatography 
(rp-HPLC) columns based on charge. Samples from the fractions were taken and tested 
for the presence of the mi3 antigen by mi3-CTL. One HPLC fraction was strongly 
recognized to comparable extent as an agonistic mimotope peptide SLGHQFAPV. This 
synthetic mimotope was identified through synthetic peptide library screen, but is most 
likely not related to the natural mi3 antigen (Fig 2). Therefore we concluded that the 
mi3 antigen is a peptide and successfully extracted from Kb molecules of RMA-S cells. 
The eluate samples will be submitted to further biochemical analysis by tandem mass 





































































































number of eluted fraction
Figure 2. Eluted peptides from RMA-S cells were tested for presence of the mi3 antigen. Kb-peptide 
complexes were purified from RMA-S cells. Peptides were eluted from the heavy chains and separated by 
HPLC in fractions based on charge. Samples from the several fractions were taken and loaded on T2.Kb cells 
to test for the presence of the mi3 antigen using mi3-specific CTL. CTL activation was measured by IFN-γ 
release. An agonistic peptide that functions as a stimulator or mi3-CTL activity was used as a positive control. 
Mi3-CTL activity was detected against one of the peptide pools indicating presence of mi3 antigen in this 
pool. Mean and standard deviation of triplicates are shown from one out of two experiments.
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The proteasome is involved in processing of the TAP-independent mi3 antigen
We were interested in the intracellular processing pathway of the TAP-independent mi3 
antigen and investigated which family of proteases was involved in the generation of this 
epitope. RMA-S cells were incubated with an array of chemical inhibitors to block the 
activity of different classes of proteases in a peptide/MHC-I recovery assay. For this, cells 
were submitted to mild acid treatment to strip surface peptide/MHC-I complexes and 
then incubated with inhibitors during the time of peptide/MHC-I re-appearance at the 
cell surface (Oliveira et al., “Signal peptide peptidase liberates immunogenic C-terminal 
peptides for MHC class-I presentation” in press). Pathways thus far known for presentation 
of TAP-independent peptides include the signal sequence-derived peptides processed by 
signal peptidase (SP) and the C-terminal liberation by furin in the Golgi. However, the furin 
inhibitor did not affect mi3 presentation and the SP inhibitor even led to an increase of mi3 
presentation (Fig 3A). We recently discovered a third way of TAP-independent peptide 
presentation, involving the SPP-mediated cleavage of C-termini in the ER (Oliveira et al., 
“Signal peptide peptidase liberates immunogenic C-terminal peptides for MHC class-I 
presentation” in press), but the SPP inhibitor ((z-LL)2-ketone) did not have an inhibitory 
effect on mi3 presentation. We therefore concluded that the processing pathway of mi3 is 
distinct from all other previously described TAP-independent pathway.  
Out of a list of fourteen inhibitors, bestatin decreased mi3-CTL recognition by ~40% 
(Fig. 3B). This broad inhibitor of aminopeptidases like the cytosolic leucine amino-
peptidase and the secretory-vesicle associated aminopeptidase B19, was only effective at 
relative high concentrations. The highest tolerated dose of bestatin (200µM) induced 
approximately 60% of inhibition (Fig. 3B). To test if these results were due to cellular 
toxicity, treated RMA-S cells were incubated with control CTL that recognize another 
TEIPP antigen. Recognition by control CTL was unaltered indicating no toxicity 
that could compromise overall MHC-I peptide presentation. These results showed a 
moderate inhibitory effect of bestatin, suggesting an indirect role for aminopeptidases or 
that bestatin was cross-reactive to other enzymes. 
Strikingly, the proteasome inhibitor epoxomicin was capable of efficient blocking of 
mi3 presentation (Fig. 3A). A dose titration of epoxomicin showed that a low dose of 
40 nM still induced 60% inhibition (Fig. 3C). The presentation of the SPP-dependent Trh4 
control peptide was even increased by treatment with epoxomicin at all concentrations 
tested, indicating that mi3 blocking was not due to toxicity of the target cells. This increase 
of Trh4 peptide presentation was previously reported by our group and was explained 
by the removal of competitor peptides from the convention proteasome-TAP pathway 
(Oliveira et al., “Signal peptide peptidase liberates immunogenic C-terminal peptides 
for MHC class-I presentation” in press). We concluded that the TAP-independent mi3 


























































































































































































Figure 3. Identification of the processing pathway that leads to presentation of the mi3 antigen. 
(A) The presentation of the mi3 antigen in RMA-S cells was tested in the presence of an array of protease 
inhibitors. RMA-S cells were briefly resuspended in mild acid buffer to disrupt surface MHC-I complexes 
and incubated with protease inhibitors. Re-emergence of peptide/MHC-I complexes at the cell surface 
occurred during this time (Oliveira et al., “Signal peptide peptidase liberates immunogenic C-terminal 
peptides for MHC class-I presentation” in press). Cells were then incubated with mi3-specific CTL to test 
for the presence of Kb-mi3 complexes. IFN-γ production by CTL was determined by intracellular cytokine 
staining. Inhibitors and concentrations used in the assay: epoxomicin (0.5µM), 3,4-Dichloroisocoumarin 
(5µM), Decanoyl-RVKR-CMK (100µM), calpeptin (60µM), calpain inhibitor IV (20µM), PD150606 
(200µM), butabindide oxalate (400µM), captopril (100µM), leupeptin (200µM), (z-LL)2-ketone 
(5µM), 1,10-Phenanthroline monohydrate (100µM), DAPT (10µM), Bestatin hydrochloride (100µM), 
z-vad-fmk (10µM). (B-C) Dose-dependent inhibition of mi3 antigen-presentation by the inhibitors 
bestatin (B) and epoxomicin (C) on RMA-S cells. Mi3-specific CTL was used to test the presentation of 
the mi3 antigen and control CTL to test for toxicity. Control CTL recognize the TAP-independent Trh4 
antigen (MCLRMTAVM) presented by RMA-S cells18. CTL recognition was determined as described in 
(A). Data are representative of three independent experiments.
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The proteasome is a major participant in peptide presentation of the 
TAP-independent repertoire
A few TAP-independent processing pathways that participate in MHC-I peptide 
presentation have been characterized. They comprise peptides generated by furin in the 
Golgi, the processing of leaders sequences from proteins in the ER by SP and the SPP-
dependent pathway for ER resident proteins11-13 (Oliveira et al., “Signal peptide peptidase 
liberates immunogenic C-terminal peptides for MHC class-I presentation” in press). 
Although these pathways do not depend on proteasome activity, our data now suggested 
the existence of additional proteasome-dependent pathway. We wondered what the 
contribution of these different pathways was for the overall MHC-I peptide presentation 
in TAP-deficient cells. For that, we incubated cells with several chemical inhibitors 
of proteases to shut down the different pathways. Cells were treated with a mild acid 
solution to strip the surface MHC-peptide complexes and incubated with the chemical 
inhibitors similarly to what was described in figure 3. After the incubation period, cells 
were stained with specific antibodies for the MHC-I molecules Db and Kb and analysed 
by flow cytometry. TAP2-deficient RMA-S lymphoma cells and the TAP1-deficient MCA 
fibrosarcoma cells were tested and the results were depicted as the inhibition of re-emerging 
MHC-I molecules at the cell surface in the presence of the inhibitors. The data revealed 
that the known TAP-independent pathways, based on furin, SP and SPP were active and 
indeed contributed to the overall MHC-I presentation in these cells but individually they 
only marginally contributed to MHC-I presentation (Fig 4). The most prevalent inhibitor 
was epoxomicin, the specific inhibitor for the proteasome. Approximately 50% recovery of 
the normal MHC-I levels could be blocked with epoxomicin. The Kb molecule was more 
sensitive than the Db molecule. We concluded that the proteasome dominantly participate 
in the formation of the TAP-independent peptide repertoire.
Contribution of other proteases
The MHC-I levels were also firmly reduced with the inhibitor phenanthroline, which 
is known to block metalloproteases (Fig 4). The activity of metallopeptidases has been 
implicated in the generation of specific CTL epitopes, such as derived from the PRAME 
tumor antigen and the HIV-1 ENV protein12, 20. The presentation of these nardilysin-
cleaved peptides followed a TAP-dependent pathway. However, metallopeptidases have 
also been shown to participate as amino-terminal trimming enzymes in TAP-deficient 
microsomes21, 22. These results suggested that the activity of phenanthroline-sensitive 
proteolytic enzymes such as metalloproteases complement the proteasome as dominant 
players in the overall TAP-independent processing pathway.
Comparison between TAP-positive and TAP-negative cells
We then analyzed if the TAP-independent pathways have different relative contributions 
in TAP-proficient cells. In TAP-proficient counterparts, the relative contribution of the 













































































































































































































































































































































































Figure 4. Contribution of different processing pathways for the overall MHC-I peptide presentation 
in TAP-deficient cells. MHC-I surface expression on stable cell lines was determined by flow cytometry 
after incubation with protease inhibitors (see procedure in Figure 3A). RMA is a mouse lymphoma cell 
line and RMA-S is a TAP-deficient variant of RMA. MCA is a mouse TAP1-/- fibrosarcoma and MCA.
TAP is TAP-transfectant variant of MCA. The mean fluorescence intensity (MFI) of Db and Kb molecules 
in the samples was measured for the untreated sample (positive control), inhibitor-treated samples and 
brefeldin-A-treated sample (negative control). The effect of the chemical inhibitors in the expression 
of each MCH-I molecule was determined by calculating the difference between the untreated sample 
and the inhibitor-treated samples. This was expressed in percentage relative to the negative control. The 
expression of Db and Kb was determined with the specific monoclonal antibodies clone 28.14.8S and 
clone AF6-88.5, respectively, that recognize peptide-bound MHC-I complexes. Protease inhibitors and 
concentrations used are: epoxomicin (0.4µM), 3,4-Dichloroisocoumarin (5µM), Decanoyl-RVKR-CMK 
(10µM), calpeptin (30µM), butabindide oxalate (400µM), captopril (100µM), leupeptin (200µM), 
(z-LL)2-ketone (5µM), 1,10-Phenanthroline monohydrate (50µM), aprotinin (10µM), DAPT (10µM), 
Bestatin hydrochloride (200µM), z-vad-fmk (25µM), L-leucinethiol (15µM) and DL-Dithiothreitol 
(0.5M). Mean and standard deviation of triplicates are shown from one out of three experiments. 
the other inhibitors ranked quite differently in the two sets of cells under influence of TAP 
status, indicating that other processing enzymes and pathways are involved. For instance, the 
metalloprotease inhibitor phenanthroline was much more dominant in TAP-deficient cells. 
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Furthermore, the influence of the SP leader peptide pathway seemed to be more pronounced 
in TAP-positive cells. DCI treatment even led to an increase of Db molecules on RMA-S 
cells, suggesting that SP would destroy potential Db-binding peptides. Interestingly, the furin 
pathway appeared to be more active in the fibrosarcoma cells than in the lymphomas. 
The surprising finding of the major contribution of the proteasome to the MHC-I peptide 
presentation on TAP-deficient cells prompted us to confirm the TAP status of our cell panel. 
For that, we performed a TAP activity assay with this cell panel in which peptide transport 
efficiency is examined and found a normal TAP function in RMA and MCA.TAP cells and 
a complete loss in the TAP-negative counterparts (Fig 5). This confirmed the expected TAP 
function and we concluded that the proteasome is the major generator of peptides for the 
conventional processing pathway as well as for the alternative TAP-independent route. 
How do cytosolic peptides get access to MHC-I in the absence of TAP?
We wanted to understand how proteasome-dependent peptides, such as the mi3 antigen, 
enter MHC-I loading compartments in the absence of TAP. Recently, it has been shown 
that autophagy promotes the processing of viral antigens for MHC-I presentation. 
Peptide loading seemed to occur within autophagic vesicles associated with lysosomes 
(autophagolysosomes)23. We tested the involvement of the vacuolar pathway in the 
presentation of the mi3 antigen. For this, RMA-S cells were treated with bafilomycin A1 
(BAF-A) which prevents acidification of lysosomes and fusion with autophagosomes. 
RMA-S cells were incubated with BAF-Ain a peptide/MHC-I recovery assay and used 
as targets for mi3-specific and control CTL. BAF-A consistently led to an increase in 
antigen presentation of the mi3 epitope, but not of the control SPP-mediated Trh4 





















Figure 5. The activity of TAP was determined by the efficiency of peptide transport. Cell lines tested 
were the tumor cell panel of TAP-positive and TAP-negative cells described in figure 4. Peptide transport 
was measured in semipermeabilized cells using the fluorescently labeled peptide CVNKTERAY. ATP-
dependent TAP transport was measured by fluorescence intensity and peptide transport is expressed a 
percentage of translocation, which is relative to the translocation in control cells4. Mean and standard 
deviation of triplicates are shown from one out of two experiments.
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suggests that acidification of endolysosomes is detrimental for the mi3 antigen, possibly 
by mediating acid-dependent enzymatic destruction of the epitope. Importantly, it also 
indicates that the mi3 antigen has access to vesicular compartments. 
We asked the question of how the proteasome-liberated mi3 peptide gets access 
to the vesicular compartments. Cytoplasmic content, such as organelles and proteins, 
is compartmentalized in vesicles during the process of autophagy that transport it to 
lysosomal-mediated destruction. We hypothesized that the mi3 antigen or peptide 
precursors could be captured into autophagosomes after liberation by the proteasome. 
To test this, we treated RMA-S cells with a compound that inhibits the formation of 
autophagic vesicles, 3-methyladenine (3-MA), and incubated these with mi3-specific. 
The treatment with 3-MA induced approximately 50% inhibition of mi3 antigen 
presentation (Fig 6B). This result suggests that autophagy is involved in the presentation 
of the mi3 antigen that might provide access to MHC-I molecules. In conclusion, the mi3 
antigen is presented by a proteasome- and TAP-independent pathway that might use the 
vesicular endocytic pathway for MHC-I antigen presentation.   
 | DISCUSSION
The currently known pathways of TAP-independent peptide processing involve leader 
peptides, which are liberated by SPase in the ER, and peptides liberated by furin, which 
cleaves C-terminal peptides in the trans-Golgi system11-13, 24. We recently identified an 
















































Figure 6. Involvement of the vacuolar pathway related to autophagy for the presentation of mi3 
antigen. (A) RMA-S (lymphoma) and MCA (fibrosarcoma) cells were treated with bafilomycin (BAF-A) 
in peptide/MHC-I recovery assays performed as described in figure 3. These cells were then incubated 
with mi3-specific CTL or control CTL. Control CTL recognize the TAP-independent Trh4 antigen 
(MCLRMTAVM) presented by RMA-S cells18. CTL recognition was measured as described in figure 3. 
(B) RMA-S cells were treated with autophagy inhibitor 3-methyladenine (3-MA) and incubated with 
mi3-specific CTL. Inhibitors and concentrations used in the assay: 3-MA (5mM), BAF-A (200nM). 
Mean and standard deviation of triplicates are shown from one out of three independent experiments.
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was responsible for the liberation of these peptides (Oliveira et al., “Signal peptide 
peptidase liberates immunogenic C-terminal peptides for MHC class-I presentation” 
in press). We here describe the intracellular processing of a T-cell epitope that requires 
proteasomal activity.  This antigen, called mi3, was presented by several TAP-deficient 
cells, both from tumor origin or from primary tissues. These proteasome-mediated 
peptides strikingly gain access to MHC-I loading machinery in a TAP-independent 
fashion and our experiments indicate that endocytic vesicular compartments are 
involved. Surprisingly, the majority of the TAP-independent peptide repertoire appears 
to be generated by the proteasome, since inhibitors for the previously known pathways 
only marginally blocked the overall surface display of MHC-I. 
MHC-I bound peptides from this processing category have been described before. 
Several epitopes from the LMP2 protein of the Epstein-Barr virus (EBV) are presented 
by a TAP-independent and proteasome-dependent manner25. The authors found a good 
correlation between the hydrophobicity index of the peptides and TAP-dependence 
in that the TAP-independent epitopes had a high hydrophobicity index,  proposing a 
mechanism by which these epitopes are produced in the cytosol and then can traverse the 
ER membrane to reach MHC-I loading compartments due to their highly hydrophobic 
characteristics. It remains to be determined if the mi3 antigen has such characteristics, 
and that will only be solved when the natural sequence is revealed. Moreover, we cannot 
exclude other possibilities for the access of the mi3 peptide into the ER. For instance, it 
could be transported into the ER via the Sec61 translocon or via other means24.
Our data showed that the process of autophagy might be involvedin the presentation 
of the mi3 antigen to CTL. During autophagy, large portions of cytoplasmic content, 
including proteins and organelles, are encapsulated in double membrane vesicles 
called autophagosomes26-29. The autophagosomes then fuse with acidic vesicles such 
as late endosomes and lysosomes to form the autolysosome. The autolysosomes are 
terminal digestive compartments where several proteases and lipases breakdown the 
encapsulated contents into its constituents such as amino-acids and lipids which are 
exported to the cytoplasm for recycling27. The autophagosomal membrane has been 
proposed to originate from the ER30, 31. In addition, during ER stress and the unfolded-
protein response, autophagy is induced and consumes portions of the ER, serving as an 
alternative to ER-associated degradation of proteins32-34. The MHC-I loading complex 
might therefore be present in the autophagosome and allow for loading of peptides in 
these compartments. Also, MHC-I molecules from the cell membrane internalized in 
endosomes can have contact with autophagosomes and return to the endocytic network. 
Although there is still much unknown about this, transit for membrane-associated 
proteins between autophagosomes and endosomes has been observed by live cell 
imaging35. In fact, autophagy has recently been shown to enhance antigen processing 
for MHC-I presentation. This recent study demonstrated that the processing of viral 
glycoprotein B for antigen presentation on MHC-I was facilitated by autophagy in HSV-1 
infected murine macrophages, which led to CD8+ T-cell activation36. In our results, we 
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observed that the compound 3-MA partly inhibited presentation of the mi3 antigen. 
This compound inhibits the action of PI3-kinases which is necessary for the formation 
of the double membrane of the autophagosome and therefore inhibits the initial steps 
of autophagy. Another compound, bafilomycin, increased the presentation of the mi3 
antigen. This compound inhibits the acidification of endosomes and lysosomes and 
therefore interferes with the maturation of autophagosomes by inhibiting the fusion with 
lysosomes37. These two observations suggest that the mi3 antigen enters the autophagic 
pathway. Possibly, the mi3 antigen is produced in the cytosol by proteasomal activity 
and then engulfed into autophagosomal vesicles. In these vesicles, the peptide antigen 
could bind MHC-I molecules that are present in these vesicles and return to the secretory 
pathway to be presented at cell surface. 
The question of how TAP-deficiency promotes the presentation of the mi3 antigen 
is interesting and might be related to the fact that TAP-deficiency leaves many peptide-
receptive MHC-I molecules in the ER38. These might be incorporated in autophagic 
compartments and sensitive for peptide loading in the endocytic pathway. Trafficking 
of MHC-I molecules to endolysosomal compartments have been described and the 
invariant chain seems to facilitate this process39.
We were surprised to observe a strong role for the proteasome in the generation of 
TAP-independent peptides and our results implies the existence of new route of peptide 
loading into MHC-I in the vesicular pathway that awaits in-depth investigation.
 | MATERIAL AND METHODS
Cell lines and mice
The mouse tumor cell lines RMA, RMA-S (TAP2-deficient), MCA (TAP1-deficient), 
and human TAP-deficient T2 cells have been described previously 16-18. T2 cells were 
transfected with H-2Kb gene via retroviral transduction using the LZRS vector containing 
GFP behind an internal ribosome entry site 40. The mouse TAP genes were introduced 
into MCA cells by gene transfer. Generation and culture of CD8+ T cell clones used in this 
study were previously described: Kb-restricted CTL clone mi3 specific for a yet unknown 
TEIPP peptide,  Db-restricted CTL clone B5 specific for the TAP-independent Trh4 peptide 
(MCLRMTAVM); 17, 40, 41. All cells were cultured in complete IMDM medium (Invitrogen, 
Carlsbad, CA) containing 8% heat-inactivated FCS, 100 U/ml penicillin, 100 μg/ml 
streptomycin (Life Technologies, Rockville, MD), 2mM L-glutamine (Invitrogen) and 
30 μmol/L of 2-mercaptoethanol (Merck, NJ, USA) at 37°C in humidified air with 5% CO2. 
C57BL/6 mice were purchased from Charles River Laboratories (France) and housed 
in the animal facility of the Leiden University Medical Center under specified pathogen-
free conditions. TAP1-knockout mice were purchased from Jackson laboratories. Mice 
were used between 8 and 12 weeks of age. Spleens from C57BL/6 and TAP-/- mice were 
harvested, mechanically disrupted with a cell strainer and depleted of CD3+ cells with 
anti-CD3 MACS beads (Miltenyi Biotec) according to manufacturer’s recommendations. 
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B-cell blasts were obtained by culturing CD3-depleted spleen cells for 3 days with 10 μg/ml 
LPS (Sigma). Experiments were performed in accordance with national legislations and 
institutional guidelines and were approved by the local ethical committees.
Protease inhibitor experiments
Experiments were performed as previously described (Oliveira et al., “Signal peptide 
peptidase liberates immunogenic C-terminal peptides for MHC class-I presentation” 
in press). Chemical inhibitors used in these assays are: epoxomicin (Sigma-aldrich), 
3,4-Dichloroisocoumarin (Sigma-aldrich), Decanoyl-RVKR-CMK (Merck), calpeptin 
(Merck), calpain inhibitor IV (Merck), PD150606 (Santa Cruz Biothecnology), 
butabindide oxalate (TOCRIS Bioscience), captopril (Sigma-aldrich), leupeptin (Merck), 
(z-LL)2-ketone (Merck), 1,10-Phenanthroline monohydrate (Sigma-aldrich), aprotinin 
(Merck), DAPT (Sigma-aldrich), Bestatin hydrochloride (Sigma-aldrich), z-vad-fmk 
(Merck), L-leucinethiol (Sigma-aldrich) and DL-Dithiothreitol (Sigma-aldrich), 
3-methyladenine (Merck), bafilomycin-A (Merck). None of the inhibitors was toxic at the 
applied concentrations, as determined by trypan-blue counting and annexin-V staining. 
T-cell activation assays and flow cytometry
Intracellular cytokine staining of IFN-γ in T cell clones was performed for the protease 
inhibitor screen and expressed as percentage positive cells42. IFN-γ secretion by T-cell 
clones was measured by ELISA as previously published18. Data shown represent mean 
values obtained from triplicate test wells and error bars represent standard deviation of 
these values. Flow cytometry analysis of surface expression of Db and Kb molecules was 
performed using directly labeled anti-Db mAb (clone 28.14.8S; BioLegend, California, 
USA) and anti-Kb mAb (clone AF6-88.5, BioLegend). Cells were measured using a FACS 
Calibur and analysed with Flowjo software (Tree Star, Ashland, OR).
Peptide elution and HPLC 
Peptides were eluted out of purified Kb molecules from RMA-S cells. Immunoprecipitation 
of Kb molecules was performed with shepharose beads covalently coupled with 
anti-Kb mAb (clone AF6-88.5, BioLegend) from two independent lysates of 20.109 
RMA-S cells as previously described16, 41. The peptide pools were prefractionated on SCX 
cation exchange columns as previously described16.
TAP-transport assay
A peptide transport assay was done as described previously4, 43. Briefly, cells were 
permeabilized and incubated with the fluorescein-conjugated synthetic peptide 
CVNKTERAY in the presence or absence of 10 mM ATP. Peptide translocation was 
terminated by adding ice-cold lysis buffer. After the removal of cell debris, isolated 
glycosylated peptides were incubated with ConA beads. The fluorescence intensity was 
measured, and peptide transport is expressed a percentage of translocation, which is 
relative to the translocation in control cells. 
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 | ABSTRACT
The nonclassical MHC Qa-1b accommodates monomorphic leader peptides and 
functions as a ligand for germ line receptors CD94/NKG2, expressed by natural killer 
cells and CD8+ T cells. We here describe that the conserved peptides are replaced by a 
novel peptide repertoire of surprising diversity as a result of impairments in the antigen 
processing pathway. This novel peptide repertoire represents immunogenic neo-antigens 
for CD8+ T cells as we found that these Qa-1b-restricted T cells dominantly participated 
in the response to tumors with processing deficiencies. A surprisingly wide spectrum of 
target cells, irrespective of transformation status, MHC background or type of processing 
deficiency was recognized by this T cell subset, complying with the conserved nature 
of Qa-1b. Target cell recognition depended on T cell receptor and Qa-1b interaction 
and immunization with identified peptide-epitopes demonstrated in vivo priming 
of CD8+ T cells. Our data reveal that Qa-1b, and most likely its human homologue 
HLA-E, is important for the defense against processing deficient cells by displacing the 
monomorphic leader peptides, which relieves the inhibition through CD94/NKG2A 
on lymphocytes and by presenting a novel repertoire of immunogenic peptides, which 
recruits a subset of cytotoxic CD8+ T cells. 
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 | INTRODUCTION
Qa-1b and its human homolog HLA-E are conserved MHC class I like molecules, often 
categorized as ‘nonclassical’ or class Ib MHC. Similar to the classical MHC molecules, they 
accommodate small peptides in their binding grooves and present these on the cell surface1, 2. 
Crystal structures of HLA-E show that the overall fold of the peptide/MHC complex is very 
similar to that of the classical MHC class I molecules3. The unique feature of Qa-1b and HLA-
resides in the very limited number of alleles that is present in the population4, 5: as few as two 
alleles exist in the human population differing just in one amino acid and this has hardly 
any functional consequence6. The monomorphic nature of Qa-1b and HLA-E is underlined 
by the finding that they are predominantly filled with one peptide ligand, which is derived 
from the signal sequence of classical MHC class I molecules, often referred to as ‘Qdm’ for 
‘Qa-1 determinant modifier’7, 8. These signal peptides are strikingly conserved in all tested 
mammalian species9, pointing at an important function of this peptide/MHC combination 
for the immune system. A substantial body of evidence reveals that it regulates natural killer 
(NK) cells and cytotoxic T-lymphocytes (CTL) via the heterodimeric receptors CD94/
NKG2A and CD94/NKG2C2, 10, 11. These germline-encoded receptors specifically engage 
the Qdm peptide when bound to Qa-1b/HLA-E, since residues at peptide position 5 and 
8 are part of the surface interface of the CD94/NKG2 receptors12, 13. Interestingly, this 
interaction is quite similar to the footprint of the hyper variable regions of the T cell receptor 
on peptide/MHC class I14. Absence of these Qdm side chain residues results in lack of 
receptor engagement15, 16, indicating that this innate receptor is truly peptide specific. Qdm/
Qa-1b complexes act as remote sensors of integrity of the MHC class I antigen processing 
machinery, because defects in proteasomal cleavage, TAP-mediated peptide transport, signal 
peptidases or tapasin-mediated peptide loading all result in failure to process and present 
Qdm peptides17-20. The lack of Qdm/Qa-1b complexes at the cell surface is sensed by NK cells 
expressing CD94/NKG2 receptors, and allows for immunosurveillance of such processing 
deficient cells21. Thus, this receptor/ligand system is a major molecular mechanism behind 
the ‘missing self ’ principle of NK cell reactivity22. 
In addition to their role in the innate immune system, Qa-1b and HLA-E serve the 
adaptive response as well. T-cell receptor recognition of these nonclassical MHC has 
been described in the context of immunity against intracellular pathogens, e.g. Listeria, 
Salmonella and Mycobacterium tuberculosis23-25, suggesting that foreign antigens can 
replace the ‘self ’ Qdm peptides and be recognized by CD8+ T cells. HLA-E-restricted 
T cells specific for Qdm do exist, but have only been reported in response to allogeneic 
MHC26, 27. Furthermore, Qa-1b-restricted CD8+ T cells have been implicated in the 
regulation of experimental autoimmune diseases (reviewed in 21, 28). The antigenic targets 
of these regulatory T cells are most likely of ‘self ’ origin, but different from Qdm. These 
data reveal that Qa-1b/HLA-E-restricted T cells are present in the host, but that the 
specificity, diversity and function of this T-cell subset await further investigation.
Here we describe the existence of a surprisingly broad peptide repertoire that is 
presented by Qa-1b on cells with impairments in the antigen processing machinery. These 
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peptides replace Qdm and are targeted by a unique population of CD8+ cytotoxic T cells. 
Normal cells with intact processing machinery were not recognized by these Qa-1b-
restricted CTL, but partial defects readily resulted in the appearance of the immunogenic 
‘self ’ peptides, which are derived from housekeeping proteins. Interestingly, we show 
that these Qa-1b-restricted T cells are abundantly present in the immune response to 
processing deficient tumors. Our data show that the nonclassical Qa-1b molecule plays a 
prominent role in the adaptive immune response as a restriction element for T cells and 
presents a much larger peptide repertoire than thus far anticipated. 
 | RESULTS
Qa-1b-restricted T cells are frequently present in the immune response 
against TAP-deficient tumors 
We previously described that the immune response against TAP-deficient tumors 
comprises Qa-1b-restricted T cells among T cells with MHC restriction to the classical 
class I molecules29. This prompted us to determine the relative contribution of this Qa-
1b-restricted subset to the overall response. Mice were immunized with syngeneic TAP-
deficient RMA-S cells expressing the co-stimulatory molecule CD80. Ex vivo cultured 
spleens were examined for IFNγ production against the parental RMA-S lymphoma, the 
β2m-negative C4.4-25 line and a panel of single class I expressing EC7.1 cells, which are 
MHC class I-loss variants of RMA-S30 (Table I). All polyclonal ex vivo cultures responded 
to RMA-S, but not against the β2m-negative lymphoma, indicating that they exhibited 
specific T-cell reactivity against TAP-deficient tumors, and not merely reflected natural 
killer (NK) cell reactivity. Dissection of these IFNγ responses revealed a co-dominance 
of Qa-1b-restricted activity compared to those restricted by the classical Db- and Kb-
molecules, as the majority of the examined twelve independent cultures produced high 
IFNγ levels when incubated with EC7.1.Qa-1b (Table I). These data suggested that the 



















































































Twelve mice were immunized with RMA-S.B7 and spleens were stimulated twice in vitro with RMA-S.B7 before testing. 
a RMA-S is TAP2-deficient; C4.4-25 is b2m-deficient; EC7.1 is a MHC class I-deficient variant of RMA-S. Single class I genes
were reconstituted in EC7.1. 
c Concentration of IFNγ released by ex vivo cultures (pg/ml) 



























nonclassical MHC class I Qa-1b frequently acts as an antigen presentation molecule for 
T cells, and even can overrule the classical MHC class I molecules.
Critical involvement of Qa-1b and the T-cell receptor in target cell recognition
To characterize these Qa-1b-restricted T cells, we isolated several T-cell clones from the 
aforementioned cultures and extensively explored the expression and function of surface 
receptors. All clones displayed a classical CTL phenotype and expressed CD3, CD8αβ 
and TCRαβ (Fig S1). Different rearranged TCR Vβ segments were used (not shown), 
validating the independent origin of the clones and indicating that Qa-1b recognition does 
not constrain the TCR repertoire. In addition to the T-cell lineage receptors, the T-cell 
clones also expressed CD94, NKG2A, NKG2C and NKG2D, receptors frequently found 
on Natural Killer (NK) cells, which interact with nonclassical MHC class I molecules, 
including Qa-1b. Importantly, NK lineage markers NK1.1 and DX5, and CD16, CD32, 
CD244 (2B4) were not expressed, neither were receptors of the lectin Ly49 family, which 
interact with classical MHC class I (Fig S1 and data not shown). We concluded that our 
Qa-1b-restricted T cells are indistinguishable at the phenotypic level from ‘conventional’ 
CD8+ T-cells restricted by classical MHC31, but are clearly distinct from the reported Qa-1-
recognizing intestinal γδ+ T cells32 and Qa-1-restricted regulatory CD8αα+ T-cell subset33.
To carefully determine the Qa-1b-restriction of our isolated T-cell clones, we examined 
their reactivity against two cell panels, based on the TAP-negative EC7.1 lymphoma and 
TAP-deficient B78H1 melanoma30, 34 (Fig 1). Both cell lines are also devoid of MHC 
class I proteins and single class I molecules were reconstituted by gene transfer. All 
isolated T-cell clones exhibited cytolytic activity (Fig 1A) and produced IFNγ (Fig 1B 
and Fig S2) against the Qa-1b-expressing cells, but not against cells in which only Db 
or Kb were introduced. These data convincingly demonstrated the Qa-1b-restriction of 
our T cells and excluded cross-reactivity to the classical class I molecules. Qdm-specific 
control CTL did not recognize the TAP-deficient tumor targets, since the presentation 
of Qdm in Qa-1b is TAP-dependent7. Exogenous loading of Qdm conferred reactivity for 
this CTL clone (Fig 1, right panels). A direct interaction with Qa-1b was revealed by the 
finding that anti-Qa-1b antibody strongly blocked the recognition by our CTL (Fig 2A). 
Next, we examined the involvement of antigen-receptors in target cell recognition. 
Although CD94/NKG2A and CD94/NKG2C do engage Qa-1b 2 and were expressed by 
our isolated T-cell clones, their involvement was not likely, because TAP-negative cells 
are devoid of peptide ligands for these receptors35. Indeed, blocking with NKG2A/C-
specific antibodies did not alter the response, whereas anti-CD3 and -CD8 antibodies 
clearly inhibited the recognition of EC7.1.Qa-1b cells (Fig 2B). A role for NKG2D was 
also not likely, since our RMA-based lymphoma panel lacks NKG2D ligands36. Together 
these data indicated that the TCR governed the reactivity of our Qa-1b-restricted CTL. 
Furthermore, exogenous loading with excessive amounts of competing Qdm peptides 
inhibited T-cell recognition of EC7.1.Qa-1b cells (Fig 2C). Similar competition was found 
when the Qdm variant L8K was used (AMAPRTLKL), but not with irrelevant control peptide 
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(Fig 2C, left panel). Qdm-specific control CTL confirmed that both peptides are efficiently 
loaded on the target cells (Fig 2C, right panel). The fact that the position 8 substitution in the 
peptide L8K prevents engagement to CD94/NKG2A receptors37, but retained the capacity to 
inhibit T-cell reactivity in our assays, substantiated our findings that target cell recognition is 
regulated by TCR-mediated interaction with Qa-1b and not by NK-receptors. 
TAP- and MHC heavy chain-deficiencies are targeted by Qa-1b-restricted CTL
To evaluate the appearance of the peptide-epitopes on target cells that express natural 
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Figure 1. Selective recognition of Qa-1b-expressing target cells. Isolated T-cell clones were tested 
against panels of TAP-deficient lymphoma (EC7.1) and melanoma (B78H1) cells. Both cell lines are also 
deficient in MHC class I30, 34 and were reconstituted with constructs encoding H-2Db, -Kb or Qa-1b. (A) 
Cytotoxic activity against Qa-1b-expressing EC7.1 cells and (B) IFNγ production against Qa-1b-expressing 
B78H1 cells by three independent T-cell clones. Control Qdm-specific CTL failed to recognize the Qa-1b 
expressing targets, due to the absence of TAP, unless pulsed with the Qdm peptide (right panels). Means 
and standard deviations of triplicate wells are shown for one out of three comparable experiments.
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Figure 2. The T-cell receptor, but not NKG2A/C, mediates reactivity of the T cells. (A) Blocking 
antibody against Qa-1b demonstrated a direct role of this molecule for T-cell recognition. Experiment 
was performed using EC7.1.Qa-1b target cells. (B) Blocking CD3 or CD8 with monoclonal antibodies 
decreased T-cell reactivity against TAP-deficient EC7.1.Qa-1b target cells. Antibodies against NKG2A/C 
did not alter the T-cell response, indicating that only the T-cell receptor is critically involved in 
mediating reactivity. (C) Exogenous peptide loading competes with endogenously presented epitopes 
on EC7.1.Qa-1b cells and inhibits the recognition of these target cells (left panel). Qdm (AMAPRTLLL) 
or Qdm L8K (AMAPRTLKL) peptides were loaded exogenously at the indicated concentrations on 
EC7.1.Qa-1b cells and IFNγ release by CTL was measured. Control peptide was the Kb-binding 8-mer 
SIINFEKL from OVA. The Qdm L8K mutant peptide/Qa-1b complexes fail to interact with CD94/
NKG2A or CD94/NKG2C37, indicating that the loaded peptides interfere with T-cell receptor mediated 
reactivity. Qdm-specific control CTL (right panel) was activated by the peptides. Means and standard 
deviations of triplicate wells are shown for one out of three comparable experiments.
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β2m-deficient mice as targets for three independently derived CTL clones (Fig 3A). 
TAP1-deficient cells were efficiently recognized by all three clones, but wild type and 
β2m-deficient cells were not. Qdm-specific control CTL selectively responded to wild 
type cells, indicating that the absence of Qdm peptides due to the TAP defect promoted 
the presentation of the new peptide-epitopes. Qa-1b surface levels on TAP1-deficient 
cells were lower than on wild type cells, but were clearly higher than the background 
levels on β2m-deficient cells (not shown). 
We also analyzed CTL reactivity against MHC class I heavy chain deficiencies with 
the use of B-cell blasts from H-2Db- and Kb-knockout mice. Qdm peptides are derived 
from the leader sequence of H-2Db 7 and loss of this allele resulted in recognition by two of 
the three CTL clones, whereas deficiency in Kb heavy chains did not result in recognition 
(Fig 3B). These subtle differences between the CTL clones suggested that the cognate 
peptides are differentially influenced by loss of MHC class I heavy chains. Strikingly, all 
three CTL clones strongly responded to cells devoid of both alleles (H-2DbKb-knockout) 
(Fig 3B). Control blasts lacking β2m in addition to H-2DbKb (triple knockout) were not 
recognized. These results revealed an unexpected influence of the Kb molecule on the Qa-
1b-presented antigenic peptides, in that removal of Kb molecules from H-2Db-deficient 
cells strongly enhanced epitope display (Fig 3B). The underlying mechanism of this 
effect is currently elusive. The degree of CTL response to H-2DbKb-knockout cells was 
comparable to TAP-deficient cells (Fig 3A), indicating that both defects led to optimal 
presentation of the new Qa-1b peptides. Interestingly, Qdm-specific CTL were able to 
differentiate between these two target populations, confirming previous findings that this 
CTL clone is also reactive to TAP-dependent peptides other than Qdm35, 38. Together, 
these results demonstrated that our Qa-1b-restricted CTL interact with peptides on 
activated B-cells with defects in the antigen presentation route. 
CTL reactivity against tumors with partial processing impairments
We then determined CTL reactivity against tumor cells with TAP-dysfunction and 
tumor cells with undefined deficiencies in the processing machinery. Ad5-transformed 
Mouse Embryo Cells (Ad5MEC) and chemically-induced fibrosarcoma cells (MCA), 
both derived from TAP1-knockout mice, were recognized by the Qa-1b-restricted 
CTL (Fig 4A). Correction of the TAP1 defect by gene transfer resulted in decreased 
recognition by our CTL and strongly increased recognition by the Qdm-specific control 
CTL (Fig 4A). Thus, the alternative Qa-1b-binding peptide antigens are expressed in a 
wide array of hematopoietic and non-hematopoietic tissues of normal and transformed 
cells, including B-cells, fibroblasts, lymphoma, melanoma and sarcoma, and emerge at 
the cell surface of cells with genetic disruption of the TAP peptide transporter.
However, human tumors mostly display partial deficiencies in their processing pathway 
that originate at the transcriptional level, resulting in impaired, but not a complete shutdown 
in the generation of the human counterpart of Qdm/Qa-1b complexes. To assess whether 
the CTL were also capable to recognize such tumor cells, we tested four chemically-induced 
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mouse colon carcinomas, which are known to possess peptide-presentation capacity39, 40. 
Qdm-specific control CTL indeed recognized all four cell lines, demonstrating a functional 
processing machinery (Fig 4B, right panel). Interestingly, our Qa-1b-restricted CTL 
responded to all carcinoma lines, albeit to a varying extent (Fig 4B, left panel). Treatment of 
the carcinomas with the immunostimulatory cytokine IFNγ, which strongly improves the 
processing and presentation capacity of cells, resulted in decreased recognition, pointing 
at partial processing defects in the carcinomas that were corrected by IFNγ. In line with 
this idea, gene transfer of the viral TAP-inhibitor UL49.541 led to a strongly increased 
recognition by our CTL. As expected, the Qdm-specific control CTL clone exhibited the 
opposite reactivity profile (Fig 4B, right panel). Of note, the four colon carcinoma lines 
were derived from two mouse strains with different MHC typing, BALB/c with H-2d alleles 
(C26 and CC36) and C57BL/6 with H-2b alleles (MC38 and CMT93), nicely illustrating 
the conserved nature of Qa-1, which is the same in these strains. 
We concluded that our Qa-1b-restricted CTL recognize peptide-epitopes that even 
appear on the surface of cells with mild or partial processing impairments, implying that 


















































































Qa-1b-restricted CTL Qdm-specific CTL
Figure 3. Qa-1b-restricted CTL are reactive against cells with defined processing deficiencies. (A) LPS-
stimulated B-cell blasts from wild type (B6), TAP1-/-, and β2m-/- mice were used as targets for Qa-1 b-restricted 
CTL (left panels) or control Qdm-specific CTL (right panel). (B) LPS-stimulated B-cell blasts from wild 
type (B6), MHC class I-knockout and MHC class I/β2m-knockout mice were tested for recognition by 
Qa-1b-restricted CTL (left panels) or control Qdm-specific CTL (right panel). Panels display representative 
experiments out of four performed. Means and standard deviations of triplicates are shown.
101
5
CD8+ T cell repertoire restricted by Qa-1b
Determination of the Qa-1b-presented peptide repertoire
We set out to determine the nature of the TAP-independent peptides that are presented 
by Qa-1b via biochemical purification and tandem mass-spectrometry. Due to lack of 
suitable Qa-1b specific antibodies, we made use of a chimeric MHC class I molecule in 
which the peptide binding domains (alpha 1 and 2) of Qa-1b were coupled to the constant 
alpha 3 domain of Db, against which good precipitating antibodies are available. This 
chimeric Qa-1b/Db molecule was introduced into TAP2-negative EC7.1 cells and in 
order to compare the corresponding TAP-dependent peptide repertoire, we also created a 
TAP2-reconstituted variant of EC7.1.Qa-1b/Db cells. Flow cytometry data confirmed that 
EC7.1.Qa-1b/Db cells only expressed this chimeric molecule on the cell surface and not 
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Figure 4. Partial deficiencies in the processing pathway of tumor cells induce the novel Qa-1b-
presented peptide-epitopes. (A) Qa-1b-restricted CTL respond to Ad5-transformed mouse cells 
(Ad5MEC) and fibrosarcoma cells (MCA) that are derived from TAP1-knockout mice. Recognition 
was lost upon gene transfer of mouse TAP1 in these cell lines (‘+ TAP1’). Qdm-specific control CTL 
displayed opposing specificity, indicating that the Qdm peptide is only presented on TAP-proficient 
tumor cells (right panel). (B) Four colon carcinoma cell lines from BALB/c (C26 and CC36) or 
C57BL/6 (MC38 and CMT93) background were used as targets for both CTL types. Pre-treatment 
with IFNγ to boost the antigen processing and presentation machinery resulted in decreased reactivity 
by the Qa-1b-restricted CTL, whereas gene transfer of the viral TAP-inhibitor UL49.5 41 led to strongly 
increased recognition. Again, Qdm-specific control CTL displayed opposing specificity (right panel). 
Means and standard deviations of triplicates are shown from one representative experiment out of four.
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with our alpha 3-directed antibody (Fig 5A). Analysis of TAP2 expression in EC7.1.Qa-
1b/Db and in the TAP-transfected variant confirmed the absence of TAP2 protein in the 
first and successful reconstitution in the other (Fig. 5B). Analysis with our Qa-1b-restricted 
CTL and Qdm-specific CTL confirmed that our EC7.1 cell lines represented two extremes 
of the antigen processing status, in that the TAP negative line did not present Qdm and 
that reconstitution of TAP2 led to a disappearance of the newly defined peptides and that 
the chimeric molecule functionally presented Qa-1b-bound peptides (Fig 5C).  
Mass spectrometry of peptide species from purified Qa-1b molecules demonstrated an 
evident difference between the two peptide repertoires. The peptide repertoire of TAP-
positive cells was strikingly dominated by the Qdm peptide AMAPRTLLL (Table II). Six 
other peptide sequences were identified, but these represented only minor constituents 
(together less than 5% of the total ion count). In contrast, Qa-1b from TAP-negative cells 
was filled with a remarkable diversity of peptides from endogenous proteins (Table II). No 
peptide clearly stood out in terms of quantity. More than 150 tandem mass fragmentation 
profiles sufficiently matched with the mouse IPI protein database (http://www.ebi.ac.uk/
IPI/IPImouse.html) and analysis of their corresponding synthetic peptides confirmed 
the amino acid sequence of 84 peptides. The other peptide masses could not be matched 
with a known peptide sequence, but did not correspond to Qdm or previously defined 
Qa-1b-binding peptides2. The lengths of the TAP-independent peptides ranged from 8 to 
18 amino acids, but the majority was 9 amino acids long (Fig 5D). Seven peptides were 
found in length variants (Table II, numbers 65 to 84) and six of these families varied at 
their C-terminus, reminiscent of leader peptide processing42. However, only one of these 
families was actually encoded in the leader domain, suggesting that amino acid trimming 
at the C-terminus might be a feature of TAP-independent peptides in general. Strikingly, 
no clear binding motif could be elucidated in our peptide repertoire, although previous 
studies with synthetic peptide libraries showed a dominant role for position 2 (M or L)37. 
The C-terminus of the peptides frequently contained an aliphatic amino acid (L, I, M, A 
and F, see Table II), as found for most mouse MHC class I alleles.
We concluded that the presence of the high affinity binding peptide Qdm in the 
groove of Qa-1b prevents the accommodation and display of a broad array of alternative 
peptides and that this new repertoire only emerges upon processing defects. 
Immunogenicity of the Qa-1b-binding peptides
A direct consequence of the absence of this alternative peptide repertoire under 
physiological conditions is that this repertoire may comprise neo-antigens for the CD8+ 
T-cell system. To estimate the immunogenicity of the identified Qa-1b-binding peptides we 
tested them in a matrix-based screening approach in which each peptide was systematically 
represented in two different peptide pools containing five peptides each. None of our 
Qa-1b-restricted T-cell clones recognized peptides from the identified repertoire, so 
polyclonal responder T cells from mice immunized with TAP-deficient EC7.1.Qa-1b.
B7 tumors were applied, assuring that the peptide-directed responses were induced by 
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Figure 5. Identification of the TAP-independent peptide repertoire of Qa-1b. (A) The chimeric 
Qa-1b/Db class I molecule was expressed in EC7.1 cells, which are TAP- and MHC class I-negative. TAP-
positive counterparts were generated by introduction of the TAP2 gene. Surface display on ‘EC7.1.Qa-
1b/Db‘ cells of the chimeric molecule and absence of the endogenous Db molecule was determined by 
flow cytometry with, respectively, Qa-1b- and Dbα3-specific antibodies, and Dbα2-specific antibody, 
as indicated in the histogram plots (clone KH95 and also H131-31 (not shown)). Staining of TAP-
reconstituted cells gave comparable results. Control TAP-proficient RMA cells displayed endogenous 
Qa-1b and Db molecules. (B) TAP expression was analyzed on RMA, RMA-S, EC7.1 and EC7.1.TAP2 
cells by Western blot using the antibody TAP2.688 against mouse TAP2. Results confirmed the lack of 
TAP2 expression on EC7.1 and RMA-S cells. (C) The chimeric construct was recognized by CTL clones: 
the TAP-negative variant only by Qa-1b-restricted CTL (black bars) and the TAP-positive variant only 
by Qdm-specific CTL (grey bars). Means and standard deviations of triplicate wells are shown from one 
representative experiment out of four. (D) Peptide purification and mass spectrometry analysis revealed 
the wide diversity of the TAP-negative peptide repertoire, whereas the TAP-positive peptide repertoire 
was mainly limited to the Qdm peptide. Data were collected from four independent experiments in the 
case of TAP-negative repertoire and two independent experiments for TAP-positive repertoire. Number 
of different peptides with indicated length is depicted of 84 identified peptides that are listed in Table II. 
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1 AMAPRTLLL 3-11 362 P01899 H-2 class I histocompatibility 
antigen, D-B alpha chain
2 AQAERTPEL 691-699 1274 A2RT67 DENN domain-containing 
protein 3
3 IINTHTLLL 1302-1310 1657 Q80UW7 IQ motif containing GTPase 
activating protein 1
4 PKFEVIDKPQS 98-108 108 P97450 ATP synthase-coupling factor 
6, mitochondrial
5 PTEEESPV 486-493 493 P53986 Monocarboxylate transporter 1
6 QAIPQGAIQ 246-254 461 Q8BG99 Homeobox protein PKNOX2
7 QLQPQQPLPQPQ 125-136 672 Q9WVH4 Forkhead protein FKHR2
TAP-negative
1 AAIENIEHL 1193-1201 1392 Q6PB66 Leucine-rich PPR motif-
containing protein, 
mitochondrial
2 AALKLGQEL 799-807 1271 Q9JJ28 Protein flightless-1 homologue
3 AAPTNANSLNSTF 454-466 575 Q8BT14 CCR4-NOT transcription 
complex subunit 4
4 AAPTSPDHSPA 699-709 709 Q66L44 Protein Dos
5 AAVIAHDFL 153-161 292 P30282 G1/S-specific cyclin-D3
6 AGIENDEAF 44-52 248 B1AWD9 Clathrin light polypeptide
7 AGPENSSKI 383-346 2075 Q80XK6 Autophagy-related protein 2 
homologue B
8 AGQFNQDYL 45-53 503 Q921F1 Annexin A11
9 AGVRNPQQHL 515-524 636 Q8BN32 Pabpc1 protein
10 ASLQNFNISNL 2103-2113 2128 B2RRJ7 Wnk1 protein
11 KSISNPPGSNL 2115-2125 2128 B2RRJ7 Wnk1 protein
12 ASQQNSEEM 202-210 210 Q9CXE2 B-cell CLL/lymphoma 7 
protein family member A
13 ASVLNVNHI 2195-2203 2603 Q99NH0 Ankyrin repeat domain-
containing protein 17
14 ASYRAQPSVSL 270-280 573 Q62019 16 kD protein
15 ATPGRLIDFL 256-265 648 Q5U222 Ddx5 protein
16 AVSEGTKAVTKYTSAK 111-126 126 Q8CGP1 Histone H2B type 1-K
17 FAPLPRLPTL 17-26 156 Q9CR21 Acyl carrier protein, 
mitochondrial
18 FAPVNVTTEVKSVE 280-293 462 P10126 Elongation factor 1-alpha 1
19 FAYEGRDYI 137-145 184 Q62143 Qa-2 cell surface antigen
20 FGPVNHEEL 33-41 147 P46414 Cyclin-dependent kinase 
inhibitor 1B
21 FQIVNPHLL 634-642 792 Q6NZB3 Ribonucleoside-diphosphate 
reductase














23 GGPINPATA 1036-1044 1107 Q80X50 Ubiquitin-associated protein 
2-like
24 GLGVLLAF 5-12 113 Q8QZT4 Crumbs protein homologue 3
25 HSIQNSQDM 61-69 210 Q91YN9 BAG family molecular 
chaperone regulator 2
26 IQKTPQIQVY 21-30 119 P01887 Beta-2-microglobulin
27 KAPPPLPPLVVF 27-38 499 P16277 Tyrosine-protein kinase BLK
28 KAPTNEFYA 190-198 198 O35988 Syndecan-4
29 KCSVSIQVVDV 
NDNYPEL
328-345 794 Q91XZ8 Protocadherin beta 22
30 KSAVGHEYV 96-107 486 Q922I8 Hematopoietic cell specific Lyn 
substrate 1
31 LAIRNDEEL 93-101 137 Q64426 Histone H2A
32 LVRPGTALEL 2294-2303 2883 NP_076331 desmoplakin
33 METLTATPQ 976-984 1241 B2RXW8 Ppfia1 protein
34 NSIRNLDTI 100-108 475 P28658 Ataxin-10
35 PADIVKNLK 12-20 341 Q8VDZ8 Calcium binding protein 39
36 PDTGISSKA 52-60 126 Q8CGP2 Histone H2B type 1-P
37 PEAFPALA 385-392 392 Q9CY58 Plasminogen activator inhibitor 
1 RNA-binding protein
38 PNKLVELNK 138-146 943 Q6DFV7 Nuclear receptor coactivator 7
39 PPSAKAAID 97-105 323 Q5SSG6 TATA box binding protein 
(TBP)-associated factor
40 PPTAKAAVE 425-433 661 Q5SUS9 Ewing sarcoma breakpoint 
region 1
41 PVKAVEIEI 155-163 930 Q7TSZ1 Xeroderma pigmentosum, 
complementation group C
42 RSPENPPSKEL 171-181 181 Q9CQA0 Centromere protein M
43 RSPGNSPTPM 186-195 469 Q8CI61 BAG family molecular 
chaperone regulator 4
44 SALINLSSF 7-15 161 Q8VE65 Transcription initiation factor 
TFIID subunit 12
45 SAPENAVRM 28-36 126 O35127 Protein C10
46 SAPSNFEHR 12-20 593 Q8BTW9 Serine/threonine-protein 
kinase PAK 4
47 SAPTGSGKTL 227-236 639 Q6P9R1 ATP-dependent RNA helicase 
DDX51
48 SAVISLEGKPL 156-166 166 P18760 Cofilin-1
49 SAVSNNYIQTL 168-178 911 P30999 Catenin delta-1
50 SHRKFSAPR 2-10 403 Q3U9L3 ribosomal protein L3P family 
member
51 SLGINPHVL 966-974 1170 B2RQL0 Nup98 protein
52 SLGKNPTDAYL 60-70 172 Q3THE2 Myosin regulatory light chain 
MRLC2













54 SSTTNPKLSTL 726-736 959 Q5NBZ5 Eukaryotic translation 
initiation factor 4E nuclear 
import factor 1
55 STIRLLTSL 458-466 545 P80318 T-complex protein 1 subunit 
gamma
56 TNPESKVFYL 155-160 284 P68254 14-3-3 protein theta
57 TQGQNIQHL 431-439 2326 Q80YT7 Myomegalin
58 VAVTNGPRS 371-379 393 Q9D6J1 LAG1 longevity assurance 
homologue 4
59 VPPVQVSPLIKFGRY 2-16 71 Q5EBI8 ATP synthase, H+ transporting, 
mitochondrial F1F0 complex
60 VQVSNFKSGKGDSTL 254-268 579 Q80WJ7 Metastasis adhesion protein
61 VSLLDIDHL 473-481 679 Q8BQM4 HEAT repeat-containing 
protein 3
62 VSLLNPPETL 411-420 422 Q8BRG1 Cyclin A2, isoform CRA
63 VTLVNHGSTF 15-24 640 P59110 SUMO-1 protease 2
64 YGYSNRVVDLM 316-326 333 P16858 Glyceraldehyde-3-phosphate 
dehydrogenase
65 AAPRSGPSV 611-619 641 Q923D5 WW domain-binding protein 
11
66 AAPRSGPSVA 611-620 641 Q923D5 WW domain-binding protein 
11
67 AGIENKFGL 648-656 676 Q9QXX4 Calcium-binding mitochondrial 
carrier protein Aralar2
68 AGIENKFGLYL 648-658 676 Q9QXX4 Calcium-binding mitochondrial 
carrier protein Aralar2
69 AGIENKFGLYLP 648-659 676 Q9QXX4 Calcium-binding mitochondrial 
carrier protein Aralar2
70 TKAVTKYTSSK 117-127 127 A0JNS9 Histone H2B
71 GTKAVTKYTSSK 116-127 127 A0JNS9 Histone H2B
72 SEGTKAVTKYTSSK 114-127 127 A0JNS9 Histone H2B
73 VSEGTKAVTKYTSSK 113-127 127 A0JNS9 Histone H2B
74 AVSEGTKAVTKYTSSK 112-127 127 A0JNS9 Histone H2B
75 PEPAKSAPAPK 2-12 126 Q64478 Histone H2B type 1-H
76 PEPAKSAPAPKKG 2-14 126 Q64478 Histone H2B type 1-H
77 LGVKNSEPA 59-67 576 Q80UG5 Septin-9
78 LGVKNSEPAA 59-68 576 Q80UG5 Septin-9
79 SSPANISSLEFEDA 583-596 773 P51125 Calpastatin
80 SSPANISSLEFEDAK 583-597 773 P51125 Calpastatin
81 SSPANISSLEFEDAKLS 583-599 773 P51125 Calpastatin
82 SSPANISSLEFEDAKLSA 583-600 773 P51125 Calpastatin
83 KPLFEILNG 1138-1146 1735 Q9IZU3 Endogenous mouse mammary 
tumor virus Mtv1
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Figure 6. Immunogenicity of Qa-1b-presented peptides in vitro and in vivo. (A) Immunogenicity of 
59 peptides was determined by compiling the IFNγ response of twenty-five T-cell cultures, which were 
induced by immunization with irradiated TAP-negative EC7.1.Qa-1b.B7 cells. Responses were measured 
using a matrix-based approach in which each peptide was represented in two independent pools. T-cell 
responses against each pool were scored from zero to three and compiled scores from the two pools were 
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Figure 6. Continued. (B) or immunized with the indicated peptide (C). Blood samples were taken and 
cells were stimulated overnight with medium or specific peptide, stained with antibodies and analyzed by 
flow cytometry. Collected data from peptide-specific frequencies of CD8+ cells from mice are depicted 
in (D). Each data point represents one mouse, and data from two independent experiments is shown. 
(E-G) Cytotoxic reactivity in vivo in the same mice as shown in (D). Specific killing was determined in 
naïve (E) or immunized mice (F) by comparing the numbers of CFSEhigh targets, which were loaded 
with relevant peptides, to CFSElow targets, which were not loaded with peptide. CFSEintermediate targets 
were loaded with Qdm and were always comparable to targets without peptide. The means of percentage 
in vivo killing is depicted with standard deviations (G). 
naturally presented antigens. Responses of twenty-five independent T-cell cultures were 
compiled and final immunogenicity scores revealed a number of immunogenic peptides 
(Fig 6A). These peptide antigens had no common amino acid motif and were derived from 
different housekeeping proteins (see corresponding numbers in Table II), again pointing 
at the broad diversity of this antigen repertoire. To assess the potency of the five most 
immunogenic peptide sequences (number 3, 12, 17, 29 and 41) to induce CD8+ T cell 
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responses in vivo, we immunized mice with the peptides in conjunction with imiquimod 
as adjuvant. After two vaccinations, clear populations of peptide-specific CD8+ T cells 
were detectable in the blood (Fig 6B-D). The peptides with the largest T cell populations 
also scored high in the immunogenicity screen in which tumor-stimulated T cells were 
applied (Fig 6A). Interestingly, peptide immunizations in H-2Db-/-Kb-/- mice did not lead 
to a population of IFNγ-positive CD8+ T cells, indicating that the T cell repertoire in these 
knockout mice is tolerant for the novel Qa-1b binding peptides (Fig S3). This is in line 
with the finding that H-2Db-/-Kb-/- target cells efficiently presented these peptides (Fig 3B), 
which are part of the normal Qa-1b peptide repertoire that induces central tolerance in the 
thymus. Importantly, the vaccine-induced CD8+ T cells in wild type mice exhibited strong 
cytolytic reactivity in vivo against target cells that were loaded with the relevant peptide 
(Fig 6E-G). Unloaded target cells and cells loaded with Qdm peptide were not killed in 
vivo. Vaccination with the Qdm peptide did not trigger any T-cell immunity, illustrating 
that the T-cell repertoire for this sequence does not exist or is functionally tolerant.
In conclusion, a broad repertoire of Qa-1b-binding peptide-epitopes of ‘self ’ origin 
emerges at the surface of cells with impairments in the antigen processing pathway and that 
this novel repertoire replaces the TAP-dependent Qdm. These results underscore a role of 
Qa-1b in adaptive immunity and infer that T cell responses are evoked via this nonclassical 
MHC molecule to prevent outgrowth of processing-deficient cells in the body. 
 | DISCUSSION
The nonclassical MHC class I molecule Qa-1b normally presents monomorphic Qdm 
peptides derived from the leader sequences of classical MHC. This Qdm peptide/MHC 
complex functions as a remote sensor of the class I processing pathway integrity through 
detection by CD94/NKG2A receptors on NK cells. Failure to present Qdm, due to 
impairments in proteolysis, TAP or other means, increases the susceptibility of cells for 
attack by these lymphocytes. We here show that Qdm under such conditions is replaced by 
a surprisingly broad repertoire of alternative ‘self ’ peptides. This novel peptide repertoire 
comprises neo-antigens for which the T-cell system is not hampered by immunological 
tolerance and can therefore induce a vigorous response of Qa-1b-restricted CD8+ CTL. 
This antigen presenting function of Qa-1b places this conserved MHC molecule at the 
intersection of innate and adaptive immunity. On one hand, it plays a role as a monomorphic 
inhibiting ligand when Qdm is presented, and, on the other hand, as a display system of 
an immunogenic ‘self ’ peptide repertoire. Our data suggest that the immune system is 
equipped with multiple mechanisms to remove processing deficient cells from the body.
The finding that Qa-1b is capable of presenting other peptides than Qdm is supported 
by previous work from several groups. The leader of the CMV protein UL40 was found 
to be presented, as well as peptides from Salmonella, Listeria, EBV and Mycobacterium 
tuberculosis2. Furthermore, an increase of Hsp60 in the cellular stress response was shown 
to result in replacement of the human Qdm homolog with the Hsp60 signal peptide43. 
110
The unique feature, however, of the peptide repertoire we have elucidated in our current 
work is the fact that these peptides are derived from endogenous housekeeping proteins 
and only emerge in Qa-1b on the cell surface when the processing pathway is hampered. 
We demonstrated the display of these peptides in cells with partial and mild deficiencies 
that do not completely prevent Qdm from appearance, but a complete block in the 
processing pathway, e.g. loss of TAP1 or TAP2, resulted in the most efficient presentation 
of the novel peptides, demonstrating that TAP-independent processing mechanisms are 
responsible for the replacement of Qdm. Surprisingly, cell surface expression of Qa-1b 
is less affected by TAP deficiency than classical MHC class I molecules44, and HLA-E 
surface expression has also been described in the absence of functional TAP proteins or 
class I-derived signal peptides45, 46. Qa-1b and HLA-E, indeed, seem to efficiently egress 
from the ER in the absence of TAP47, 48. These data implicate that our mouse studies are 
relevant for the human setting. Two alternative processing routes have been described 
by which peptides can bypass the TAP transporter: N-terminal signal peptides, which 
are processed by signal peptide cleaving enzymes42 and C-terminal ends of ER-resident 
proteins can also be loaded without TAP function, although the responsible proteolytic 
enzymes have not been identified for this pathway49. Forty percent of the 84 identified 
peptides in our search was indeed located at the N- or C-terminus. Interestingly, one of the 
most immunogenic Qa-1b peptide-epitopes FAPLPRLPTL is encoded in the N-terminal 
signal sequence of a mitochondrial carrier protein (UniProt Q9CR21). The fact that 
sixty percent of the peptides cannot be explained by these two processing mechanisms 
suggests the existence of other yet uncharacterized processing pathways for MHC class 
I antigen presentation. It has been proposed that autophagy might contribute to MHC 
class I-restricted antigen presentation50. Autophagy is a crucial cellular mechanism 
responsible for the clearance of old or damaged cellular components, including 
organelles and macromolecules. This pathway might lead to the generation of peptides 
susceptible for MHC class I loading. Previous characterizations of peptides bound to 
classical MHC class I from TAP-deficient cells revealed similar features: predominance 
of signal peptides, increased peptide lengths, and selective presentation on TAP-negative 
variants51, 52. The Qa-1b peptide repertoires present on TAP-positive versus TAP-negative 
cells were extremely different (Table II), in that the high affinity binding monomorphic 
Qdm strongly dominated the TAP-positive pool for more than 95%, whereas a broad 
diversity of other peptides was present in the TAP-negative pool. Previous comparisons 
of peptide repertoires presented by classical MHC class I molecules showed much more 
overlap between the TAP-positive and -negative pools51, 52. This indicates that the high 
affinity binding Qdm competes with the TAP-independent peptides and thereby prevents 
their presentation under normal circumstances. However, even mild or partial processing 
deficiencies in tumor cells already led to the presentation of both type of peptides, as 
illustrated by the fact that Qdm-specific CTL as well as our Qa-1b-restricted CTL were 
able to recognize the four colon tumors (Fig 4). Importantly, Qdm is not immunogenic 
due to the widespread presentation in the normal host, including thymus53, and thereby 
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prevent tolerance mechanisms for CTL specificities that recognize the new emerging 
peptide-epitopes. We indeed found that T cells specific for these novel Qa-1b peptides 
are deleted in mice that do present these peptides in Qa-1b molecules during T-cell 
development, as in H-2Db-/-Kb-/- mice (Fig S3). 
Our Qa-1b-restricted T-cells exhibit a normal phenotype for CD8+ T-lymphocytes 
(Fig S1) and use rearranged αβTCRs and thereby distinguish themselves from reported 
Qa-1-recognizing intestinal γδ+ T-cells32 and the Qa-1-restricted regulatory CD8αα+ 
T-cell subset33. Target cell recognition was mediated by the TCR and this receptor did not 
cross-react with classical class I molecules, indicating that also at the functional level this 
subset is not different from conventional CD8+ T-lymphocytes. This is in line with data 
from mice lacking classical MHC class I molecules arguing that approximately 10% of the 
total CD8+ T-cell subset is restricted by nonclassical molecules23, 54-56. This T cell repertoire 
is heterogeneous, as witnessed by a diverse usage of TCRVβ segments54, 56. Selection of 
Qa-1b-restricted T-cells in the thymus indeed does occur53, but it remains puzzling how 
a monomorphic Qdm/Qa-1b complex can mediate positive selection resulting in such a 
broad repertoire. Furthermore, the relationship between the suppressive Qa-1b-restricted 
T-cells21, 28 and the tumor-reactive T-cells described here remains elusive.  
We speculate that comparable T-cell subsets exist in human beings, especially because 
Qa-1b and HLA-E are rather conserved in structure and function2. TCR-mediated 
recognition of HLA-E has been described25-27 and it is highly likely that a similar subset as 
our Qa-1b-CTL, which responds against tumors with processing impairments, is present 
in humans. HLA-E surface expression is ubiquitous in the body and even detected in 
the absence of the human Qdm homolog45, 46, although MHC class I leaders strongly 
stimulate HLA-E display19, 57. The lack of polymorphism in the human population infers 
that identified neo-antigens presented in HLA-E constitute universal epitopes that might 
be exploited for the therapy of frequently occurring tumor immune escape variants and 
persistent infections by viruses encoding immune evasion proteins.
 | MATERIAL AND METHODS
Cell lines and mice 
The origin and culturing of most cell lines used in this study was described previously29. 
C4.4-25- is a β2m deficient variant of EL4. RMA-S.B7-1 is a CD80 transfectant of 
RMA-S. EC7.1 is a Kb- and Db-negative variant of RMA-S30. B78H1 is a TAP-deficient 
and MHC class I deficient melanoma34. Tap1–/– and wild type mouse embryo fibroblasts 
were immortalized by the adenovirus type 5 E1 gene (Ad5MEC, clone XC3). Tap1–/– 
fibrosarcoma was induced with methylcholantrene (MCA, clone MCB6TAP). Gene 
transfer of mouse TAP1, mouse TAP2, H-2Db, H-2Kb and Qa-1b (T23 gene) was 
performed with retroviruses based on the MuLV vector LZRS. Generation of CTL 
clones was performed according to previous description29. Briefly, syngeneic C57BL/6 
mice were immunized with irradiated RMA-S.B7-1 cells and in vitro stimulated weekly 
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with a mixture of RMA-S.B7-1 and EC7.1.Qa-1b.B7-1 cells, naïve splenocytes and IL-2. 
Qa-1b-restricted CTL clone B12i that is reactive with the TAP-dependent AMAPRTLLL 
peptide was isolated from a B6.Tla mouse38.
All mice were purchased from Iffa Credo (France) and housed in the animal facility 
of the Leiden University Medical Center under specific pathogen-free conditions and 
used between 8 and 12 weeks of age. TAP1-knockout mice were purchased from Jackson 
laboratories and MHC class I-knockout animals were obtained from Dr. F. Lemonnier56. 
Experiments were performed in accordance with Dutch national legislation and 
institutional guidelines and were approved by the local ethical committee.
CTL assays and flow cytometry 
CTL activity was measured by chromium (51Cr) release assay or IFN-γ ELISA as described 
before58. Data shown represent mean values obtained from triplicate test-wells and the 
error bars represent standard deviation of these values. For antibody blocking, CTL were 
pre-treated with 20 µg/ml antibodies, washed and added as responders to target cells for 
IFN-γ release. The following antibodies were used in functional blocking assays: hamster 
anti-CD3 (Fab2 fragments of clone 145-2C11), control hamster anti-TNP, rat anti-CD4 
(clone GK1.4), rat anti-CD8 (clone 2.43) anti-NKG2A/C (clone 20d5) and anti-Qa-1b 
(clone 6A8.6F10.1A6). For flow cytometry analysis, the following monoclonal antibodies 
were purchased from Becton Dickenson: Ly49AB6 (clone A1), Ly49C/I (clone 5E6), 
Ly49G (clone LGL-1), Qa-1b (clone 6A8.6F10.1A6), NKG2AB6 (clone 16a11), CD94 
(clone 18d3), CD3 (clone 145-2C11), CD8α (clone Ly2), CD8β (clone Ly-3.2.), CD4 
(clone GK1.4), CD16/CD32 (clone 2.4G2), NK1.1 (clone PK136), CD49b (clone 
DX5), CD244 (clone 2B4). From eBioscience we purchased NKG2D (clone CX5).
Peptide elution, HPLC and mass spectrometry 
Peptides were eluted out of purified chimeric Qa-1b/Db molecules from EC7.1 cells. The 
genomic H-2Db construct in which the alpha 1 and alpha 2 domains were exchanged with 
those of Qa-1b was kindly provided by Dr. PJ Dyson (United Kingdom)38. This genomic 
construct was expressed in HeLa cells and cDNA was then cloned into the retroviral 
construct LZRS. EC7.1 cells transduced with this construct were twice sorted by FACS. 
TAP-positive counterparts were generated by retroviral gene transfer of the mouse TAP2 
gene. Immunoprecipitation of Qa-1b/Db molecules was performed with protein A beads 
covalently coupled with anti-Db mAb 28-14-8S from two and four independent lysates of 
40.109 TAP-positive and TAP-negative EC7.1 cells, respectively, as previously described58. 
The peptide pools were prefractionated on a C18 RP-HPLC system (200 µm x 15 cm; 
Reprosil-C18-AQ 3 µm (Dr. Maisch GmbH, Ammerbuch, Germany)). Fractions were 
reduced to near dryness, diluted in 95/3/0.1 v/v/v water/acetonitril/formic acid and 
subsequently analyzed by tandem mass spectrometry. Peptides were analyzed by nanoflow 
liquid chromatography using an Agilent 1100 HPLC system (Agilent Technologies), 
as previously described29, coupled on line to a 7-tesla LTQ-FT mass spectrometer 
(Thermo Electron, Bremen, Germany). The end of the nanocolumn was drawn to a tip 
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(ID approximately 5 µm), from which the eluent was sprayed into the mass spectrometer. 
Peptides were trapped at 5 µl/min on a 1-cm column (100-µm ID, ReproSil-Pur C18-AQ, 
3 µm) and eluted to a 15 cm column (50-µm ID, ReproSil-Pur C18-AQ, 3 µm) at 150 nl/min 
in a 60-min gradient from 0 to 50% acetonitrile in 0.1% Formic acid.
The mass spectrometer was operated in data-dependent mode, automatically switching 
between MS and MS/MS acquisition. Full scan MS spectra were acquired in the FT-ICR 
with a resolution of 25,000 at a target value of 3,000,000. The two most intense ions 
were then isolated for accurate mass measurements by a selected ion monitoring scan in 
FT-ICR with a resolution of 50,000 at a target accumulation value of 50,000. The selected 
ions were then fragmented in the linear ion trap using collision-induced dissociation at 
a target value of 10,000. In a post analysis process, raw data were converted to peak lists 
using Bioworks Browser software, Version 3.1. For peptide/protein identification, MS/
MS data were submitted to the mouse IPI database using Mascot Version 2.1 (Matrix 
Science) with the following settings: 5 ppm and 0.8-Da deviation for precursor and 
fragment masses, respectively; no enzyme was specified. All peptides with a mascot ion 
score above 30 were manually inspected. This resulted in an initial set of 150 peptides. 
These peptides were synthesized and their MS/MS spectra compared with the MS/MS 
spectra of the Qa-1b-eluted peptides. This resulted in 84 confirmed peptide identifications. 
Immunogenicity screen of Qa-1b presented peptides
C57BL/6 mice were immunized twice with irradiated EC7.1.B7-1 cells with stable 
expression of Qa-1b. Spleens of immunized mice were cultured with the same cells for 
one to two weeks and reactivity of the cultures was tested against the EC7.1 cell panel 
to confirm Qa-1b restriction of the T-cells. Reactivity against the identified peptides was 
assessed using a matrix-based system with pools of 5 different peptides and in which each 
peptide was represented in two independent pools. The peptide pools were loaded on 
spleen cells and IFNγ production by T-cell was measured with sandwich ELISA after 18 h. 
Reactivity against each pool was arbitrarily scored from zero to three, according to the 
mean background response. Twenty five independent cultures were assayed in this way 
and the scores of each pool compiled. The final immunogenicity score for each peptide was 
then obtained by multiplying the scores of two pools containing that particular peptide. 
Peptide immunizations and in vivo cytotoxicity assay
For peptide immunizations, C57BL/6 and H-2Db-/-Kb-/- mice were injected s.c. at the 
flank with 50 µg peptide mixed with 50 µg helper peptide from MuLV (H1929) in PBS on 
day 0 and 7. Immediately following injection, 60 mg Aldara™ cream (3M Pharmaceutical) 
containing 5% imiquimod was applied to the skin at the injection site. Mice received i.p. 
injections of 500,000 IU recombinant human IL-2 (Novartis) on the day of the second 
vaccination and on the day thereafter. T-cell frequencies were determined from blood 
lymphocytes after four days and from spleens after seven days with intracellular cytokine 
staining, as previously described59. In short, cells were cultured overnight with medium 
or 5 µg/ml of peptide and stained for CD8 and intracellular IFNγ. Killing capacity of 
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 | SUPPLEMENTARY FIGURE LEGENDS
Figure S1. Qa-1b-restricted T-cells display a conventional CD3+CD8+ phenotype. Flow cytometry 
analysis of Qa-1b-resticted CTL revealed expression of T-cell lineage markers, but not NK cell markers. 
Conventional anti-tumor T-cells restricted by classical MHC class I molecules show comparable 
phenotype (not included in this graph). All markers were tested twice. One Qa-1b-resticted T-cell clone 


















































































































































































B6 mice DbKb-/- mice 
Figure S2. Selective recognition of Qa-1b-expressing target cells. Isolated T-cell clones were tested 
against a panel of TAP-deficient lymphoma (EC7.1) cells. EC7.1 cells are also deficient in MHC class I30 
and were reconstituted with constructs encoding H-2Db, -Kb or Qa-1b. IFNγ production against Qa-1b-
positive EC7.1 cells by three independent T-cell clones. Control Qdm-specific CTL failed to recognize 
the Qa-1b expressing targets, due to the absence of TAP. TAP-positive lymphoma cells (RMA) were 
recognized by this CTL clone (right panel). Means and standard deviations of triplicate wells are shown 
for one out of three comparable experiments.
Figure S3. Immunogenicity of Qa-1b-presented peptides in MHC class I knockout mice. H-2Db-/-
Kb-/- and control B6 mice were immunized with two TAP-independent peptides FAPLPRLTL (peptide 
17) and KCSVSIQVVDVNDNYPEL (peptide 29) and Qdm. PBL from blood samples were incubated 
overnight with selected peptides (panel A) or PMA/Ionomycin mitogens (panel B) and intracellular 
IFNγ production in CD8+ T cells was determined by flow cytometry. Frequencies of IFNγ producing 
T-cells were observed against Qa-1b peptides in control B6 mice but not in MHC class I knockout mice. 
PMA induced activation of T cells from all mice. Each data point represents one mouse.
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 | ABSTRACT
The non-polymorphic MHC molecule Qa-1 and its human counterpart HLA-E present 
monomorphic signal peptides to innate receptors and thereby regulate lymphocyte 
activity. Under stress, this peptide content is replaced with a surprisingly diverse 
repertoire of novel peptides that are associated with heat shock proteins, infectious 
agents or antigen processing defects. 
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 | INTRODUCTION 
MHC class I molecules serve to pickup and present intracellular antigens to circulating 
lymphocytes, which recognize these target structures after physical interaction with their 
T cell receptors (TCR). The immune system is thereby enabled to recognize and remove 
pathogens and transformed cells from the body. MHC class I molecules can be divided into 
classical Ia and non-classical Ib. The most striking feature of MHC class Ib molecules is their 
highly conserved nature. Whereas MHC class Ia genes display extensive polymorphism 
among their family members, the prototypic mouse MHC class Ib Qa-1 and its direct human 
homolog HLA-E are essentially nonpolymorphic. In this review we will refer to Qa-1 and 
HLA-E molecules as Qa-1/HLA-E. It is of interest that the Qa-1/HLA-E bound peptide 
content is normally highly restricted, comprising mostly of signal peptides derived from 
MHC Ia proteins. The resulting non variable peptide/MHC-Ib complexes constitute a 
ligand for the germ line encoded receptors CD94/NKG2. This function of Qa-1/HLA-E 
molecules is well established. However, in times of cellular stress, Qa-1/HLA-E shows 
its other face, like the Roman god Janus, typically portrayed with two faces in opposite 
directions (figure 1). This alternative face of Qa-1/HLA-E is associated with the replacement 
of bound signal peptides by a novel much more diverse repertoire of peptides, which can be 
sensed by αβ TCRs. We have recently described two such novel peptide repertoires that were 
presented by Qa-1/HLA-E molecules to specific CD8+ T cells, which were related to sensing 
intracellular infection with mycobacteria, or to antigen processing defects in tumors1, 2. These 
two situations of intracellular stress illustrate that Qa-1/HLA-E probably serve a much 
broader function in adaptive immunity than thus far anticipated.
Figure 1. The Roman god Janus is always portrayed with two faces in opposite directions. Thereby, 
he represented an intermediary between two worlds. Qa-1/HLA-E molecules have an important 
function in innate immunity through interacting with innate, invariable CD94/NKG2 receptors. In 
addition, these conserved MHC class I molecules have an novel function in adaptive immunity since 
they can present diverse intracellular stress related peptide repertoires to hypervariable T cell receptors.
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 | Qa-1/HLA-E NORMALLY PRESENT MONOMORPHIC 
PEPTIDES IN THEIR BINDING GROOVES
The mouse Qa-1 protein is a nonclassical (class Ib) MHC molecule, encoded by the T23 
locus and constitutes the mouse homolog of HLA-E. Like its human counterpart, Qa-1 
is virtually nonpolymorphic, as sequencing of multiple mouse strains and even outbred 
mice revealed only two dominant allelic variants: Qa-1a and Qa-1b 3. Strikingly, while 
human HLA-E and mouse Qa-1 share 73% homology at the protein level, their function 
and the non-variable peptides that they bind are surprisingly similar4, 5. Both MHC class 
Ib molecules accommodate signal peptides in their hydrophobic peptide binding groove, 
mostly derived from the leader sequences of classical MHC class Ia molecules. In the 
mouse, this peptide comprises the amino acid sequence AMAPRTLLL and has been 
called Qdm for ‘Qa-1-determinant-modifier’, since this factor had a strong influence on 
Qa-1 stability. It was a surprise-discovery that the Qa-1 bound signal peptide appeared 
to be encoded within the MHC I region6 and was derived from the classical class Ia 
molecules H-2D and H-2L.  The other MHC class Ia protein in the mouse, H-2K, does 
not encode Qdm signal peptides and thus does not contribute to stabilization of Qa-1. 
Peptide elution studies of Qa-1 revealed that this Qdm peptide represented up to 70% 
of the total peptide content of Qa-17. We recently confirmed the dominance of this one 
particular peptide using state-of-the-art mass-spectrometry2. Although we also found 
other peptide sequences in Qa-1, these represented only minor amounts compared to 
Qdm. Not surprisingly, the AMAPRTLLL peptide seems to have an amino acid sequence 
optimal for binding and stabilization in the hydrophobic groove of Qa-1. Changes in 
amino acid residues in this 9-mer peptide invariably lead to decreased binding affinity8, 9. 
Compared to classical peptide/MHC complexes, though, the Qdm/Qa-1 complex is 
relatively unstable at the cell surface, and its expression therefore probably reflects the 
actual Qdm availability in the cell10. 
As mentioned, humans share a nearly identical Qa-1 like MHC-Ib molecule, HLA-E. 
Only one single amino acid difference has been identified between the two HLA-E subtypes; 
this coding variation is located at position 107 (HLA-E*0101 has an arginine and E*0103 
carries a glycine) on the loop between β-strands in the α2 domain of the heavy chain, outside 
the peptide binding groove11, 12. Both variants are indistinguishable in their structure and 
peptide binding features, although HLA-EG homozygous cells seem to express higher levels 
of HLA-E at the cell surface5, 12, 13. The frequency of both variants is equal amongst different 
populations suggesting balanced selection at the population level14. HLA-E molecules 
are filled with peptides with striking similarity to the mouse Qdm: some classical HLA 
class Ia proteins comprise signal peptides with the sequence VMAPRTLLL, differing at 
only one amino acid position from Qdm. Due to the extensive repertoire of human HLA 
class I, which comprises more than hundred allelic variants, the exact sequence of the 
human Qdm counterpart differs somewhat between different HLA class Ia backgrounds, 
especially at positions 2, 7 and 8 (Table I). Most of these signal peptides indeed efficiently 
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bind to HLA-E, implying that they all support cell surface display of HLA-E. Exceptions 
are Qdm-like peptides from some HLA-B alleles, which carry a threonine amino acid at 
position 2, and HLA-E itself, which is too short and, in contrast to HLA-Ia molecules, 
does not contain the Qdm motif (Table I). A direct consequence is that HLA-E can not 
support its own stabilization at the cell surface, but is dependent on the de novo production 
of classical HLA Ia proteins15. All individuals in the human population carry at least one 
allele that provides a HLA-E-binding Qdm peptide. Interestingly, the leader sequence 
of the class Ib molecule HLA-G, which shows a highly restricted expression in placenta 
tissue, is one of the most optimal binding peptides16. HLA-G and HLA-E are amongst the 
few HLA molecules expressed in human throphoblasts, which invades the maternal part 
(the decidua) of the placenta17. Increased regulatory T cell numbers are observed in the 
placenta, mostly at this site of feto-maternal contact, maybe as a result of HLA-E. In any 
case, expression of HLA-G and HLA-E is associated with immunosuppression, needed to 
prevent rejection of the immunologically ‘foreign’ fetus17.
Another interesting aspect of the variations of Qdm-like peptides in the human 
population is the finding that these peptides behave as minor histocompatibility antigens 
(mHAGs). In mixed lymphocyte cultures, in which alloreactive T cell responses are 
induced, HLA-E restricted T cells can be detected that are specific for a ‘non-self ’ Qdm 
peptide variant18-20. These T cells might have been induced by viruses, as CMV has been 
shown to encode exactly the same Qdm-like peptide variants5.
 | Qa-1/HLA-E AS REMOTE SENSORS OF THE 
INTRACELLULAR ANTIGEN PROCESSING MACHINERY
Qdm-like peptides are encoded by the N-terminal regions of MHC I molecules, which 
serve as hydrophilic segments to co-translationally target the newly synthesized proteins 
to the ER. Once in the ER, the hydrophilic N-terminus is released from the class I proteins 
by the dedicated enzyme signal peptidase (SPase)21. The native class I protein is further 
Table I. Qdm peptide sequences from HLA class I molecules
Locus sequence examples of HLA types HLA-E binding
HLA-A VMAPRTLLL A*01, A*03 yes
VMAPRTLVL A*02, A*24 yes
HLA-B VMAPRTVLL B*07, B*08 yes
VTAPRTLLL B*13, B*27 no
HLA-C VMAPRTLLL Cw*02, Cw*15 yes
VMAPRTLIL Cw*03, Cw*04a yes
HLA-E MVDGTLLL E*01 no
HLA-F MAPRSLLL F*01 no
HLA-G VMAPRTLFL G*01 yes
a except Cw*0402 subtype
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chaperoned by calnexin and incorporated into a protein complex responsible for peptide 
loading, the so-called peptide loading complex (PLC)22. The chopped signal peptide of 
MHC I molecules, which is in most cases 24 amino acids long, remains in the ER membrane 
due to its hydrophobicity and needs liberation from this location by a second cleavage 
mediated by the signal peptide peptidase (SPPase), an aspartic protease, which acts 
within the ER membrane23. This SPPase mediated cleavage results in release of the Qdm-
containing part of the leader into the cytosol21. This cytosolic part is not just degraded, but 
gets a second life as peptide ligand of Qa-1/HLA-E. For this loading process, the precursor 
peptide is further sculpted by the proteasome to make it suitable for transport back into the 
ER by the peptide transporter TAP24. In the ER, the PLC facilitates loading of the signal 
peptide into the groove of Qa-1/HLA-E, followed by transport to the cell surface15, 25, 26. 
This complicated intracellular processing pathway of MHC class I leader peptides thus 
implicates a large set of proteins that is necessary for proper display of the class Ia-derived 
peptides in Qa-1/HLA-E: classical HLA Ia molecules, SPase, SPPase, proteasome, TAP 
and tapasin (figure 2). Deficiencies in each of these enzymes and chaperones have been 
demonstrated to result in failure to load and bind Qdm-like peptides. In other words, if one 
of these components is absent or disabled, the Qdm peptides are not presented anymore 
at the cell surface by Qa-1/HLA-E. This way, the Qa-1/HLA-E system elegantly reveals 
the integrity of the whole MHC I antigen processing pathway and is therefore often called 
‘remote sensors of proper class I presentation’. Malfunctioning cells, in cases of stress, 
VMAPRTLVL
MA VMAPRTLVL LLSGALALTQTWA GSHS--------
1: Signal Peptidase
MA VMAPRTLVL LLSGALALTQTWA
2: Signal Peptide Peptidase
MA VMAPRTLVL LLS
3: Proteasome
4: TAP-transport to ER 5: Loading in HLA-E
mediated by 
peptide-loading complex
Figure 2. The processing requirements for proper presentation of Qdm peptides by Qa-1/HLA-E. 
The signal sequence of HLA-A2 molecules is taken as an example in this figure. The liberation of the Qdm 
peptide from its protein context needs at least three distinct proteolytic enzymes: signal peptidase (1) 
to remove the leader from HLA-A2 proteins, the signal peptide peptidase (2) to release the membrane 
associated peptide from the ER membrane and the proteasome (3) to generate the right C-terminus. It 
is unknown if the two N-terminal amino acids are removed by the proteasome or by aminopeptidases in 
the ER. The peptide loading complex involves at least tapasin, ERp57 and calreticulin.
126
infection or transformation, are thus marked for detection by immune cells, due to the lack 
of Qdm presentation. Intracellular pathogens are, however, able to sabotage this system 
and escape immune detection. Intriguingly, processing defects can lead to replacement 
of Qdm-like peptides with an alternative, surprisingly broad repertoire of peptides2, 
supporting earlier indications that the binding motif of Qa-1/HLA-E molecules is much 
less stringent as generally appreciated27. This novel repertoire is a clear witness of the other 
face of Qa-1, which will be discussed later.
 | PRESENTATION OF Qdm PEPTIDES BY Qa-1/HLA-E IS 
SENSED BY CD94/NKG2 RECEPTORS
The importance of Qa-1/HLA-E is illustrated by the fact that Qdm-like peptides have 
been broadly determined across mammalian species, including mouse, rat, dog, cat, 
cow, gorilla, chimpanzee and human28. The sequences of all these peptides are strikingly 
conserved and actually all efficiently bind HLA-E.  The identification of the cognate 
receptor for this non-variable Qdm/MHC-Ib complex was a breakthrough and strongly 
boosted the unraveling of biological functions of this receptor-ligand pair. Tetramerized 
peptide/HLA-E complexes revealed the heterodimeric CD94/NKG2 surface 
molecules as the specific and selective receptors for HLA-E when filled with Qdm-like 
peptide29, 30. These receptors are invariant transmembrane molecules that are expressed by 
approximately half of all natural killer (NK) cells and activated CD8+ T cells31. The CD94 
subunit makes most contact with peptide residues and the upward pointing alpha helices 
of HLA-E32-34. The NKG2 subunit hardly interacts with peptide residues, but contains the 
signal transduction domain32-34. NKG2 receptor genes are clustered in the NK-complex 
locus, and come in different flavors: NKG2A, NKG2C, and NKG2E. These three variants 
differ from each other only at few amino acids, which determine their affinity for CD94 
and whether the specific CD94/NGK2 heterodimer acts as an inhibitory or activating 
receptor. NKG2C and NKG2E are less frequently expressed on lymphocytes, lack an 
ITIM motif in their cytoplasmic domains and associate with the activating adaptor 
molecule DAP12, whereas the inhibitory ITIM-bearing NKG2A recruits phosphatases, 
like SHP-1 to the signal transducing synapse5, 31. The overall structures of the inhibiting 
and activating receptors are quite similar and their ‘footprint’ on the peptide/HLA-E 
complex is also conserved32-34. However, the binding affinity of the activating receptors is 
considerably lower than that of the inhibitory ones. 
Reactivity of NK cells is governed by the balance between incoming activating and 
inhibiting signals from surface receptors; the CD94/NKG2A receptor behaves like a 
strong silencer on NK cells. We have to keep in mind that the non-variable Qdm/HLA-E 
molecules are widely expressed by most nucleated cells of the body, so that NK cells, 
which constitute approximately 10% of lymphocytes in the blood continuously sense the 
presence of HLA-E. NK cells have to overcome this input of inhibitory signals by ligation 
of activating receptors. On the other hand, the absence of this Qdm/HLA-E complex on 
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target cells increases their susceptibility to killing. Hence, CD94/NKG2A enables NK 
cells to sense the absence of ‘self ’ MHC on target cells in an indirect way and behaves 
like a remote sensor for NK cells to select target cells for lysis31. The discovery of such 
HLA-interacting receptors forms the molecular basis of the ‘missing self ’ hypothesis that 
was postulated by Ljunggren and Kärre in the 1980’s35, which formulated that NK cells 
exhibit preference for tumor cells with low MHC class Ia expression. More recently, the 
important role of Qa-1 to protect normal cells from NK mediated lysis was illustrated by 
using genetically modified mice completely lacking Qa-1, or expressing Qa-1 molecules 
that failed to interact with CD94/NKG2A receptors36. T lymphocytes from mice 
carrying an aberrant Qa-1 molecule failed to expand in vivo and were very sensitive for 
NK attack. Depletion of NK cells completely restored the clonal expansion upon antigen 
encounter36. Furthermore, the Qdm peptide could be exploited to protect adoptively 
transferred cells37, 38. Collectively, these studies indicate that immunosurveillance of 
NK cells is particularly efficient in the hematopoietic system and that sensing the Qdm 
presentation by Qa-1/HLA-E plays a key role in the regulating NK reactivity. 
During the last decade it has become evident that also activating receptors contribute 
to the establishment of NK cell reactivity31. The activating partners of CD94 (NKG2C 
and NKG2E) engage the same Qdm/HLA-E complex as the inhibiting receptor NKG2A, 
although with lower affinity39. It is still puzzling how two receptors recognizing the same 
ligand can have opposing functions. Nevertheless, the increase of NKG2C positive 
NK cells after CMV infection40 eludes to an adaptation of the NK repertoire favoring 
protection against infectious agents.
 | CD94/NKG2A RECEPTORS ARE ALSO EXPRESSED BY 
LYMPHOCYTES IN ADAPTIVE IMMUNITY
In addition to being expressed on NK cells, CD94/NKG2A receptors are also expressed 
on CD8+ T cells. Approximately 5% of circulating CD8+ T cells express both CD94 
and NKG2A. The expression of these NK receptors is found on conventional antigen-
specific T cells with classically rearranged TCRαβ chains, and it has created considerable 
confusion to designate these cells as a separate subpopulation called NKT cells. The 
currently emerging picture instead is that this subpopulation of CD8+ T cells belongs 
to the antigen-experienced memory pool, and that the CD94/NKG2A receptors are 
induced by activation at T cell priming or by the cytokines IL-12, IL-15 or TGFβ31. 
These receptors might even directly promote the formation of memory cells, since 
CD94/NKG2A positive T cells seem to be less prone to activation-induced cell death41. 
Viruses are again likely involved in inducing CD94/NKG2A receptor expression on T 
cells: examples include the strong increase of this receptor on antigen-specific T cells 
after polyoma virus infection in a mouse model; the regulating effect of CD94/NKG2A 
on the cytolytic function of T cells in a Herpes Simplex virus model; and the steep 
increase of T cell subpopulations carrying this receptor after CMV seroconversion in 
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transplant patients42-44. In general, the frequencies of CD94/NKG2A expressing T cells 
are much higher than those expressing other NK-related receptors, e.g. NK1.1, DX5, 
Ly49 and KIR. Considering the large pool of T cells that expresses the Qdm/HLA-E-
recognizing receptor in a given individual, these receptors might be regarded in fact as 
‘T cell associated receptors’ instead of ‘NK receptors’. Anyhow, the prevailing conclusion 
seems that expression of CD94/NKG2A on activated CD8+ T cells is common, and that 
QA-1/HLA-E detection by these adaptive lymphocytes might dampen overt cytotoxicity. 
Pathogens are apparently able to exploit this system to prevent total eradication.
 | HCMV BRINGS ALONG ITS OWN Qdm PEPTIDE
Viruses and especially herpes viruses are able to inhibit MHC class I presentation as a 
strategy to hide from adaptive T cell immunity. For most herpes viruses, which induce 
live long persistent infections, this strategy is quite successful. The host is not capable of 
clearing herpes virus family members like CMV, EBV and HSV, and a high percentage of 
the human population is latently infected. In situations of immune suppression, such as 
post transplant patients and the elderly, herpes viruses can reactivate from latency into a 
productive phase and pathology. A multitude of dedicated viral proteins cooperate in this 
stealth technology45. The important bottleneck of the intracellular processing machinery 
is the peptide transporter TAP: several herpes virus proteins have been identified with 
a TAP-destabilizing function. TAP deficiency will directly block the presentation of 
Qdm-like peptides by HLA-E, since its loading is TAP dependent. This poses the question 
as to why do such infected cells in the body survive NK controlled immunosurveillance, 
since an effective shutdown of MHC class Ia presentation should sensitize these cells for 
NK attack. Part of the answer was provided by studying the HLA-E cell surface display on 
human CMV infected cells. Infection with CMV indeed led to the decrease of Qdm-like 
peptides in HLA-E, due to the action of immune evasion molecules that target the display 
of classical HLA. However, HLA-E cell surface presentation was retained by loading a 
peptide from one of the viral proteins, UL4046, 47. The signal peptide from UL40 contains 
an exact Qdm-like sequence and the supply of this viral peptide is able to substitute for 
the lack of natural leader peptides from classical MHC class Ia. Of course, loading of the 
UL40 leader peptide needed to be TAP-independent since this transporter is blocked by 
US6 in CMV infected cells45. Intriguingly, the flanking amino acids of the UL40 signal 
peptide differs from that of the class Ia and it is exactly this segment that specifies the 
SPPase cleavage site48. The final result is that the processed UL40 leader directly falls back 
in the lumen of the ER, instead of arriving in the cytosol where it would need to regain 
access to the ER via TAP. In this manner, CMV bypasses the normal HLA-E loading 
system by developing a shortcut which is necessary because of its own obstruction of the 
classical peptide presentation pathway. HCMV is not the only virus that brings along an 
own Qdm peptide, but this example clearly illustrates that viral pathogens have developed 
dedicated mechanisms to protect themselves for NK recognition via the HLA-E pathway. 
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 | CELLULAR STRESS REMOVES Qdm PEPTIDES FROM 
Qa-1/HLA-E MOLECULES
Thus far, we discussed Qa-1/HLA-E molecules carrying signal peptides derived from 
classical MHC Ia molecules, which are the dominant constituents of the HLA-E binding 
groove. These Qdm-like peptides bind with relatively high affinity to HLA-E and render 
this molecule an essentially non-variable structure, in contrast to other MHC class I a/
peptide molecules. On this side of the Janus face Qa-1/HLA-E looks and acts like an 
innate molecule with an important role in NK- and T-cell reactivity via interacting with 
the conserved receptors CD94/NKG2. However, in situations of cellular stress and 
induced expression of heat-shock proteins, HLA-E replaces its Qdm-like peptides by 
alternative peptides such as heat-shock protein-derived peptides49, 50. These peptides share 
some sequence homology with Qdm, but are clearly distinct. The most interesting aspect 
of this finding was that the CD94/NKG2A receptors failed to recognize HLA-E molecules 
binding an hsp60 peptide. As a direct consequence, the stressed cells were no longer 
protected from NK cell lysis50. The CD94/NKG2A receptor was indeed shown to directly 
interact with side residues of the Qdm peptide and changes at certain amino acid positions, 
especially p5 and p8, results in failure to bind Qdm/MHC complexes8, 33, 34. Thus, this 
NK receptor is truly Qdm peptide-specific. Interestingly, the crystal structure of a Qdm-
specific alloreactive TCR showed an interface with the Qdm/HLA-E ligand that was quite 
similar to that of CD94/NKG2A51. In that sense, the heterodimer CD94/NKG2A shares 
unique characteristics with the peptide-sensing TCRαβ chains of T lymphocytes. 
 | Qa-1/HLA-E AS THE RECOGNITION ELEMENT FOR T CELL 
RECEPTORS: SELF PEPTIDES
The other side of the Janus face of Qa-1/HLA-E shows a MHC class I molecule presenting 
a surprisingly diverse repertoire of peptides. At first glance, the extensive variability of TCRs 
and the high specificity for their peptide targets do not associate well with the knowledge 
we have on the nonpolymorphic QA-1/HLA-E molecules. The fact that TCRs are able 
to recognize Qdm peptide variants in QA-1/HLA-E was evidently shown in alloreactive 
responses, as described above. Furthermore, one of the hsp60 peptides that can replace Qdm 
is also a target for TCRs49, 52. These Qa-1-restricted CD8+ T cells cross-react to the Salmonella 
derived GroEl peptide, an example of molecular mimicry, and might explain autoimmune 
pathology in reactive arthritis52. Examples of other ‘self ’ peptides presented by Qa-1/HLA-E 
are those that arise from TCR chains, multidrug resistance-associated protein and those 
that are associated with antigen processing defects2, 53, 54. The peptides that are derived from 
V-segments of TCRs are targeted by a population of CD8+ regulatory T cells and mediate 
alleviation of autoimmune disorders via dampening the pathogenic CD4+ T cells55.
Recently, we described a diverse repertoire of Qa-1-presented peptides that is 
associated with antigen processing defects2, 56 As mentioned above, the presentation of 
Qdm is strictly dependent on the integrity of the antigen processing machinery (figure 2). 
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In cases were one of the processing components is downregulated or mutated, as found 
in a high frequency in tumor cells, Qdm does not emerge at the cell surface. Interestingly, 
the surface expression of Qa-1/HLA-E molecules is relatively preserved10, 57, 58, most 
likely due to the replacement with an unique set of ‘self ’ peptides. The novel peptides that 
replace Qdm in TAP-negative cells originated from normal proteins within the cell and 
constitute epitopes for CD8+ T cells, since they represent neo-antigens that are normally 
not displayed by Qa-12, 56. This T cell subpopulation was reactive against tumors with 
processing deficiencies like TAP defects, and our findings strongly suggested that the 
novel Qa-1 peptides are suitable for vaccination-based therapies, benefiting from the 
selective activation of the Qa-1-restricted effector CD8+ T cells. Interestingly, multiple 
tumors of different MHC haplotypes were recognized by this T cell subset, due to the 
conserved nature of Qa-1. Moreover, tumors of different tissue origin were targets, 
because Qa-1 is expressed by most nucleated cells of the body. In contrast to what is 
sometimes thought, Qa-1/HLA-E proteins are not restricted to the hematopoietic 
system, but can be detected ubiquitously. Together with the organization of the Human 
Protein Atlas (www.proteinatlas.org), we charted all human tissues for HLA-E expression 
and observed an expression pattern quite similar to that of HLA class Ia molecules.  
Importantly, the novel peptide repertoire that we determined in Qa-1 did not fulfill 
the binding motif as previously described for Qa-1 and HLA-E8, 9, 59. The major anchor 
binding pockets for the peptides, positions 2 and 9, are optimally accommodating leucine/
methionine and aliphatic amino acids, respectively. This binding motif is not unique for 
Qa-1/HLA-E and is actually similar to the binding motif for the classical HLA-A2 allele60, 61. 
Our study seems to indicate that binding requirements of Qa-1/HLA-E are not so strict, as 
suggested before27. Together, these findings portrait Qa-1/HLA-E as a highly flexible MHC 
class I molecule with an important function to present a broad peptide repertoire to αβ T 
cells, completely different from the non-variable Qdm structure described above.
 | HLA-E AS THE RECOGNITION ELEMENT FOR T CELL 
RECEPTORS: PATHOGEN-DERIVED PEPTIDES
The adaptive face of Qa-1/HLA-E is also revealed in studying infectious pathogens. Several 
pathogens have been reported to encode HLA-E binding peptides: Salmonella, Listeria 
monocytogenes, LCMV, HIV, HBV, EBV, HCV and Mycobacterium tuberculosis (Mtb)4, 5. This 
long list points at the existence of a subset of CD8+ T cells that sense pathogen derived 
antigens in Qa-1/HLA-E molecules with their TCRs. How large this population of non-
classically restricted cells is, remains elusive and in addition to Qa-1/HLA-E, also other non-
classical presentation molecules have been associated with T cell recognition. The T cell 
repertoire in mice that lack classical MHC class Ia molecules suggests that approximately 
10% of the CD8+ pool is restricted by non-classical MHC class Ib molecules62.
First indications that Mtb antigens are presented by the conserved HLA-E molecule 
date back to 200263. The identity of the peptide-epitopes recognized by the human HLA-E-
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restricted CD8+ T-cell clones, however, remained elusive. Recently, we studied CD8+ T cell 
recognition of peptides that contained in silico predicted HLA-E epitopes for recognition 
by human T cells1. Newly identified Mtb peptide epitopes were found by measuring 
proliferation of human CD8+ T-cells from PPD-responsive adults and BCG-vaccinated 
infants. The responding cells had cytotoxic activity, and lysed target cells in a peptide-
specific and HLA-E dependent fashion, strongly suggesting peptide/HLA-E engagement 
by the TCR. Live mycobacterium infected monocytes were killed by these effector 
T cells, demonstrating proper antigen presentation by infected target cells. Strikingly, in 
addition to their cytolytic capacity, these Mtb-reactive T-cell lines also exhibited strong 
immunosuppressive properties, as they inhibited proliferation of unrelated responder 
T-cells. This suppression was dose-dependent, required cell-cell contact and was mediated, 
at least in part, by membrane bound TGFβ1 (mTGFβ1)1. T cell lines and clones derived 
from limiting dilution assays demonstrated that the dual activity could be, but was not 
necessarily mediated by the same HLA-E/peptide induced T cells. So, both types of HLA-E 
mediated immune reactivity might play a role during infection. The relative contribution of 
these two activities to resolution and persistence of the mycobacteria remains to be studied. 
We need to decipher if HLA-E mediated antigen presentation in tuberculosis preferentially 
activates T-cells with regulatory properties as compared to T-cells with cytolytic activity. 
Interesting in this context is the finding that mycobacteria reside in phagosomes of antigen 
presenting cells, especially macrophages, and that these phagosomes are enriched in 
HLA-E. This at least suggests a relatively large presentation of mycobacterial peptides on 
human HLA-E64. Recent mouse experiments have indicated that regulatory T cells are 
“bad guys” in tuberculosis when it comes to control of bacterial growth, especially early 
during infection65-67. This balance between effector and regulatory immunity in the context 
of HLA-E might allow partial clearance of pathogen from the host, thus providing sufficient 
levels of protection while avoiding excessive inflammation and pathology, but at the expense 
of pathogen persistence and chronic infection. 
In addition to its potential contribution to immune suppression via regulatory 
T cells, HLA-E might offer unique opportunities to embark on vaccination strategies 
for tuberculosis, due to the low level of variation in HLA-E in human populations. Mtb 
vaccination strategies that focus on HLA-E might be beneficial especially in settings with 
highly prevalent co-infection with HIV. In Southern Africa alone approximately 70% of 
TB-patients are also HIV-infected. HIV infection down-regulates expression of classical 
HLA-A and -B molecules through its Nef proteins, thus decreasing antigen presentation 
capacities68. In contrast, however, HLA-E is resistant to HIV-nef-mediated down-
regulation due to a single amino acid substitution in the HLA-E cytoplasmic tail69. Thus, 
while HIV might inhibit antigen presentation by HLA class Ia molecules on monocytes 
and macrophages70, HLA-E dependent antigen presentation is likely less affected by HIV 
co-infection. Thus, targeting Mtb-specific HLA-E-restricted immunity by vaccination 
may be a novel and advantageous approach.
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 | SUMMARY AND PROSPECTS
We have reviewed recent studies which demonstrate that Qa1/HLA-E molecules reveal 
different faces and phases in NK- and T-cell immunity, with important implications for 
immuno-surveillance and immune regulation: first, Qa1/HLA-E molecules interact in an 
‘innate’ immune fashion, through one molecular face, with members of the heterodimeric 
CD94/NKG2 receptor family. The NKG2 member determines whether ligation leads to 
inhibiting (NKG2A) or stimulating (NKG2C) signals to NK- and T-cells.   The second 
role of Qa1/HLA-E molecules has only more recently become appreciated, notably their 
capacity to present a highly variable array of antigenic peptides to T cell receptors on 
CD8+ T cells.  Under usual homeostatic conditions the peptide repertoire bound to Qa1/
HLA-E is highly restricted, and largely confined to self MHC signal sequences.  However, 
under cellular stress conditions such as malignant cell transformation or intracellular 
infection with chronic pathogens, a new peptide repertoire is loaded onto Qa1/HLA-E 
molecules and is presented to CD8+ T cells with cytotoxic activity, able to kill tumor cells 
or infected cells. A brief overview of these different roles is summarized in Table II.
These new findings not only significantly extend the role of Qa1/HLA-E in NK and CD8+ 
T cell surveillance, but due to the extremely limited genetic polymorphism of Qa1/HLA-E 
also offer interesting perspectives for vaccination with high affinity peptides in cancer and 
infectious disease. In both cases efforts should similarly evolve around identifying the relevant 
antigens, which potentially can be useful in therapeutic as well as prophylactic vaccination. 
Clearly, more research is needed to dissect the role of Qa1/HLA-E bound peptides in 
cancer and infection. One question concerns their precise vaccine potential, that is the 
efficiency by which peptide-specific CD8+ T cells are capable of detecting and eradicating 
MHC-class Ia downregulation on tumor cell escape variants. The potential adverse effects 
need to be assessed as well, such as induction of auto-immune like phenomena in the case that 
such peptides are also expressed during “normal” cellular stress during local inflammation. 
Another key question is what functional roles Qa1/HLA-E peptide-specific CD8+ T cells 
exactly play: next to CTL, it is clear that also Tregs are induced. What dictates the balance in 
immune effector vs. regulatory mechanism at this level? Are different CD8+ T cell subsets 
involved with either unique CTL or Treg activity, or is dual functionality the common rule? 
Table II. Peptides presented by Qa-1/HLA-E to innate and adaptive immune receptors
Immune receptor peptide origin self or non-self
CD94/NKG2 Qdm from self MHC Ia self
Qdm from HCMV non-self
T cell receptor Qdm from allo MHC Ia non-self
hsp60 and GroEl self and non-self
Vβ TCR self  
associated with processing defects induced self 
  M. tuberculosis non-self
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How can we identify and manipulate these functional activities for therapeutic purposes? 
Clearly, the recent studies we have discussed here shed exciting new light on the potential new 
role of Qa1/HLA-E mediated antigen presentation in cancer and infection.
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 | MODEL OF TEIPP-PEPTIDE IMMUNOGENICITY
The study of immunity against TAP-deficient cells led to the discovery of peptides 
presented by such TAP-deficient cells. Some of these peptides constituted antigens to 
CTL and these CTL only recognized TAP-deficient cells but not normal cells1. These 
peptides were called “T-cell epitopes associated with impaired peptide processing” 
(TEIPP). Therefore, TEIPP corresponds to immunogenic peptides that are presented 
only in cases of processing deficiency and not by normal cells. Also, they are derived 
from normal housekeeping proteins and therefore constitute normal self-peptides (non-
mutated, not pathogen- or tumor-specific). The immunogenicity of TEIPP peptides 
exists because they are not presented by normal cells including the thymus. Therefore, 
there is no central tolerance against these peptides and the TEIPP-CTL can be released 
in the periphery. Because of this TEIPP peptides can be regarded as neo-antigens. 
Why are TEIPPs not presented by MHC-I of normal cells?
TEIPPs are present in normal cells
Since the peptides recognized by TEIPP-specific CTL are derived from housekeeping 
proteins, it became interesting to understand why TEIPPs are not presented by processing-
intact cells. Convincing data shows that TEIPP peptides are actually produced within 
processing intact cells, but somehow are not or not sufficiently presented by their surface 
MHC-I molecules. Previous studies have shown that TAP-positive tumor cells can be 
rendered sensitive to TEIPP-specific CTL after treatment with proteasome inhibitors 
(e.g. lactacystin) or by deficiency of other APM components (e.g. tapasin)1. Furthermore, 
introduction of viral TAP inhibitors in DCs brings these internal peptides to the cell surface 
for MHC-I presentation2. Taking the Trh4-derived TEIPP peptide as a model, we have 
analyzed the expression of the Trh4 gene in several epithelial populations isolated from 
wild-type and TAP1-ko mice (data presented in chapter 2). This analysis revealed the same 
level of RNA transcripts between the normal and knockout populations, suggesting that the 
proteins levels would also be comparable. The liberation of the Trh4 peptide is performed 
by SPP which is active in TAP-positive as well as TAP-negative targets. Therefore, the 
generation of the Trh4 peptide is comparable between normal and TAP-deficient cells. 
But while APC from TAP-ko mice were recognized by Trh4-specific CTL, the wild-type-
derived APC were not. This shows that there is difference in the MHC-I presentation of 
this TEIPP but not in expression. Additionally, enhancement of Trh4 expression in TAP-
positive RMA cells by gene transfer, using vectors with a strong heterologous promoter, 
resulted in presentation of the Trh4-derived peptide. Therefore, there is strong evidence 
for the production of Trh4-derived peptide and other TEIPP in normal cells and that the 
failure to present on normal cells has to be explained by failure to load in MHC-I.
Peptide competition hypothesis
What does prevent TEIPP from being presented in normal cells? One hypothesis is that 




loose competition with high affinity peptides that arrive in the ER via the TAP-transport. 
However, we found that the Trh4-derived TEIPP peptide has a good binding affinity and 
is capable of forming stable Db/Trh4 complexes, showing that it is an optimal MHC-I 
ligand (data presented in chapter 2). Nevertheless, it is still possible that other TEIPPs are 
indeed poor binders and that explains their absence from normal cells, but so far we did 
not find evidence for that. To understand the absence of the Trh4-peptide from normal 
cells we decided to look for the limiting step of Trh4 peptide presentation. We found that 
increasing the availability of MHC-I molecules in TAP-deficient cells did not augment the 
presentation of Trh4, indicating that TAP-deficiency per se creates the opportunity for all 
available Trh4 peptides to be loaded, irrespective of MHC-I levels. This suggested that the 
peptide quantity available for loading into MHC-I was the limiting factor. Indeed, increasing 
the quantity of the Trh4 peptide in TAP-deficient cells increased the presentation of Trh4 
and in normal cells resulted in the presentation of Trh4 whereas it does not normally 
occur. Interestingly, increasing recognition by the TEIPP-specific CTL clone correlated 
with fold of overexpression in target cells showing that the Db/Trh4 complexes increased 
proportionally, implying that TAP function constitute a strong barrier for TEIPP. A vast 
excess of TAP-pumped competing peptides is present in the ER and prevents TEIPP loading 
to MHC-I. These findings argue that TEIPP peptides, such as Trh4, are underrepresented 
in the ER and under normal conditions fail to find peptide-receptive MHC-I molecules in 
the ER (Figure 1). We have confirmed that the C-terminal Trh4 peptide is liberated in the 
ER, by the activity of SPP, as described in chapter 3. The study of a human TEIPP antigen 
corroborates these findings. This antigenic peptide is encoded by the human CALCA gene 
and derives from the signal sequence of preprocalcitonin (ppCT) protein. This peptide 
is liberated in the ER lumen by sequential cleavage with SP and SPP, independently from 
proteasomes and TAP3. The presentation of the ppCT peptide to specific-CTL was found 
in human lung and medullary thyroid carcinomas (MTCs) that had very low expression 
of TAP. Presentation of the ppCT peptide occurred also in normal non-transformed 
cells, such as DCs, after knockdown of TAP. Overexpression of the CALCA gene in DCs 
and TAP-positive tumor cells resulted in recognition by the specific CTL clone4. Thus, 
these facts support the model of peptide competition in the ER as a factor that prevents 
presentation of TEIPP antigens in normal cells. 
Mechanism of peptide competition
We can speculate how such a peptide competition mechanism actually works. TAP is 
one of the components of the PLC and links peptide transport into the ER with peptide 
loading. These two processes physically linked by TAP enhance the efficiency of peptide 
presentation. TAP-transported peptides readily get in contact with trimming enzymes 
and chaperones needed for optimal peptide binding to MHC-I that are also part of the 
PLC. The MHC-I molecules within the PLC have direct contact with the peptides that 
come from the cytosol, a big pool that contains peptides with optimal binding properties. 
Therefore these are favored over peptides situated in the ER lumen separate from the 
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Figure 1. Schematic illustration to explain why Trh4 peptides fail to be presented by processing-
proficient cells. We hypothesize that Trh4 peptides are underrepresented in the ER and lose competition 
with the vast excess of TAP-pumped peptides under normal conditions. Under TAP-deficiency, those 
peptides are not transported to the ER and Trh4 peptides get the chance to be presented instead. Binding 
affinity and stability of the Trh4 epitope with its MHC-I molecule seem sufficient for presentation. 
Adapted from: Seidel U.J. et al. A novel category of antigens enabling CTL immunity to tumor escape 
variants: Cinderella antigens. Cancer Immunology, Immunotherapy 2012, 61(1): 119-125. 
transport complex. As discussed above, peptides such as the TEIPP Trh4-derived peptide 
are liberated in the ER in normal cells but are not loaded into MHC-I. The quantity of 
these peptides seems to be too low to overcome the competition of the TAP-transported 
peptides.  In cases where the PLC does not have a functional TAP there is no direct 
link between the entering peptides and the specialized loading complex. However, the 
dynamical process of MHC-I presentation continues even without TAP. The available 
peptides, probably situated in the vicinity of the PLC have the opportunity to be loaded 




secretory route might get in contact with peptide-receptive MHC-I molecules on their 
way to the cell surface, which might exchange their ligands. Indeed, a higher number of 
intracellular peptide-receptive MHC-I molecules is found in TAP-deficient cells5. 
Alternative ways to be loaded into MHC-I: find peptide-receptive MHC-I 
in cells
Peptides located in the N- and C- terminus
The mechanism of peptide competition discussed here is a model that explains the 
immunogenicity of TEIPP peptides, such as the prototype example Trh4-derived 
peptide. This mechanism might be the base of the immunogenicity of other TEIPP that 
are liberated in the ER similarly to the Trh4 and ppCT peptides. These are examples of 
peptides situated in the N- and C-terminal regions of the proteins and can therefore be 
“easily” liberated by mechanisms such as the processing of leaders and the action of SPP 
on C-terminal regions of ER-resident proteins. The ER is equipped with sophisticated 
machinery for optimizing ligand length and quality, and for facilitating peptide loading 
onto nascent MHC-I molecules. This includes aminopeptidases as well as folding 
chaperones and editing molecules in the peptide loading complex. In the absence of TAP 
transporters the loading of peptides into MHC-I occurs without a fully functional peptide 
loading complex. The details of this mechanism are not yet understood. It has been 
shown that the loading of peptides in MHC-I can occur with the minimal components of 
tapasin-ERp57-MHC-I complexes6. TEIPP peptides generated inside the ER may have 
readily access to peptide-receptive MHC-I molecules associated with tapasin-ERp57 or 
might be actively chaperoned towards these open grooves. Chaperones with high peptide 
binding capacity in the ER are heat shock proteins (e.g. Hsp96) and PDI, an isomerase 
that efficiently binds free peptide7. It is possible that TAP-independent peptides are 
captured by these molecules and chaperoned to MHC-I.
Peptides located within proteins
A significant fraction of TAP-independent peptides identified thus far are derived from 
internal regions of cytosolic proteins8, 9.  These peptides, most likely, need the degradation of 
the entire protein for being liberated in more complex degradation steps than the liberation 
of N- or C-terminal ends. This normally occurs by the action of the proteasome, alone or in 
combination with other proteases.  We studied a TEIPP peptide antigen that was processed by 
the proteasome and presented independently from TAP (chapter 3 of this thesis).  In contrast 
to Trh4, it is likely that in this case the peptide is generated outside the ER, via one or more 
proteolytic steps. Novel transport mechanisms from the cytosol into vesicular compartments 
that enable loading into MHC-class I molecules have been proposed. Apparently such 
cytosol-derived peptides can have access to MHC-I loading compartments, such as the ER, 
without the action of TAP. Several epitopes from the LMP2 protein of the Epstein-Barr virus 
(EBV) are produced by the proteasome and presented without TAP10. It was suggested that 
they cross the ER membrane by diffusion due to their hydrophobicity, because all of these 
were highly hydrophobic. Maybe there are TEIPP peptides with such characteristics of being 
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generated in the cytosol by the action of the proteasome and then traverse membranes due to 
their hydrophobic characteristics and do not need TAP.
Peptides generated in post-ER compartments possibly might travel back to the ER 
for loading in MHC-I molecules. Peptides generated along the secretory route, including 
Golgi, may use retrograde vesicular transport to get from distant organelles to the ER11. 
Secondly, MHC-I molecules with sub-optimally bound peptides may exchange them at 
a second quality control check point in the Golgi12-14. Peptidic ligands generated in these 
secretory compartments may bind to MHC class I molecules in these compartments 
when the exchange occurs. It is likely that TAP-deficiency promotes the availability of 
sub-optimally loaded MHC-I molecules and this increases the efficiency of presentation 
of vesicular and secretory MHC-I ligands.
Autophagy as a way to load MHC-I?
Autophagy could provide a pathway to facilitate the loading of potential MHC-I ligands 
in endovacuolar compartments. During autophagy, large portions of cytoplasmic content 
are encapsulated in vesicles, the autophagosomes, and then fused with other vesicles 
such as lysosomes. The contents of cellular organelles are degraded in these vacuolar 
compartments in this conserved cellular process of self-eating. Antigens could be liberated 
by proteases in a lytic vacuole after autophagy and encounter MHC-I complexes that 
were recycled from the cell surface. It is known that MHC-I molecules constantly recycle 
from the cell surface to early endosomes as part of the normal MHC-I trafficking. Upon 
entering gradually acidic environments they might exchange their ligands. This vacuolar 
pathway of antigen presentation might be of particular importance in TAP-deficient 
cells or cells infected with viruses that can interfere with TAP or MHC-I processing and 
transport. In a recent study it has been shown that autophagy promotes the processing 
of viral antigens for TAP-independent MHC-I presentation. The MHC-I presentation of 
an endogenous human cytomegalovirus (HCMV) latency associated protein, pUL138, 
was followed the vacuolar pathway dependent on autophagy15. Peptide loading occurred 
within autophagic vesicles associated with lysosomes (autophagolysosomes). Curiously, 
this pathway generated the same peptide epitope as that generated from conventional 
processing. Thus, it is likely that this autophagy mediated pathway supplements the 
conventional pathway and contributes to viral clearance. 
The autophagosomal membrane has been proposed to originate from the ER16, 17. If 
the loading occurs in these compartments, the advantage created by TAP could be the 
higher number of peptide-receptive MHC-I heavy chains that could enter other loading 
compartments such as the autophagosome vesicles. However, more research is needed to 
get further insight on the role of autophagy for MHC-I antigen presentation.
Conclusion
In summary, there are many new interesting pathways ready to be elucidated. And many 
TEIPP antigens generated and presented via these pathways occur and stimulate the 




since it can be exploited in the combat of many diseases. The study of alternative pathways 
could be exploited to develop new therapies to combat viral infections and cancer where 
TAP is frequently inhibited. As we have shown, following TAP-inhibition there is a 
generalized decrease in MHC-I presentation and the emergence of an alternative peptide 
repertoire18. TEIPP peptides are among these TAP-independent peptides and might 
constitute an important line of host defense for exploitation in therapeutic strategies.
 | EXPLOITATION OF TEIPP ANTIGENS IN IMMUNOTHERAPY
Many tumors resist to consecutive conventional treatments such as chemotherapy. 
Frequently it is observed the outgrowth of tumor escaped variants. These variants 
frequently display defects in the APM machinery, for example TAP-deficiency, and 
sometimes complete loss of antigenic presentation or MHC-I or MHC-II alleles19-21. 
These observations are common in advanced stages of the disease such as the metastatic 
state22, 23. TAP-deficiency causes MHC-I downregulation and hampers the presentation 
of many TAP-dependent tumor antigens that could be already the target of T-cell 
therapies. TEIPP antigens are presented in TAP-deficiency or other APM-deficiencies 
and therefore provide a way to target this escaped variants. 
Therapeutic peptide vaccines
The applicability of TEIPP antigens for immunotherapy of cancer has been tested in 
preliminary studies using mice. The 9-mer TEIPP peptide Trh4 was used as a CD8+ T-cell 
vaccine, combined with a T helper peptide to also stimulate CD4+ T-cells. This vaccination 
scheme prevented the outgrowth of a TAP-deficient lymphoma1. These results showed that 
TEIPP antigens can be used in combination with other antigens to be used as a vaccine that 
can tackle tumor immune escaped variants. In the tumor vaccination field, several immune 
intervention strategies have been designed and tested to stimulate the power and specificity 
of the immune system to treat cancer. However, until recently, most of the immune-therapies 
developed have provided poor tumor regression in humans. Some of these were based on 
vaccination strategies to induce CD8+ T-cell responses against tumor-associated antigens 
using single CTL epitopes comprising the exact HLA-I binding peptide. Peptide epitopes 
used in clinical trials to treat metastatic cancer included melanoma-differentiation antigens 
such as MART-1, gp100, tyrosinase or TRP-2 and cancer-testes antigens such as NY-ESO-1, 
MAGE-12 or Her2/neu24. The low efficacy of vaccines using minimal CTL epitopes may be 
caused by inefficient T-cell activation that precludes the ability of the T-cells to infiltrate the 
solid tumors and become activated. In preclinical mouse studies it was shown that synthetic 
peptides that were much longer and could reach up to 27 amino acids in length were more 
effective25-29. These longer peptides may be retained in the draining lymph nodes where they 
could be processed and presented by professional APCs to prime CD8+ T-cells. Additionally, 
some of the synthetic peptides also contained CD4+ T-cell helper epitopes. These two 
factors, processing and presentation of peptides by APCs and the induction of CD4+ T-cell 
help are important factors that enhanced efficacy of these studies in mice but lacking in most 
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of the clinical trials in humans. This realization provided the development of even more 
complex peptide formulations, for instance the synthetic long peptides (SLP). These contain 
overlapping long peptides that span the whole protein and contain multiple CD8+ and CD4+ 
T-cell epitopes. A clinical trial was conducted in twenty women carrying pre-malignant vulvar 
lesions associated with HPV16 infection using synthetic long peptides (SLP)30. This vaccine 
formulation contained multiple MHC-I and MHC-II overlapping peptides (27-34 amino-
acids) spanning the sequence of HPV16 E6 and E7 proteins. Five women had complete 
regression of the lesion and this was associated with the induction of interferon-γ-associated 
CD4+ and CD8+ T-cell responses. Therefore, it might be worthwhile to test if we can formulate 
long-TEIPP antigens to use as vaccines. One advantage of TEIPP antigens relative to tumor 
associated antigens, such as differentiation antigens, it that they behave like foreign antigens 
because they are not presented in the thymus in normal conditions. This implies that the 
T-cells are not affected by tolerance which might contribute to the development of a robust 
anti-tumor response and enhance the efficacy of tumor-specific immunotherapy.
Tumor-cell based vaccines
Others demonstrated that tumor-cell vaccines consisting of TAP-impaired tumor cell 
lines that present TEIPP peptides might also induce immune protection, provided that 
enough co-stimulation on the tumor cell vaccine is at hand31, 32. The applicability of this 
variety of therapeutic immune interventions shows that TEIPPs can be exploited alike 
conventional tumor antigens, despite their unconventional character (Table 1). Altogether, 
the understanding of the mechanisms underlying the generation of tumor immunity and 
tumor escape is needed to provide a framework for developing novel immunotherapies.
Dendritic cell-based vaccination
As mentioned above, the processing of tumor antigens by APCs is important in 
immunotherapies. DCs are potent antigen-presenting cells of the immune system and can 
promote protective immunity. Upon acquisition of antigens, DCs can instruct the type of 
immune response to be induced. Immunization with TAP-deficient DCs mediated protection 
to TAP-deficient tumor challenge2. This DC-based cellular vaccine is characterized by 
Table I. Categories of human tumor antigens recognized by CTL
Category Description Examples
Viral antigens Virus-induced tumors (e.g. EBV, HPV) EBNA-1, E6, E7
Point mutations Unique for each tumor MUM-1, CDK-4, p53, 
Caspase-8
Differentiation antigens Expressed in tissue lineage Tyrosinase, GP100, Mart-1
Cancer testis antigens Largely expressed during development and cancers MAGE, NYO-ESO-1
Cryptic epitopes Associated with aberrant transcription and translation RU2, GnT-V, HPX42B
TEIPP Associated with antigen processing defects CALCA




presentation of a variety of endogenous TEIPP antigens by MHC-I molecules. Importantly, in 
this vaccination strategy TEIPP antigens do not require to be molecularly identified. Clinical 
trials have shown that DC-based vaccines can directly induce specific antitumor immune 
responses. A prostate cancer vaccine that includes DCs pulsed with prostate cancer-associated 
antigens has been approved for cell-based immune-therapy. Patients given this formulation, 
called Provenge (Dendreon), showed a small improvement in overall survival in a clinical trial, 
highlighting the need to improve current DC-based vaccination strategies33, 34. 
The TAP-deficient DCs can also be used to treat viral infections.  Many viruses 
establish persistent infections in their host. Herpesviruses, for instance, employ several 
immune evasion strategies to accomplish this. They code for specific molecules that 
greatly interfere with presentation of viral antigens and therefore “hide” from the immune 
system35. These molecules interfere with many steps of the MHC-I antigen presentation 
route35-37. A frequent target within this pathway is the TAP transporter. Herpes simplex 
virus (HSV)-1 and 2 code for ICP47, a cytosolic protein that inhibits TAP function by 
interfering with peptide binding to the transporter. Others, such as the transmembrane 
glycoprotein US6 of human cytomegalovirus (HCMV) inhibit ATP binding to TAP and 
impair peptide transport. However, cells that have these TAP-inhibitors are still capable 
of presenting TEIPP peptides. Introduction of viral TAP-inhibiting molecules into 
dendritic cells efficiently induces the display of TEIPP peptides, resulting in recognition 
by TEIPP-specific CTL. Human DCs electroporated with RNA encoding the bovine 
herpes virus (BHV)-1 gene UL49.5 were used for stimulations of autologous peripheral-
blood mononuclear cells (PBMCs)38. The UL49.5 protein from this herpes-virus 
efficiently inhibits the human peptide transporter TAP2. The CD8+ T-cell clones isolated 
from these cultures exhibited different specificities, by virtue of different TCR usage, 
and displayed different HLA-I restrictions. These CTL clones were capable of lysing 
other TAP-inhibited targets and did not react against TAP-positive cells, showing that 
these CTL clones exhibited TEIPP-specificity38. Moreover, these target cells displayed 
other viral TAP-inhibitors, showing that the T-cell clones raised strategy can be used to 
fight different viral infections. Together, these findings show that it is possible to raise 
CD8+ TEIPP-T-cell responses against viral infected cells by using professional antigen 
presenting cells, such as dendritic cells, rendered TAP-inhibited. These DCs are able to 
display TEIPP peptides as the infected cells and can prime naïve T-cells into effector cells. 
Partial inhibition of TAP-function in the DCs is sufficient to exhibit these responses2, 38. 
The technique of RNA electroporation, that could be used to introduce the viral TAP-
inhibitors, is feasible in clinical settings. Also, it has the advantage that the nucleotides are 
not integrated in the host genome, which happens with the use of viral vectors.
Therefore, TEIPP might also be exploited in several ways to combat infections of 
viruses that hide from T cell immunity by down modulation of conventional antigen 
processing. The study of alternative presentation pathways will most likely provide further 
fundamental insight in TEIPP peptide presentation and facilitate the future application 
of this knowledge for immunotherapeutic intervention of cancer and infectious diseases.
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Adoptive T-cell transfer
Cell-based vaccinations using adoptively transferred TEIPP-specific CTL were able to 
eradicate TAP-deficient tumor cells in vivo and control the outgrowth of a lethal dose1. In 
adoptive cell transfer (ACT) techniques tumor-specific T-cells are expanded in vitro and 
then reintroduced in large numbers into the patients. During this in vitro growth phase, the 
properties of these cells may be monitored such as their recognition potential. It has been 
shown that T-cell characteristics such as young and rapidly growing cells were beneficial39-42. 
Immune cells generated and activated ex vivo can be infused in a highly activated state, 
already displaying the necessary lytic and cytokine secreting activities required to mediate 
the destruction of even large solid tumor masses. Antitumor T-cells used for cell transfer can 
be generated in vitro from tumor infiltrating lymphocytes (TILs) or from peripheral blood 
lymphocytes. Also, during in vitro procedures these cells may be modified through genetic 
engineering, such as T-cell receptor (TCR) gene transfer strategies43. In this strategy, TCR 
of desired specificity are introduced by gene transfer into autologous or donor-derived 
T-cell populations in short-term ex vivo cultures, and then infused into the patients to 
provide T-cell reactivity against defined antigens43-46. TCR gene transfer experiments with 
TEIPP specific TCRs has shown that TEIPP reactivity can be obtained via this strategy. 
Therefore, ACT and gene transfer techniques can be applied for TEIPP.
Advantages of HLA-E-presented TEIPP in immunotherapy
TEIPP-specific CTL restricted by the non-classical MHC-I molecule Qa-1 are capable of 
targeting TAP-deficient tumor cells such as other TEIPP-specific CTL restricted by classical 
MHC-I molecules1, 2, 9. The particular characteristics of Qa-1 turn this molecule into an 
attractive target for TEIPP studies. The Qa-1 binding groove shares a conserved structure 
with the human homologue HLA-E47. Therefore the peptides presented by these two MHC-I 
molecules would be very similar, implying that the discovery of Qa-1 presented peptides could 
directly provide TEIPP epitopes to be used in human experiments. In fact, it was observed 
that human cells transfected with Qa-1 were recognized by our mouse Qa-1-TEIPP CTL 
clones (unpublished data)  We found a surprisingly diverse peptide repertoire of more than 
100 different peptides in Qa-1 on TAP-deficient cells, described on chapter 5. The peptides 
originated from housekeeping proteins within the cell and some of them constituted neo-
antigens according to the TEIPP concept with the ability to give rise to CD8+ T cell responses. 
Therefore a high number of antigens can be targeted in tumors by Qa-1-specifc CTL. 
Qa-1 and HLA-E exhibit low polymorphism, consequently the presented peptides 
are widely distributed within the population47-49. The independency of MHC typing on 
the application of treatment strategies based on Qa-1/HLA-E-binding peptides contrasts 
with most of the other MHC-I molecules. Interestingly, Qa-1-TEIPP CTL clones 
recognized TAP-deficient tumors from different mouse MHC haplotype backgrounds 
by virtue of the conserved nature of Qa-1. Therefore, Qa-1/HLA-E-presented TEIPP 
antigens fulfill some requirements of ideal tumor antigens. As such, the potential use of 




Moreover, Qa-1 shows a wide tissue distribution which allows the targeting 
of different histological tumor types. One Qa-1-TEIPP CTL clone was capable of 
recognizing colon tumors, melanoma and lymphoma (described on chapter 5). Qa-1 
shows a relative maintenance of surface levels on TAP-negative conditions even in cells 
that lost expression of classical MHC-I heavy chains47, 48, 50.  This implies that tumors with 
processing defects as well as tumors with MHC-I allele loss can be targeted by these 
Qa-1-TEIPP CTL. In ovarian and cervical cancers, HLA-E expression was found in 
equal or even higher levels than normal tissues. This was strongly associated with APM 
deficiencies such as TAP-deficiency, HLA-I and HLA-II loss51. 
Conclusion
For more than 60 years it has been shown that the host’s immune system is capable of fighting 
against cancer. One challenge of immune-therapy against cancer is the start of a robust and 
specific CD8+ and CD4+ T-cell response that is capable of fighting against an established 
disease. Tumors normally harbor immune suppressive environments and it might be useful 
to relief the local suppressive milieu in combination with T-cell vaccination strategies. For 
instance, tumors can be infiltrated with regulatory T-cells (Tregs) and myeloid-derived 
suppressor cells (MDSCs)52-55. Therapeutic strategies that aim to break the tolerogenic 
environment and induce inflammation might greatly enhance attraction of T-cells to the tumor 
area and promote T-cell infiltration56. Therefore, the use of chemotherapy or radiotherapy 
or other means that promotes the release of proinflamatory signals in combination with 
immune-therapy might beneficial and are now focus of research57. For instance, TLR ligands 
might increase the magnitude of T-cell response by strongly activate DCs and polarize it into 
an inflammatory type of immune response (T-helper 1). Covalent linking of TLR ligands to 
peptide vaccines is one strategy currently under study. Since the vaccine might also activate 
pre-existing antigen specific T-regs it may be useful to deplete T-regs prior to the vaccination, 
for instance by administering cyclophosphamide to the patients. These and other techniques 
might help to improve the T-cell responses stimulated by therapeutic vaccines. TEIPP 
antigens can be exploited to tackle T cell defense against processing deficient tumors and thus 
be complementary to conventional tumor antigen vaccination. 
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 | NEDERLANDSE SAMENVAT TING
Het immuunsysteem speelt een essentiële rol in de  bescherming van ons lichaam tegen 
bedreigingen zoals bacteriën, virussen en andere ziekteverwekkers, maar ook tumorcellen. 
Het immuunsysteem bestaat uit verschillende groepen van cellen, waaronder de 
Cytotoxische T-Lymfocyten (CTL). Deze cellen zijn gespecialiseerd in het aanvallen van 
door ziekteverwekkers geïnfecteerde cellen en tumorcellen. Zij ruimen deze  cellen op 
door moleculen uit te scheiden waardoor de doelwit cel “zelfmoord” pleegt en vervolgens 
uit het lichaam verwijderd wordt.  In enkele nieuwe behandelingsvormen van kanker 
wordt gebruik gemaakt van deze CTL, zoals bijvoorbeeld therapeutische vaccins die anti-
tumor CTL activeren. In ons lichaam gaan ze naar de plek van de tumor om deze daar te 
bestrijden. De lymfocyten kunnen ook gekweekt, geactiveerd en opgegroeid worden in 
laboratoria om daarna terug gespoten te worden in de patiënt. Dergelijke experimentele 
therapieën worden in verschillende klinische studies gebruikt voor de behandeling van 
verschillende types kanker, zoals bijvoorbeeld baarmoederhalskanker en huidkanker. 
De activatie van CTL is belangrijk voor hun functioneren en is afhankelijk van 
bepaalde factoren. De doelwit cellen worden gezien via een moleculaire receptor die op 
de oppervlakte van de CTL zit, genaamd de T-cel receptor (TCR). Elke CTL heeft een 
unieke TCR die ervoor zorgt dat heel selectief een afwijkend stukje eiwit wordt herkend, 
genaamd het antigeen, op de doelwit cel. Deze kleine stukjes eiwit zijn afkomstig vanuit de 
cel zelf en worden getransporteerd naar de oppervlakte van de doelwit cel waar ze zichtbaar 
zijn voor de CTL. Deze peptiden worden alleen herkend door de CTL als ze gebonden 
zijn aan grotere moleculen, de Major Histocompatibility Complex moleculen (MHC). 
Vaak kunnen tumor cellen ontsnappen aan de CTL-gemedieerde verwijdering 
door te voorkomen dat ze herkend worden door de CTL. In zulke tumor cellen werkt 
de presentatie van antigenen niet correct en kan drastisch gereduceerd worden. Deze 
vermindering in het zichtbaar maken van antigenen wordt veroorzaakt door een hapering 
van een of verschillende moleculen geassocieerd met deze transport route, bijvoorbeeld 
de proteasoom, tapasin en TAP. Tumor cellen met verminderde oppervlakte presentatie 
van tumor-geassocieerde antigenen zijn een grote barrière voor de doeltreffendheid van 
CTL-gebaseerde therapieën die momenteel in ontwikkeling zijn voor kanker. 
Niettemin zijn er de laatste tijd vindingen die nieuw licht op dit onderwerp schijnen. 
Er is een nieuwe categorie van CTL ontdekt die dergelijk ontsnapte tumor cellen 
toch kan opruimen. De defecten in MHC-I antigeen verwerking zorgt er namelijk 
voor dat tumor cellen andere peptiden gaat presenteren. De hapering in de normale 
antigeen presentatie route resulteert in de uitschakeling van de normale peptiden, maar 
tegelijkertijd in de presentatie van nieuwe tumor antigenen. Deze nieuwe peptiden 
worden niet gepresenteerd door normale cellen. Er is nu veel onderzoek naar deze CTL 
en hun gebruik in tumor beschermingsexperimenten. Tumor cellen met een slecht 
functionerend transportsysteem door TAP of het proteasoom worden herkend en 
doodgemaakt door deze CTL terwijl de normale cellen hier geen last van hebben. Deze 
categorie van peptiden worden TEIPP genoemd, dat staat voor ’T cell epitopes associated 
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with impaired peptide processing’. Hoewel ze niet gepresenteerd worden door normale 
cellen, komen deze peptiden van eiwitten die niet gemuteerd zijn en die normaal tot 
expressie komen in alle cellen, zogenaamde huishoud genen. CTL die TEIPP peptiden 
herkennen kunnen veel verschillende tumor types doodmaken, zoals darm kanker, 
huidkanker, lymfoom en sarcoom. De eerste onderzoeken naar TEIPP zijn ontwikkeld 
in muis modellen, maar recent werk laat zien dat TEIPP-CTL ook in mensen voorkomen 
en ook verschillende kanker types herkennen terwijl normale cellen intact blijven. 
De studies naar TEIPP antigenen hebben tot zover laten zien dat deze antigenen 
veelbelovende kandidaten zijn voor het bestrijden van tumoren die aan een aanval van het 
immuunsysteem ontsnapt zijn. Echter, verschillende aspecten van TEIPP worden nog slecht 
begrepen. De studies die in dit proefschrift worden gepresenteerd zijn ontwikkeld om de 
TEIPP peptiden beter te begrijpen, en dus ook hoe de peptiden gebruikt kunnen worden in 
de toekomst om kanker te bestrijden. In hoofdstuk 2 komt ter sprake waarom TEIPP peptiden 
immunogeen zijn. Het muis antigeen van het Trh4 eiwit is gebruikt als model. Wij verhoogde 
de hoeveelheid van Trh4 eiwit en MHC-I moleculen in cellen met normale TAP functie, om 
de beperkende stap van Trh4 peptide presentatie te identificeren. De verhoogde expressie 
van Trh4 was het enige mechanisme dat resulteerde in peptide presentatie in deze cellen. Wij 
concluderen dat de normale TAP activiteit de presentatie van de Trh4 peptiden onderdrukt 
en wanneer de TAP functie lager is, dan hebben de Trh4 peptiden en andere gerelateerde 
peptiden een kans om gepresenteerd te worden aan het cel oppervlakte. Omdat deze peptiden 
onder normale omstandigheden niet gepresenteerd worden, zien de immuun cellen ze als een 
“gevaarlijke” situatie en vallen de cellen aan die deze peptiden laat zien. Dit is een model om 
uit te leggen dat de TEIPP peptiden immunogeen zijn. 
In hoofdstuk 3 laten wij zien hoe het Trh4-afgeleide peptide geknipt wordt uit 
het Trh4 eiwit binnenin de cel. We hebben gevonden dat het enzym ‘signal peptide 
peptidase’ (SPP), dat tot een familie van I-CLiPs hoort (intra-membraan knippende 
aspartyl proteases), de 9-meer Trh4-eiwit vrijmaakt in het endoplasmatisch reticulum 
(ER). In hoofdstuk 4 bekijken wij de verwerkingsroute van een ander TEIPP antigeen 
dat aan CTL wordt gepresenteerd. Verassend genoeg ontdekten wij dat deze presentatie 
zeer afhankelijk was van de functie van proteasomen. Dit betekent dat het peptide vrij 
gemaakt wordt door het proteasome, maar via een TAP-onafhankelijke route naar het 
cel oppervlak gaat. Onze data suggereren een rol voor ‘autophagy’ in de presentatie van 
dit TAP-onafhankelijke en proteasoom-afhankelijke antigeen. Autophagy is een cellulair 
mechanisme waarbij organellen in stukjes uiteenvallen en worden “gerecycled”.
In hoofdstuk 5, bekijken wij de TEIPP-specifieke CTL die antigenen herkennen via 
het MHC-I molecuul Qa-1. Qa-1 presenteert normaal peptiden die strikt afhankelijk 
zijn van TAP activiteit. Echter, eerste onderzoeken laten zien dat TEIPP-specifieke CTL 
worden geactiveerd wanneer ze gebonden zijn aan Qa-1 moleculen in TAP-negatieve 
cellen maar niet in TAP-normale cellen. Meer dan 80 peptide sequenties werden gevonden 
in Qa-1 moleculen op TAP-negatieve cellen. Verschillende van deze peptiden zijn zeer 
immunogeen, wat laat zien dat ze veelbelovend  zijn in het gevecht tegen ontsnapte 
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tumor cellen. In hoofdstuk 6 is er een overzicht van de verschillende rollen van Qa-1 en 
de humane variant, HLA-E, in immuniteit. Hoofdstuk 7 rondt dit proefschrift af met een 
overzicht van de vindingen in dit boekje waarbij onze resultaten bediscussieerd worden.   
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